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SUMMARY 
The topic of antiretroviral adherence remains a subject of continued importance, as it is 
associated with positive health outcomes amongst patients attending public healthcare 
facilities. Available literature on adherence behaviour mainly focuses on the psychological 
and behavioural barriers, while overlooking the multitude of structural barriers within the 
patient’s environment affecting the patient’s adherence to antiretroviral treatment and care. 
The present study provides a unique perspective on adherence behaviour amongst persons 
living with HIV and receiving antiretroviral treatment, as it identifies important structural 
barriers to clinical attendance and pill-taking.  
The sample for this study were selected from patients attending an infectious diseases 
clinic at a major peri-urban secondary hospital and receiving antiretroviral therapy, nurses 
and doctors providing health services to patients, and patient advocates providing 
psychosocial support to patients under the auspices of a local non-governmental organisation. 
The participants included in this study were selected by means of convenience sampling to 
participate either in semi structured interviews or focus group discussions. Participants were 
assured of the confidentiality of the process and their anonymity in both cases. Both semi 
structured interviews and focus groups were digitally recorded and transcribed after which 
transcriptions were entered into Atlas.ti for textual analysis. Transcriptions were thematically 
analysed according to the perceptions of various participants. The main themes that emerged 
from the present study included individual barriers, poverty-related barriers, institution-
related barriers, and social and community-related barriers. 
The results of the present study were triangulated by considering the concurrences and 
discrepancies between the patients, clinicians and patient advocates on the main, and 
subthemes. These themes were then discussed according to Bronfenbrenner’s (1972) 
Ecological Systems Theory, which divided the main themes identified according to the 
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different systems operating within the patient’s environment, i.e. the micro-, exo-, and 
macrosystem. The microsystem included both individual psychological and behavioural 
barriers and poverty-related barriers. Institutional barriers were considered within the exo-
system of the patient’s ecological environment. And the social and community-related 
barriers were considered within the macrosystem of the patient’s ecological environment. 
The significance of this study lies in the identification of adherence behaviour as the 
product of the patient’s environment through the examination of triangulated data. Future 
research may include effective ways in which patients can be assisted in developing the 
necessary skills to cope with their environment and to enhance social support. The 
development of strategies to support newly-enrolled patients also still needs investigation. 
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OPSOMMING 
Volgehoue antiretrovirale behandeling bly ‘n onderwerp van voortdurende belang omdat dit 
geassosieer word met positiewe gesondheidsuitkomste onder pasiënte wat van openbare 
gesondheidsfasiliteite gebruik maak. Beskikbare literatuur oor volhoudings gedrag fokus 
grootliks op sielkundige en gedragshindernisse, terwyl veelvuldige strukturelehindernisse 
binne die pasiënt se omgewing steeds misgekyk word. Dié studie bied ‘n unieke perspektief 
op volhoudingsgedrag onder MIV-positiewe pasiënte wat tans antiretrovirale terapie ontvang, 
aangesien dit belangrike strukturele hindernisse tot kliniek bywoning en die neem van 
medikasie identifiseer. 
Dié steekproef sluit pasiënte in wat tans antiretrovirale terapie by ‘n aansteeklike 
siektes-kliniek by ‘n peri-stedelike sekondêre hospitaal ontvang. Dit sluit ook dokters en 
verpleegsters in wat gesondheidsdienste aan dié pasiënte verskaf, en pasiënt- advokate wat 
psigo-sosiale ondersteuning aan pasiënte verskaf onder die vaandel van ‘n plaaslike nie-
regerings organisasie. Dié deelnemers is deur middel van gerieflikheidssteekproef geselekteer 
om aan semi-gestruktureerde onderhoude of fokusgroepbesprekings deel te neem. 
Deelnemers van albei groepe is van hul anonimiteit en die vertroulikheid van die proses 
verseker. Beide die semi-gestruktureerde onderhoude en die fokusgroepbesprekings is 
digitaal opgeneem en transkripsies is daarvan gemaak, waarna die transkripsies in Atlas.ti 
gelaai is vir tekstuele analise. Transkripsies is tematies geanaliseer volgens die persepsies van 
die verskeie deelnemers. Die hooftemas wat na vore gekom het, sluit in individuele 
hindernisse, armoedeverwante hindernisse, institusieverwante hindernisse asook sosiale en 
gemeenskapsverwante hindernisse. 
Resultate van dié studie is getrianguleer deur die verskille en ooreenkomste te vind 
tussen pasiënte, klinici en pasiënt-advokate oor die hoof- en subtemas. Die hooftemas is toe 
volgens Bronfenbrenner (1972) se Ekologiese Sistemeteorie verdeel in die verskillende 
vi 
 
sisteme teenwoording in die pasiënt se omgewing, naamlik die mikro-, ekso-, en 
makrosisteem. Die mikrosisteem het individuele sielkundige en gedragshindernisse asook die 
armoedeverwante hindernisse ingesluit. Institusieverwante hindernisse is binne die 
eksosisteem van die pasiënt se ekologiese omgewing beskou en sosiale en 
gemeenskapsverwante hindernisse is beskou binne die makrosisteem van die pasiënt se 
ekologiese omgewing. 
Die belang van dié studie lê in die identifisering van volhoudingsgedrag as produk 
van die pasiënt se omgewing, soos beskou deur die Ekologiese Sistemeteorie. Toekomstige 
navorsing kan fokus op effektiewe maniere waarop pasiënte bygestaan kan word om die 
nodige vaardighede te ontwikkel om hul omgewing beter te kan hanteer en beskikbare sosiale 
ondersteuning te kan verbeter. Die ontwikkeling van strategieë om nuwe pasiënte by te staan, 
benodig ook verdere navorsing. 
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CHAPTER ONE: INTRODUCTION 
1.1 Introduction and rationale for the present study 
The Human Immunodeficiency Virus (HIV) has emerged as a pandemic with an impending 
catastrophic impact on human societies worldwide (Burden of Disease Research Unit, 2007). 
Globally the number of HIV infections have risen from 8 million in 1990 to 33.2 million in 
2007 (Department of Health South Africa, 2007; UNAIDS, 2007). In South Africa alone, 
there is currently 5.7 million people living with HIV (UNAIDS, 2007), accounting for nearly 
11% of the population (Burden of Disease Research Unit, 2007), making South Africa home 
to the largest population of people living with HIV in the world. HIV accounts for nearly 
1,400 new infections per day in this region and it is estimated that HIV will also account for 
75% of premature deaths by 2010 (Burden of Disease Research Unit, 2007). 
The commencement of antiretroviral therapy (ART) in the early 1990’s, brought the 
hope that this therapy would serve as a cure for HIV. It was, however, soon realized that this 
was an improbable goal, not likely to be realized, since it would require HIV-infected 
individuals to adhere to long term antiretroviral therapy, as they would have to receive ART 
for many years, if not life (Finzi et al., 1999; Ware, Wyatt, & Tugenberg, 2006). Adherence 
to ART regimens are vital for the individual patient and for the general public since non-
adherence can result in drug-resistant strains being easily transmitted from one individual to 
another (Roberts & Mann, 2000). Yet, non-adherence to medical treatment still continues to 
be a challenge (Stone et al., 2001). 
Poor treatment adherence is currently the most important barrier to effective ART 
treatment (Stone et al., 2001). Consistent and near perfect adherence to antiretroviral therapy 
regimens is needed to attain the maximum benefit from these potentially effective treatments 
(Kalichman et al., 2001). Antiretroviral therapy, however, is an unforgiving drug, as clinical 
studies have shown that a particularly high level of adherence (90%-95% or greater) is 
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required for an improved virological outcome, a greater increase in CD4+ lymphocyte count, 
and a lower hospitalization rate among individuals infected with HIV (Chesney, Morin & 
Sherr, 2000; Forgarty et al., 2002; Paterson et al., 2000). The likelihood of sustaining therapy 
over a longer period of time has also been associated with patients who show higher levels of 
adherence (Bangsberg et al., 2003). Poor adherence to ART, on the other hand, is the most 
likely cause for therapeutic failure, associated with virologic failure, immunologic failure, 
and clinical progression of the disease (Carpenter et al., 2000; Department of Health and 
Human Services, 2008). 
Reasons for poor adherence to ART have frequently been documented in the 
literature. According to the literature those reasons have most recurrently been associated 
exclusively with individual psychological and behavioural barriers relating to specific patient 
and regimen characteristics (Forgarty et al., 2002; Ware et al., 2006). These barriers 
commonly include forgetfulness (Schuman et al., 2001), pill burden (Berg, Michelson, & 
Safren, 2007), side-effects (Davies et al., 2006), beliefs and perceptions about treatment 
regimens, substance abuse (García & Cóte, 2003), literacy and self-efficacy (Wolf et al., 
2007), and emotional distress (Penna & Treisman, 2005). 
Little emphasis has been placed on the structural barriers to ART treatment, factors 
that patients may have little control over (García & Cóte, 2003). Adherence behaviours 
related to social, economic, political and cultural domains, which collectively make up social 
structures, and how they act as barriers, have greatly been ignored until recently (Shriver, 
Everett, & Stephen, 2000). Research should therefore examine how the environment affects 
patients’ adherence behaviour to the same extent as how individual psychological and 
behavioural factors affect patients’adherence behaviour (Sumartojo, 2000). 
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1.2 Need for the present study 
The prevalence of HIV among South Africans remains at a very high level. Currently 5.2 
million of South Africa’s population are infected with HIV, adding to a prevalence rate of 
10.6% (Shisana et al., 2009). When excluding HIV-infected children under the age of 2 years, 
the prevalence rate of HIV rises to 10.9% (Shisana et al., 2009). The prevalence rate differs 
between the nine provinces, ranging from 6.6% in the Eastern Cape to 14.9% in the Western 
Cape in 2008, for the age group of 2+ years (Shisana et al., 2009). Within the same year the 
Western Cape showed a prevalence rate of 10.7% for the same age group (Shisana et al., 
2009).  
South Africa is currently the country with the largest number of HIV and AIDS-
infected individuals enrolled in antiretroviral therapy in the world (National Department of 
Health, 2007). The local AIDS and Demographic model (ASSA, 2003) projects that in 2009 
(mid year) 583,264 adults and 68,505 children will be receiving antiretroviral therapy in 
South Africa (Nicolay & Kotzé, 2008). It is also projected that 470,379 adults and 26,391 
children with AIDS are not on antiretroviral therapy, contributing to the 1,148,539 HIV-
infected individuals currently eligible for antiretroviral therapy (Nicolay & Kotzé, 2008). 
April 2004 saw the initiation of the national rollout programme in South Africa, with 
demonstration projects being launched in Khayelitsha in 2001 and in Gugulethu in 2002 
(Boulle et al., 2008).  
HIV-infected individuals participating in the Khayelitsha demonstration project 
demonstrated high levels of adherence to antiretroviral therapy, as they sustained the 
suppression of viral replication, with a reduced risk of developing resistance (Medicénes Sans 
Frontirés South Africa, 2003). The demonstration project launched reported that 90.6% of 
adults achieved virological suppression within six months after initiation of antiretroviral 
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therapy, and only 1.3% of individuals were reported to be on second-line regimens by the end 
of 2005 (Boulle et al., 2008). 
This demonstration project firmly required potential candidates to undergo an 
assessment of clinical and social conditions, as well as their expected ability to adhere to 
antiretroviral treatment (Medicénes Sans Frontirés South Africa, 2003). Candidates’ ability to 
adhere to antiretroviral therapy was assessed according to their adherence to co-trimoxazole 
prophylaxis and turbuculosis treatments, their ability to attend regular clinic visits and the 
prerequisite of having disclosed their status to at least one other person (Medicénes Sans 
Frontirés South Africa, 2003). 
After the candidates had been enrolled in the demonstration project, they were 
provided with support materials, such as pill boxes and drug identification charts, daily 
schedules, diaries, educational materials explaining the risks and benefits of antiretroviral 
therapy (Medicénes Sans Frontirés South Africa, 2003).They were also required to have a 
treatment assistant, and received peer support through support groups hosted by the clinic 
twice monthly. There they could discuss barriers to adherence, adverse effects, and 
psychosocial problems (Medecins Sans Frontieres South Africa, 2003). 
In the national rollout, the criteria by which candidates were selected for antiretroviral 
therapy changed, as the distribution of antiretroviral therapy became more widespread than 
the Khyalitsha demonstration project. Many of the patients receiving antiretroviral therapy 
did not have access to the same amount of social, psychological and material support, as the 
candidates of the demonstration project. The same level of adherence could therefore not be 
expected from the national rollout patients. Adherence in this group was likely to be much 
lower. 
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1.3 Aims of the present study 
The first aim of the present study was to determine the difficulties patients experience in 
adhering to treatment and care and the factors involved making it difficult for patients to take 
their medication. The second aim was to gain insight into what doctors and nurses perceived 
to be barriers to patients’ adherence to care and their perception of factors that seem to play a 
role in patients’ ability to adhere to medication. The third aim was to uncover the perceptions 
of patient advocates around the issue of patients’ adherence to care and their adherence to 
medication. 
In addressing the above mentioned aims, it was possible to: (a) identify a triangular 
view of the barriers patients face in attending clinic appointments and taking their 
medication; that is from the perspective of patients, clinicians (doctors and nurses) and 
patient advocates, (b) to discuss these barriers through a theoretical framework, which 
included the Bronfenbrenner’s (1972) Ecological Systems Theory. 
1.4 Overview of chapters 
Chapter 2 provides an overview of the HIV pandemic, incidence and prevalence of the HIV 
pandemic, antiretroviral therapy, adherence to antiretroviral therapy, individual barriers to 
antiretroviral therapy, structural barriers to antiretroviral therapy, and a theoretical 
framework. Chapter 3 describes the method that was used for the present study, including the 
research design, the selection of participants, data analysis and ethical considerations. 
Chapter 4 includes the findings of the present study. In chapter five the results are discussed 
and explained by incorporating theory with the findings, the implications of the findings of 
the present study as well as the implications for future research are discussed. 
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CHAPTER TWO: REVIEW OF THE LITERATURE 
2.1 HIV pandemic 
AIDS was first identified as a new pandemic in 1981 (Turkoski, 2006). It took an additional 
two years to isolate and pinpoint the HIV to be the forerunner to AIDS (Turkoski, 2006). 
Unknown 28 years ago, HIV-related causes have already contributed to a human toll of 25 
million deaths worldwide, since the beginning of the pandemic (Joint United Nations 
Programme on HIV/AIDS (UNAIDS), 2008; World Health Organization, 2007). 
In 2000 HIV overtook tuberculosis (TB) as the world’s leading infectious cause of 
adult deaths (Farmer et al., 2001). The HIV and AIDS pandemic has proved to be a global 
pandemic, which continues to be a problem of unprecedented dimensions (WHO, 2007) and a 
critical challenge to health (Department of Health South Africa, 2007). HIV infection and 
AIDS-related conditions have become more important than ever before (Department of 
Health, South Africa, 2007). The total number of infections has increased from around 8 
million in 1990 to virtually 40 million today, and increasing (Department of Health South 
Africa, 2007). As the pandemic developed, a growing number of people are reaching 
advanced stages of HIV infection (Antiretroviral therapy coverage among people with 
advanced HIV infections (percentage), 2008), reducing life expectancy by more than 20 years 
(WHO, 2007). The estimated number of people newly infected with HIV each year continue 
to exceed the increase in the number of people receiving antiretroviral drugs 2.5 to 1 (Joint 
United Nations Programme on HIV/AIDS (UNAIDS), 2008; WHO, 2007). 
2.2 Incidence and prevalence of HIV 
Globally statistics of people living with HIV, indicate that in 2007 there were over 32.3 
million people living with HIV worldwide, and 2.5 million of those being new infections 
within this period. This infection rate indicates that 8,600 individuals were infected with HIV 
per day (Dorrington, Bradshaw, Johnson & Budlender, 2004). In the same year, it was 
7 
 
estimated that 2.7 million people worldwide died because of AIDS, with more than 5,700 
individuals dying of AIDS daily, mainly due to poor access to HIV treatment and prevention 
services (Dorrington et al., 2004). 
Sub-Saharan Africa is the most seriously affected by the HIV epidemic (Joint United 
Nations Programme on HIV and AIDS [UNAIDS], 2008; World Health Organization 
[WHO], 2007). This region accounts for more than a third (32%) of new HIV infections 
globally in 2007, as well as 76% of AIDS-related deaths (Dorrington et al., 2004). AIDS, 
therefore, remains the leading cause of death in this region. 
In South Africa the demographic impact of HIV is even greater (Dorrington et al., 
2004). The Joint United Nations Programme on HIV and AIDS Organization (2008) declared 
South Africa to be the country with the largest number of HIV infections in the world. It was 
estimated that in 2004 more than 5 million of the total South African population of 46 million 
were HIV positive, with a daily infection rate of 1,400 individuals (Burden of Disease 
Research Unit, 2007). HIV and AIDS were also the main cause of death in this region 
(UNAIDS, 2007). The World Health Organization estimated that 1.8 million South Africans 
had died from AIDS-related diseases since the start of the pandemic (WHO, 2007), killing 
336,000 between mid-2005 and mid-2006 alone (Dorrington, Johnson, Bradshaw & Daniel, 
2006). HIV/AIDS accounted for 47% of deaths in 2006, which, without an intervention 
strategy, would account for 75% of premature mortality by 2010 (Burden of Disease 
Research Unit, 2007). In reality the pandemic was taking a bigger toll than shown by 
statistics. Causes of death statistics significantly underestimated the number of AIDS deaths, 
due to stigma associated with HIV and AIDS. Details completed on the death certificate 
tended to focus on opportunistic infections or mechanisms of death rather than providing the 
underlying cause (Dorrington, Bourne, Bradshaw, Laubscher & Timacus, 2001). 
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2.3 Antiretroviral therapy 
Antiretroviral therapy is the main type of treatment for HIV and AIDS (Introduction to HIV 
and AIDS treatment, 2008). The objective of antiretroviral therapy was to treat the illness and 
lessen the concentration of viral load in the blood, or if possible, to maintain it at an 
undetectable level, thereby slowing the evolution of the illness (Gallant, 2000). The greatest 
aim of antiretroviral therapy is to improve the length and quality of the lives of patients living 
with HIV or AIDS (García & Côte, 2003), and to provide infected individuals with control 
over the damage HIV causes to their immune system (Kalichman, 1998). 
These early antiretroviral therapies presented problems, as these therapies were not 
convenient as potent combination therapies expected infected individuals to take more than 
one drug (Introduction to HIV and AIDS treatment, 2008). This could entail taking up to 20 
pills per day (Gulick, 2006). These regimens which involved several medications not only 
included complicated schedules which usually divided every 8 hours in a fasting state 
(Gulick, 2006), but also included dietary restrictions (Safren, Radomsky, Otto & Solomon, 
2002; Weiss et al., 2003; Yeni et al., 2002). Over time the complexity of antiretroviral 
treatment had been reported to lead to poor adherence (Bova, 2000). 
Strategies for antiretroviral therapy are now more successful than those formerly 
available (Centers for Disease Control and Prevention, 1998). Triple-combination therapies 
introduced a dramatic decrease in the incidence of new opportunistic infections, as well as a 
reduction in hospitalisations (Powderly, Landay & Lederman, 1998), and AIDS-related 
deaths in persons with AIDS and those in the intermediate stage of HIV (Hoggs et al., 1998; 
Yeni et al., 2002). 
Taking highly active antiretroviral treatment will be a lifelong requirement (Bova, 
2000) as the dynamic and chronic nature of HIV necessitates these potent and continuous 
therapies for the duration of viral replicative capability (Wainberg & Friedland, 1998). 
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Patients should know that the first regimen more often than not presents the best chance of a 
simple regimen with long term treatment success and prevention of drug resistance 
(Department of Health and Human Services, 2008). The durability of the first regimen first 
and foremost is associated with adherence, tolerability and convenience (Yeni et al., 2002).   
2.3.1 Antiretroviral medications 
2.3.1.1 Combination antiretroviral therapy.  
Combinations of various antiretroviral drugs need to be taken at the same time. If a single 
drug out of these combinations were to be taken on its own, HIV would quickly become 
resistant to it and the drug will not be effective any longer (Introduction to HIV and AIDS 
treatment, 2008). The combination of several antiretroviral drugs into one treatment regimen 
to be taken at the same time immensely decreases the rate at which resistance would develop, 
increasing the success of these antiretroviral combinations in the long run (Introduction to 
HIV and AIDS treatment, 2008). Antiretroviral therapy regimens thus consist of a 
combination of three drugs, which include two Nucleoside/Nucleotide Transcriptase 
inhibitors (NRTIs) plus one Non-Nucleocide Reverse Transcriptase Inhibitor (NNRTI) 
(WHO, 2006).  
2.3.1.1.1 Nucleoside/Neocleotide Transcriptase Inhibitors (NRTIs).  
NRTIs are known to interfere with the action of an HIV protein called reverse transcriptase, 
which is needed for the HIV virus to make new copies of itself (Introduction to HIV and 
AIDS treatment, 2008). NRTIs are also the backbone of antiretroviral therapy combinations, 
and should be used with a companion NNRTI (WHO, 2006). List of Nucleoside/Neocleotide 
Transcripase Inhibitors (NRTIs) indicated in Table 1. 
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Table 1  
Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs) 
Abbreviation Generic name Food restrictions Description of drug 
3TC Lamivudine Take with or 
without food 
Lamivudine (3TC) is vital to all 
first-line ARV regimens in 
resource limited countries. It has 
been proved safe, has a 
favourable toxicity profile, 
relatively cheap to produce and 
widely available. 
ABC Abacavir Take with or 
without food 
Abacavir (ABC), the use is 
generally reserved to second-
line regimens. It provides an 
effective backbone for the use of 
NNRTIs or as part of triple 
nucleoside regimen. ABC is 
associated with severe 
hypersensitivity reaction to 2-
5% of patients who receive the 
drug. 
AZT or ZDV Zidovudine Take with or 
after food 
Zidovudine (AZT) is included 
as  
d4T Stavudine Take with or 
without food 
Stavudine (d4T) is recognized 
as a life saving drug that has 
played a crucial role in ART 
rollout because of its availability 
in FDC’s, the low cost of FDC 
and the clinical efficacy of 
regimens recommended. FDC is 
also preferred over AZT 
because of the requirement for 
limited or no laboratory 
monitoring. d4t may be used as 
substitute for AZT if intolerance 
occurs and TDF and ABC are 
unavailable. 
FTC Emtricitabin
e 
Take with or 
without food 
Emtricitabine (FTC) is a new 
NRTI that has recently been 
included in the WHO’s 
recommended first-line 
regimens. FTC is an equivalent 
alternative to 3TC, and it shares 
the same efficacy against HIV 
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Table 1 Continued 
Abbreviation Generic 
name 
Food restrictions Description of drug 
TDF Tennofovir Take with or 
without food 
Tenofovir (TDF) is included as 
preferred first-line NRTI because of 
efficacy, ease of use and safety 
profile. TDF has a long half life and 
can be used as once-daily regimens. 
Availability of TDF in resource 
limited settings is currently limited 
but it is hoped that it will become 
more available at reduced costs. 
Note: From “Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in 
HIV-1-infected adults and adolescents,” by Department of Health and Human Services, 2008, Retrieved from 
http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. And “Antiretroviral therapy for HIV infection in 
adults and children: Recommendations for public health,” by the World Health Organization. 2006. WHO Library 
Cataloguing in-Publication Data. 
2.3.1.1.2 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs).  
NNRTIs are vigorous drugs, and an important antiretroviral class, to be combined with two 
NRTIs in first-line therapy, and assist the construction of a rather simple initial regimen 
(WHO, 2006). The NNRTIs act by stopping HIV from replicating within cells by inhibiting 
the reverse transcriptase protein (Introduction to HIV and AIDS treatment, 2008). The 
NNRTIs efavirenx (EFV) and Nevirapine (NVP) are well-known for clinical efficacy when 
administered in the proper combination regimen (WHO, 2006). List of Non-Nucleoside 
Reverse Transcriptase Inhibitors (NNRTIs) indicated in Table 2. 
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Note: From “Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in 
HIV-1-infected adults and adolescents,” by Department of Health and Human Services, 2008, Retrieved from 
http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. And “Antiretroviral therapy for HIV infection in 
adults and children: Recommendations for public health,” by the World Health Organization. 2006. WHO Library 
Cataloguing in-Publication Data. 
2.3.1.2 First-line regimens.  
First-line drugs for adults and adolescents infected with HIV include a preferential two 
NRTIs/NNRTI approach, which includes two NRTIs of either (1) Zidovudine (AZT) or 
Stavudine (d4T); or (2) Tenofovir (TDF) or Abacavir (ABC); plus either (3) Lamivudine 
(3TC) or Emtricitabine (FTC) to be grouped with one NNRTI consisting of either (4) 
Efavirenz (EFV) or Nevirapine (NVP) (WHO, 2006).   
The choice of which antiretroviral drug to be included in first-line regimens depends 
on several factors, including (1) the price and availability of antiretroviral drugs, (2) the 
number of pills needed to be taken, (3) the side-effects of the various antiretroviral drugs, (4) 
the laboratory monitoring requirements associated with the various antiretroviral drugs, and 
Table 2 
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs): 
Abbreviation Generic name Food restrictions Description of drug 
EFV Efavirenz Take on an empty 
stomach 
Efavirenz (EFV) can be used once 
daily and is generally well tolerated. 
EFV should be avoided in patients 
with a history of psychiatric 
illnesses, when there is a potential 
for pregnancy and during the first 
trimester of pregnancy. 
NVP Nevirapine Take with or 
without food 
Nevirapine (NVP) is widely 
available and is less costly than EFV. 
The initiation of NVP at the same 
time as other new drugs that can also 
cause rash should be avoided where 
possible. 
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(5) whether there are co-blister packs or fixed dose combinations available (Introduction to 
HIV and AIDS treatment, 2008). 
2.3.1.3 Second-line regimens.  
It was recommended that patients who show virological failure, indicated by resistance to a 
specific combination, or patients whose side-effects are particularly bad, be switched to 
second-line antiretroviral therapy regimen (Introduction to HIV and AIDS treatment, 2008; 
Provincial Government of the Western Cape, 2004). 
Second-line antiretroviral regimens include a minimum of three new drugs, of which 
one drug is from a new class, in order to increase the likelihood of treatment success 
(Introduction to HIV and AIDS treatment, 2008). In the case of second-line antiretroviral 
regimens triple NRTIs can be considered as an alternative to first-line antiretroviral therapy 
regimens. Where NNRTIs provide additional complications protease inhibitors (PI) can be 
introduced to this regimen (WHO, 2006). 
2.3.2 Improved health outcomes due to antiretroviral therapy.  
The development of combination antiretroviral therapy with protease inhibitors contributed to 
a radical transformation of the disease. HIV/AIDS, sometimes a riotous terminal illness, 
which included several opportunistic infections, has become a fairly reversible and 
controllable chronic condition for a considerable amount of people living with HIV and 
AIDS, especially those having access to treatment (Bova, 2000; Nischal, Khopkar & Saple, 
2005; UNAIDS/WHO Working Group on Global HIV/AIDS and STI Surveilance, 2008), 
even when administered at a late stage. The decrease in the incidence of death from AIDS 
and the increased number of people living with HIV/AIDS can be directly ascribed to the 
improvement and widespread use of antiretroviral medication, particularly protease inhibitors 
(Centers for Disease Control and Prevention, 2001a). It was estimated that without 
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antiretroviral therapy 495,000 infected individuals would die due to AIDS-related deaths in 
South Africa by the year 2010 (Dorrington et al., 2004).  
2.4 Adherence to antiretroviral therapy 
Adherence not only entails taking antiretroviral drugs exactly as prescribed (Continuing 
antiretroviral treatment, 2008), but literature also defines adherence to treatment as the match 
between the patient’s behaviour and healthcare advice (Haynes, Sackett & Taylor, 1980), or 
as the reflection of the patient’s desire to participate actively in the treatment regimen and the 
patient’s collaboration with a healthcare professional. 
2.4.1 Non-adherence is a challenge 
Non-adherence had been a predicament for as long as remedies had been prescribed 
(Chesney, 2006). The increase in chronic illness, accomponied by long-term therapies, 
resulted in the recognition that patient non-adherence was an omnipresent and costly problem 
(Chesney, 2006). 
Notwithstanding the advances that had been made in adherence research, non-
adherence rates continued nearly unaffected during the last decade of the previous century 
(Burke, Dunbar-Jacob, & Hill., 1997). The lack of strict adherence to antiretroviral therapy 
was a persistent problem and one of the key challenges to AIDS care worldwide (Van 
Dulmen et al., 2007; Weiser et al., 2003). Because treatment resistant strains emerge after 
even a brief lapse in therapy, non-adherence presents a serious concern. 
2.4.2 The importance of adhering to antiretroviral therapy  
The dawn of antiretroviral therapy meant a second chance at life for patients living with HIV 
and AIDS (Ware et al., 2006). Recognizing the promise of a second chance meant that HIV-
infected individuals may have to receive therapy for many years, if not life (Finzi et al., 1999; 
Ware et al., 2006), and entails a commitment from the patient as well as the healthcare team 
(Department of Health and Human Services, 2008).  
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Medication adherence and regular clinic attendance are essentially vital for successful 
treatment outcomes, functional recovery (Continuing antiretroviral treatment, 2008; Maskew, 
MacPhail, Menezes & Rubel, 2007; Paterson et al., 2000; Wagner & Rabkin, 2000) and to 
attain successful and prolonged viral load suppression in plasma (Bangsberg et al., 2000; 
Bangsberg et al., 2003; Haubrich, 1999). Adherence has shown to be the main determinant of 
the biological outcome measures of HIV (Mannheimer et al., 2005). The significance of 
optimal adherence stems from the fatal consequences that occur otherwise, both in treatment 
efficacy and the development of resistance (Moralejo, Ines, Marcos, Fuertes & Luna, 2006). 
Individuals with high levels of adherence not only sustained therapy over a longer 
period of time (Bangsberg et al., 2003) but also achieved the greatest virological and 
immunological gains (Mannheimer et al., 2005) and slowed progression to AIDS (Bangsberg 
et al., 2000). Therapeutic gain was not achieved by patients who had not properly adhered to 
their antiretroviral regimens (Davies et al., 2006; Wainberg & Friedland, 1998). A 
considerable amount of patients did not receive the maximum benefits from medical 
treatment, resulting in poor health outcomes, lower quality of life and increased health costs 
(Burke & Ockene, 2001). Even short term non-adherence (as little as one week) could result 
in treatment failure (Vanhove, Schapiro, Winters, Merigan & Blanschke, 1996). 
The majority of patients benefit from antiretroviral therapy (Department of Health and 
Human Services, 2008). The likelihood of the success of antiretroviral therapy, however, is 
directly related to the level of adherence and commitment to the therapy (García & Côte, 
2003; Montaner, Hoggs, Raboud, Harringan & O’Shaughnessy, 1998; Vanhove et al., 1996). 
Low adherence or even partial adherence to prescribed antiretroviral medication is possibly 
the key cause of therapeutic failure (Carpenter et al., 2000; Deeks, Smith, Holodniy, & Kahn, 
1997; Liu et al., 2001; Stone et al., 2001), with treatment failure in approximately half the 
patients it has been prescribed to (Valdez et al., 1999).  
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2.4.3 Methods for assessing adherence  
Antiretroviral adherence is important for treatment outcome, but determining adherence 
continues to be a complicated and demanding task (Plipat et al., 2007). While adherence is 
vital to treatment response, it has been found repeatedly that healthcare workers are meagre 
predictors of their patients’ adherence to therapy (Bangsberg et al., 2002; Paterson et al., 
2000). The measurement of adherence to therapy represents a challenge, and there is less 
agreement on the best strategy for assessing antiretroviral therapy adherence, as there is no 
‘gold standard’ of measurement (Chesney, 2006; Simoni et al., 2006). An ideal assessment 
measure would be reliable, valid, logistically practical, and would have low participant and 
staff burden (Simoni et al., 2006). There is no single optimal assessment strategy for all 
situations, even in developed countries (Chesney, 2006). There are many validated tools and 
strategies to choose from (Department of Health and Human Services, 2008). Each of these 
approaches has its strengths and weaknesses.  
Simoni et al. (2006) suggested that adherence to antiretroviral therapy could be 
measured by direct and indirect methods. Direct methods would consist of a biological 
analysis of active drug metaboline or other markers in a patient’s blood, urine or other bodily 
fluids to verify active drug ingestion of antiretroviral drugs. Indirect methods, on the other 
hand, would not measure the presence of antiretroviral drugs in the individual, but rather 
include methods such as self reporting calenders and record of missed doses (Chesney, 2006; 
Ickovics, 1997; Pliphat et al., 2007), clinical assessments, medical chart reviews, clinical 
attendance, pharmacy refill records (Bangsberg et al., 2002; Cramer, Mattson, Prevey, 
Scheyer & Ouellette, 1989; Kagee, 2004; Simoni et al., 2006), electronic drug monitoring 
(Chesney et al., 2000; Wagner & Rabkin, 2000; Waterhouse, Calzone, Mele & Brenner, 
1993) and therapeutic impact data such as immunological and virological data as indicated by 
HIV-1 RNA viral load and CD4 count (Plipat et al., 2007; Simoni et al., 2006). 
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2.4.4 Adherence rates  
Despite the wide recognition it enjoys as vital to treatment success, rates of adherence to 
antiretroviral therapy have commonly been suboptimal (Reynolds, 2004). Expected 
adherence among patients with chronic conditions such as diabetes, arthritis, cardiovascular 
disease and HIV (Chesney et al., 1999; Osterberg & Blaschke, 2005), have been found to be 
particularly low when compared to those with acute conditions, such as flu and appendicitis. 
Van Dulmen et al. (2007) found that treatment adherence among patients with chronic 
conditions dropped most dramatically after six months of treatment. 
Poor adherence is a widespread problem, with as many as two thirds of patients 
adhering to less than 90% of their prescribed doses (Bangsberg & Moss, 1999). The rate of 
non-adherence to antiretroviral therapy is estimated to range between 50% and 70% (Chesney 
et al., 2000; Weiser et al., 2003), in patients taking their antiretroviral medication in 
accordance to dosage, time and dietary restrictions (Reynolds, 2004). Poor adherence is 
associated with poor medical outcomes as measured by viral load or CD4 count (Bangsberg 
et al., 2000). Dangers of non-adherence may even be greater for patients who take simplified 
regimens as compared to more complex ones (Roberts & Mann, 2000). 
Within other therapeutic areas such as diabetes or hypertension, the consumption of 
80% of prescribed doses is believed to be adequate, but is associated with a 50% failure rate 
in antiretroviral therapy (Paterson et al., 2000). Intake of less than 80% of antiretroviral 
medication is not sufficient to demonstrate viral and immunological suppression after six 
months of therapy (Haubrich, 1999). 
Non-adherence rates to HIV therapy are similar to those in other illnesses. However in 
HIV, near perfect adherence to complicated antiretroviral therapy is necessary to obtain 
successful treatment outcomes (Chesney et al., 2000; Sackett & Haynes, 1979). The success 
of antiretroviral therapy largely depends on the patient’s ability to fully adhere to treatment 
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(Kalichman, Catz, & Ramachandran, 1999). Full adherence to antiretroviral therapy is 
considered to be an adherence level of more than or equal to 95%. This level is necessary to 
sustain total supression of the virus and prevent the development of resistance to the therapy 
(Chesney et al., 2000; Gulick, 2006; Kitahata et al., 2004; Nischal et al., 2005; Paterson et al., 
2000; Plipat et al., 2007). Patients with levels of 95% or higher had superior virological 
outcome, a greater increase in CD4 lymphocyte count, lower hospitalization rate than those 
with lower levels of adherence (Paterson et al., 2000). However, adherence rates to treatment 
and to medical recommendations are rarely that high (Darnell, Murry, Martz & Weinberger, 
1986). 
2.4.5 The consequence of poor adherence 
2.4.5.1 Quality of life, morbidity and mortality.  
Patients who are non-adherent to antiretroviral therapy regularly demonstrate negative health 
outcomes which may impact not only on their morbidity and mortality, but also on their 
quality of life (Dick, Schoeman, Mohammed & Lombard, 1996; Lange, 2003; Ledergerber et 
al., 1999). Adherence to antiretroviral regimens allow for the level of HIV in an infected 
person’s blood to remain suppressed, and for CD4 counts to remain at a high level. These can 
greatly improve the quality of life (Turkoski, 2006). Antiretroviral therapy can also prolong 
the infected patient’s life, as patients with a high level of adherence sustained therapy over a 
longer period of time than those with a low level of adherence (Bangsberg et al., 2003; García 
& Côte, 2003). 
2.4.5.2 Mutation of the virus and the development of resistance.  
As adherence decreases, failure rates sharply increases with the dose-response effect 
(Ickovics & Meade, 2002). The lack of strict adherence results in inadequate dosage, which 
allows for HIV to rapidly mutate and form new variants of the virus (Kalichman et al., 1999). 
This may then contribute to resistance to a particular treatment regimen. Patients who miss as 
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few as 5% of their scheduled doses of antiretroviral medication demonstrated major setbacks 
(Paterson et al., 2000). This 5% non-adherence rate can rapidly lead to virus mutation, 
resistance to current medication and the development of medication resistant strains of the 
virus (Mellors, Riley, & Erlen, 1997).  
Once resistance to one particular antiretroviral therapy has occurred, it may be 
necessary for patients to resort to second-line drugs (Kalichman, 1998). Second-line 
antiretroviral medications may prove to be problematic, as they’re not available in generic 
drugs and cost approximately $1500 per patient per year in comparison to first-line generic 
antiretroviral regimens priced at $150 per person per year (Mukherjee, Ivers, Leandre & 
Farmer, 2006). 
2.4.5.3 Development of opportunistic infections.  
Patients infected with HIV are at risk of developing opportunistic infections which might 
include Pneumocystis carinii pneumonia, cytomegalovirus retinitis, various oral diseases and 
complications, changes in bone mass, and increased risk for bone diseases, cervical cancer, 
kaposi sarcoma, toxoplasmosis, tuberculosis, nontuberculosis mycobacterial disease, 
esophageal candidiasis and non-hodgkin lymphoma (Ledergerber et al., 1999; 
UNAIDS/WHO Working Group on Global HIV/AIDS and STI Surveilance, 2008). The use 
of antiretroviral therapy is crucial to successfully control opportunistic infections, because it 
contributes to the recovery of the immune function by halting virus induced immunologic 
damage (Powderly et al., 1998), which considerably lessen the risk of suffering from 
opportunistic illnesses (Heiden et al., 2007). AIDS-related opportunistic illnesses continue to 
occur due to poor adherence (Michelet, 1998). When patients do not properly adhere to their 
antiretroviral therapy regimen, it leads to a less durable regimen which contributes to an 
increase in the incidence of opportunistic infections among HIV-infected individuals (Glor & 
Smith, 2005). 
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2.4.5.4 The importance of adhering to antiretroviral therapy for public health. 
Adherence to antiretroviral regimens is essential, not only for the health of the individual 
patients, but also for the public as a whole (Roberts & Mann, 2000). The problem is of 
significant clinical importance at both individual and collective level, given the transmission 
of multidrug-resistant strains into the community, may reduce the advances made in 
antiretroviral therapy (Chesney, 2006; Imrie, Beveridge, Genn, Vizzard & Cooper, 1997; 
Moralejo et al., 2006; Wainberg & Friedland, 1998). Patients with suboptimal adherence to 
antiretroviral therapy and poor adherence to the use of safer sex practices, such as the use of 
condoms, may infect others with their own antiretroviral drug-resistant strain virus (Paterson 
et al., 2000). Proper adherence to antiretroviral therapy have shown success in reducing the 
viral load in an infected individuals’ blood and genital secretions, this implies that successful 
antiretroviral therapy have the potential to decrease the possibility of transmission of the HI-
virus to others (Wainberg & Friedland, 1998). 
2.5 Individual barriers to antiretroviral adherence 
Prevalence and consequences of poor adherence to HIV medication have frequently been 
acknowledged in literature (Altice & Friedland, 1998; Forgarty et al., 2002; Murri et al., 
2000). Reasons that may add to non-adherence are abundant and may vary depending on 
population and setting (UNAIDS/WHO Working Group on Global HIV/AIDS and STI 
Surveilance, 2008). The reasons involve far more than simply failing to take medication 
(Chesney, 2006) but also include factors such as sleeping through scheduled dosage times, 
patient and regimen characteristics, such as adverse side-effects (Davies et al., 2006), 
relationship with healthcare providers (Rabkin & Chesney, 1999), beliefs in the drugs’ 
effectiveness.  
Research on barriers to treatment adherence has almost exclusively focused on 
individual psychological and behavioural barriers (Kagee, 2004), such as stigma, fear of 
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disclosure (Ware et al., 2006), beliefs and perceptions about self-efficacy, perceptions about 
illness and social support (García & Côte, 2003). Substance abuse and emotional distress can 
also diminish adherence to medical regimens such as antiretroviral therapy (Kalichman et al., 
1999). 
Demands for adherence may not always be perceived by patients as the highest 
priority, and often compete with those factors created by other life stressors such as poverty, 
homelessness and even discrimination (Remien, Hirky, Johnson, Weinhardt & Le, 2003). 
Understanding these reasons is essential to develop interventions that will improve adherence 
to therapeutic regimens among people living with HIV/AIDS (García & Côte, 2003) 
2.5.1 Regimen characteristics. 
2.5.1.1 Forgetfulnes.  
Forgetting is the main reason patients give for missing their dosages (Chesney, 1997; 
Chesney et al., 1999), especially when patients are asymptomatic (Kagee, 2004). Other 
reasons connected to forgetfulness include explanations of “was busy”, or “was away from 
home” (Reynolds, 2004). Although forgetfullness is cited as the primary reason for non-
adherence, non-adherence involves far more than simply forgetting to take medication 
(Chesney, 1997). 
2.5.1.2 Pill burden.  
Even though antiretroviral treatment provides benefits, it is often complicated and 
challenging, which can make extraordinary demands on individuals infected with HIV, as 
patients need to take pills for an indefinite period of time (Gordillo, Del Amo, Soriano & 
Gonzalez-Lahoz, 1999; Roberts & Mann, 2000). Previous studies done on HIV-infected 
patients and patients with other chronic diseases indicated that the rate of adherence is likely 
to decrease as the the number of medications, the frequency of dosages, and the increasing 
complexity and duration of the treatment increase (Berg et al., 2007; Samet et al., 1992). The 
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interaction among medications, and between food and medication may easily lead to 
confusion, also contribute to non-adherence (Haynes, 1979; Moyer et al., 1999; Nischal et al., 
2005; White, 2005). The size of pills has also been reported to be an issue (Starting 
antiretroviral treatment, 2008). It has been reported across a variety of medical disorders and 
diseases, such as hypertention, diabetes, and vascular disorders that less frequent dosage 
results in better adherence (Van Dulmen et al., 2007). 
2.5.1.3 Side-effects.  
Often experiencing side-effects makes it hard for patients to adhere to antiretroviral therapy 
(Chesney, 1997; Continuing antiretroviral therapy, 2008; Wall et al., 1995). The link between 
side-effects and non-adherence seems to be one of which HIV positive people are aware of, 
with side-effects being cited time after time as a reason for non-adherence (Chesney et al., 
2000). Up to half of patients on antiretroviral therapy may encounter the unpleasant effects of 
medication (Felley et al., 2001). The truth is that many patients may face the downsides of 
therapy, long before they see the benefits if they ever do (Glor & Smith, 2005; Walsh, Horne, 
Dalton, Burgess & Gazzard, 2001). 
The downside of antiretroviral therapy vary according to regimens, and may include 
nausea, fatigue (Continuing antiretroviral therapy, 2008), chronic diarrhea, abnormal fat 
distribution, weight changes, anemia, peripheral neuropathy (Bova, 2000), hypersensitivity, 
lactic acidosis, increased blood lipids, bleeding events, lipodystrophy and pancreacitis 
(UNAIDS/WHO Working Group on Global HIV/AIDS and STI Surveilance, 2008). Side-
effects from HIV treatment impact not only a patient’s adherence to therapy, but also impact 
on the quality of the life of the patient (Johnson & Neilands, 2007). Side-effects may also be 
viewed as controllable, that is that one has the power to stop medications and consequently 
eliminate the side-effects of antiretroviral therapy (Johnson & Neilands, 2007). 
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2.5.2 Patient characteristics 
2.5.2.1 Demographic characteristics.  
In general sociodemographic factors do not seem to predict behaviour related to adherence, 
even though some studies found that male sex, white ethnicity, older age, higher income and 
higher education and literacy correlated with better adherence (Icovics & Meade, 2002). 
Some studies confirmed race and ethnic background to be associated with treatment 
adherence (Kalichman et al., 1999; Metha, Moore, & Graham, 1997). Although ethnicity 
appears to be important in predicting HIV treatment adherence, the mechanisms that account 
for these differences are unknown (Kalichman et al., 1999). 
2.5.2.2 Emotional distress.  
Poor adherence has been related to unsuccessful life events, depression, depressive 
symptoms, emotional upset (Catz, Kelly, Bogart, Benotsch & McAuliffe, 2000; Sarna et al., 
2008; Sullivan, Dukes, Harris & Dittus, 1995), anxiety, hopelessness, and other patient 
factors related to decreased adherence including dementia, psychosis, and personality factors 
(Penna & Treisman, 2005).  HIV positive people with relatively high levels of depression and 
low sense of social support were less likely to follow medication and health advice, and to 
keep appointments than people with a high sense of social support (García & Côte, 2003). 
Emotional and cognitive disturbances that occur as part of the depressive symptom picture 
may inhibit the patient’s ability to concentrate and to remember important details, such as the 
recommended time of day or the sequence of administrating the medications (Kagee, 2004). 
Depression can reduce the motivation to seek healthcare, impare adherence to prescribed 
treatment, decreased quality of life, and increased mortality (Cook et al., 2004). 
2.5.2.3 Health literacy.  
Knowledge of medication instructions is certainly a requirement for adherence (Weiss et al., 
2003). A higher level of adherence is related to sufficient knowledge of treatment, and the 
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costs of poor adherence (Schuman et al., 2001). Knowledge may also encourage the 
development of adherence-related skills that may increase motivation, or it may be that 
knowledge is a substitute for motivation. A person, who makes the effort to learn about an 
illness, will also make the effort to control it (Weiss et al., 2003). 
2.5.2.4 Patients’ beliefs.  
Attitudes and beliefs about the normative behaviour have also been shown to play a role in 
adherence (Kagee, Le Roux & Dick, 2007). A greater belief in one’s ability to adhere to 
antiretroviral therapy and the confidence in its benefits were associated with higher quality of 
health and health functioning (Reynolds, 2004). Positive beliefs that antiretroviral regimen 
would prolong life or improve the RNA level are associated with improved adherence 
(Paterson et al., 2000). 
2.5.2.5 Patient literacy and self-efficacy.  
Low literacy and low self-efficacy are factors associated with poor adherence to antiretroviral 
treatment (Kalichaman et al., 1999; Schuman et al., 2001). In general, patients with low 
literacy have less knowledge of the management and treatment of their chronic diseases and 
have poor disease outcomes (Hope, Wu, Tu, Young & Murray, 2004). The ability to read and 
comprehend medical instructions play an important role in treatment adherence (Kalichman 
et al., 1999), as patients with low literacy have the highest rate of non-adherence. Wolf et al. 
(2007) found that patients with marginal literacy skills were least likely to self-report missing 
any dosages of antiretroviral therapy. Poor patient literacy was associated with a more than 
three times greater likelihood of missed doses, as these patients were 3.3 times more likely to 
be non-adherent to their antiretroviral regimen (Wolf et al., 2007). Higher levels of literacy 
was associated with a more than 95% adherence rate (64% of those who adhered had an 
education level equal or above ninth grade, versus a 40% who had an eduction level below 
ninth grade) (Graham, Bennett, Holmes & Gross, 2007). Certain individual characteristics of 
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people with low literacy may create obstacles for direct patient-physician communication 
and, in turn, increase the likelihood of embracing mistaken beliefs (Wolf et al., 2005). An 
example of this is incorrect perceptions of the goals of HIV medications (Kalichman et al., 
2001). 
In addition to the likelihood of poorer knowledge of HIV treatment, patients reported 
lower self-efficacy for taking medication as prescribed (Wolf et al., 2007). Self-efficacy 
refers to individuals’ own perceived ability to perform specified behaviours or sets of 
behaviour (Wolf, et al., 2007), and is associated with higher antiretroviral therapy adherence 
(García & Côte, 2003; Reynolds, Testa, Su, Chesney & Robbins, 2003). If low literacy were 
a significant risk factor for improper adherence to medication, then self-efficacy mediated the 
relationship between the two (Wolf et al., 2007). Self-efficacy, but not knowledge, mediated 
the impact of low literacy to medication adherence (Wolf et al., 2007). Self-efficacy relating 
to the managing of medication may explain why many lower literate patients may not adhere 
to their antiretroviral therapy (Wolf et al., 2007). Self-efficacy has previously been 
investigated in a variety of contexts; it was repeatedly found to be a measure to predict the 
likelihood of initiating communication (Makoul & Roloff, 1998), and the likelihood of 
adjusting to illness and treatment (Forsyth & Carey, 1998).Self-efficacy was also found to 
contribute to individuals’ confidence about the benefits of antiretroviral therapy and to adhere 
to it (Reynolds, 2004). 
2.5.2.6 Relationship with healthcare provider.  
A supportive relationship with healthcare providers is as imperative as the decision to begin 
with antiretroviral therapy (Trzynka & Erlen, 2004). Trust and collaboration between the 
patient and the healthcare provider positively reinforce the patient’s adherence to medication 
(Catz et al., 2000). Research suggests that only 50% of professional advice is likely to be 
taken by patients (WHO, 2001). Poor patient adherence to medical treatment and advice has 
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wide-ranging consequences that include medical and psychological complications, associated 
with the disease, which compromise the patient’s quality of life and also cause a waste of 
healthcare resources (Cleemput & Kesteloot, 2002). 
2.5.2.7 Social Support.  
Social support has proved to be a strong predictor of medical adherence (Reynolds, 2004; 
Simoni et al., 2006; Williams & Bond, 2002). Social support can be defined as 
encouragement from family and friends for patients to co-operate with the prescriptions of 
health professionals (WHO, 2001). Social support comes from many sources such as the 
provider-patient relationship, family, significant others, peers and networks within the 
community (Trzynka & Erlen, 2004). Social support can be directly enhanced by providing 
reinforcements or reminders, or indirectly by enhancing patient motivation or mitigating the 
negative effects of other stressful events (Singh, Berman, Swindells, Mohr & Squire, 1999). 
2.5.2.8 Stigma.  
AIDS-related stigma is a major barrier to HIV treatment. HIV is a stigmatizing disease 
(Davies et al., 2006). Stigmatizing attitudes to HIV and those most at risk of HIV infection 
derive from the fear of infection and a negative value based on assumptions about people 
living with HIV. These factors fuel prejudice and discrimination (UNAIDS/WHO Working 
Group on Global HIV/AIDS and STI Surveilance, 2008). The public and private nature of 
pill-taking behaviour has also created a new domain for adherence barriers (Davies et al., 
2006). 
2.5.2.9 Substance abuse.  
Alcohol and drug abuse have frequently been reported to have a relationship with not only 
risky behaviours and exposure to HIV, but have also been associated with poor adherence 
and poor appointment keeping (Trzynka & Erlen, 2004). The abuse of substances also 
influences the effectiveness of antiretroviral therapy, not only by affecting the adherence to 
27 
 
regimen, but also through an independent mechanism (Garcia & Cote, 2003). Alcohol 
consumption has also been shown to have a direct effect on HIV progression (Parsons, Rosof, 
& Mustanski, 2008). Better adherence was associated with recent abstinence from a moderate 
to high-risk level of alcohol use (Parsons et al., 2008). 
2.6 Structural barriers to antiretroviral adherence 
Biomedical and behavioural research have dealt primarily with HIV at the level of the 
individual, but reasons for non-adherence are complex involving more than the patient’s 
characteristics and attitudes (Sumartojo, 2000). Literature suggests there is more to 
antiretroviral therapy adherence than simply remembering to take medications, but it is rather 
a complex issue, involving social, cultural, economic and personality factors as well 
(Chesney, 2006).  
Because there are multiple levels of causation research on antiretroviral adherence 
needs to target various levels, including individuals and their environments. Many view 
behaviour as personally motivated or exclusively resulting from a person’s conscious 
decisions (Sumartojo, 2000). By solely looking at the individual psychological and 
behavioural barriers, adherence knowledge or motivation is explained without addressing the 
root or the context that contributes to poor adherence. The role of the environment is often 
overlooked (O’Leary & Martins, 2000). 
These factors have different names in literature, such as environmental, structural, 
societal, political, and contextual factors, often reflecting the disciplines of the writers 
(Sumartojo, 2000). HIV-related structural barriers are defined as the barriers to, or facilitators 
of an individual’s adherence behaviour, which may relate to economic, social, polical, 
organizational or other aspects of an individual’s environment (Sumartojo, 2000). 
Little emphasis has been placed on the structural barriers or structural facilitators to 
treatment adherence which individuals may have little direct control over (Garcia & Cote, 
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2003). Sumartojo (2000) suggested that research should focus on the environment, to the 
same extent as research had, until recently, focused on individual and psychological factors. 
Demands for adherence often compete with other life stressors, such as poverty, and is 
therefore not always perceived by patients as the highest priority (Remien et al., 2003). 
Parker and Easton (2000) suggested that most research on structural factors could be 
grouped into a smaller number of analytically distinct but interconnected categories such as 
economic (under)development and poverty, migration, seasonal work, and social disruption. 
Kagee et al. (2010) also suggested that structural barriers could be grouped into categories, 
but divided into more detailed sub-categories namely, poverty-related structural barriers, 
institution-related factors, and social and community-related barriers. According to these 
authors poverty-related structural barriers would include poverty, transport, and food 
insecurity, lost wages, disability grants and migration. Institution-related factors would 
include barriers related to the healthcare facility, overburdened healthcare facilities, and 
clinicians as well as medical resources available to patients. Lastly, social and community-
related barriers would include stigma, disclosure, religion, culture, substance abuse 
programmes, and social resources. 
Poverty-related factors are outside an individual’s control. In the South African 
context these factors include lack of transport, lack of food security, out-of-pocket fees 
associated with travelling, as well as factors related to healthcare institutions and to social 
and community-related barriers (Sumartojo, 2000).These poverty-related factors are more 
significant barriers to the adherence to long-term antiretroviral therapy than patients’ 
individual behaviour (Mukherjee et al., 2006). 
2.7 Theories to understand adherence 
According to Eccles, Grimshaw, Walker, Johnson and Pitts (2005) theory provides a 
“coherent and non-contradictory set of statements, concepts or ideas, organizes, predicts and 
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explains phenomena, events, and behaviour”. Although theory played an important part in 
explaining adherence behaviours, existing theory has primarily been developed from 
individual psychological and behavioural research into social and cognitive theories (Kagee, 
2008; Remien et al., 2006). These theories include the Health Belief Model, Theory of 
Reasoned Action, and Theory of Planned Behaviour. 
2.7.1 Health Belief Model 
The Health Belief Model was proposed by Rosenstock in 1966 (Rosenstock, Strecher, 
Becker, 1988). The basic components of this model attributes adherence to two variables: (1) 
the value patients place on a particular goal; and (2) the patient’s estimate of the likelihood 
that a certain action will contribute to a particular goal (Mainman & Becker, 1974). When 
these variables are conceptualized within the context of adherence behaviour, the associations 
are: (1) the desire to achieve good or better health; and (2) the belief that adherence will 
improve the patient’s health (Janz & Becker, 1984). Furthermore, the Health Belief Model 
also theorizes that patients are more likely to adhere to treatment under conditions which 
include: (1) them at least possessing some health knowledge and being motivated to stay 
healthy; (2) them clearly perceiving HIV as a serious medical and health problem; (3) them 
being convinced that ARV treatment is effective, meaning that it is possible for them to 
obtain control over the disease at an acceptable cost and that the cost does not outweigh the 
benefits; and (4) the presence of an internal or external stimulus referred to as a “cue to 
action”, which would include barriers that prohibit the patient from adhering to ARV 
treatment (Ilongo, 2004). Thus, the Health Belief Model proposes that if the patient was 
presented with the facts and alternatives surrounding ARV treatment, the patient would 
adhere (Kagee, 2008). 
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2.7.2 Theory of Reasoned Action and Theory of Planned Behaviour 
The Theory of Reasoned Action was first introduced by Ajzen and Fishbein (1980) and 
assumed that the patient’s intent to perform a given health behaviour was influenced firstly, 
by their attitude towards a given action; and was based upon their positive or negative beliefs 
and evaluation of the outcome of the given action (Munro, 2007). Secondly, the decision to 
perform given health behaviour was also based upon the subjective norms or perceived 
expectations of important others and the motivation for the patient to comply with others’ 
wishes (Munro, 2007). Self-efficacy is a third influencing factor, i.e. the patient’s sense of 
self control and perception of their ability to perform a given health action (Spring, 2008). 
Thus, the Theory of Reasoned Action assumes that adherence behaviour is under the 
volitional control of the patient, and intention to be adherent is the single best indicator of 
their motivational readiness to act (Prochaska & Velicer, 1997; Sutton, 1997). 
The Theory of Reasoned Action was renamed by Ajzen (1985) as the Theory of 
Planned Behaviour adding the concept of perceived control over opportunities, resources and 
skills necessary to perform particular health behaviours. This concept of perceived 
behavioural control is similar to the concept of self-efficacy as proposed by the Theory of 
Planned Behaviour, which, instead of only focusing on the perception of control over 
personal capabilities, also includes external circumstances (Munro, 2007). 
2.7.3 Social Action Theory 
Although the previous theories mainly described adherence in terms of social cognitive 
theory, Ewart’s (1991) Social Action Theory touches on social context when understanding 
adherence as a health behaviour. According Johnson et al. (2003) and Gore-Felton et al. 
(2005) this theory proposes that health behaviours result from the interaction between three 
domains: (1) the self-regulation capabilities of the patient such as the adherence self-efficacy 
and treatment expectations; (2) responses to internal affective states that influence the self-
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regulation process, such as depression, anxiety and positive affect; and (3) the larger 
environmental context, which include socio-demographic and treatment variables. Thus, this 
theory ascribes patients’ ability to be adherent to ARV treatment to their ability to change 
behaviours that endanger their health. This ability to change behaviour is influenced by the 
patient’s self-change processes (cognitive capability, information processing, self-efficacy, 
outcome expectancies, social skills, self-regulation skills, rewards). It is also influenced by 
contextual factors such as environmental factors and social interactions that encourage or 
discourage the change process (Ewart, 1991). 
2.8 Theoretical framework for this study 
While the previously mentioned social and cognitive theories were mainly based upon 
individual psychological and behavioural barriers and explained adherence behaviour 
accordingly, the present study will explain adherence according to an ecological perspective 
as such a theory posits multiple levels of influence and reciprocal causation (Chisholm et al., 
2007). A theory such as Bronfenbrenner’s (1972) Ecological Systems Theory thus has the 
potential to illustrate how structural factors may act as barriers or facilitators to individual 
adherence behaviour. Ecological Systems Theory (Bronfenbrenner, 1975), suggests that 
behaviour is shaped by three levels of environmental influences, namely the intermediate 
environment such as the family in which a person operates, social institutions such as the 
healthcare system, transportation system, local economy, and the larger social and 
community context in which people live (Bronfenbrenner, 1975). 
2.9 Conclusion 
The present chapter indicated the scale of the HIV and AIDS pandemic on a global as well as 
a local level. The importance of ART regimens and the importance of precise adherence to 
ART have also been stressed, since non-adherence to ART impacted on both individuals and 
their communities. However, to date adherence behaviour was mainly addressed in the 
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context of individual psychological and behavioural barriers, with very little focus on the 
barriers present within the patient’s context or environment.  
In the next chapter the following will be reported on: the method of collecting the data 
on the structural barriers to ART adherence, recruitment of participants, informed consent 
procedures, data analysis and ethical approval. 
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CHAPTER THREE: METHOD 
In the present study a qualitative research design was used. 
3.1 Participants 
By means of convenience sampling, a total of 26 participants were recruited to participate in 
the study. The sample comprised four groups, namely, patient advocates (n=10), patients 
(n=10), doctors (n=3) and nurses (n=3).  
For the patients to be eligible to take part in the study, they had to (1) have a formal 
clinical diagnosis of HIV, (2) be enrolled in the antiretroviral treatment programme offered at 
Helderberg Hospital. 
Healthcare workers (nurses and doctors) enrolled in the study were employed at 
Helderberg Hospital and working at the Infectious Diseases Clinic with HIV patients enrolled 
in the ART programme. Patient advocates were employed by the Phillipi Trust, a local non-
governmental organization (NGO) that provides HIV positive patients with psycho-social 
support.  
3.1.1 Recruitment of the participants 
3.1.1.1 Patient advocates.  
Patient advocates were recruited from Phillip Trust, an NGO in Somerset West that provides 
psycho-social assistance to HIV-infected individuals in the local community. Two groups 
consisting of five participants each were recruited to take part in focus groups. One of the 
research team members contacted the head of the Phillipi Trust who then arranged for 
participants to take part in the focus groups. 
3.1.1.2 Patients.  
Patients were recruited through the Phillipi Trust to take part in semi-structured interviews. 
Patients were contacted by the patient advocates at the Phillipi Trust, informed about the 
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study and invited to participate. Appointments were made with patients who agreed to 
participate in the study and meetings with them were held at the Phillipi Trust offices.  
3.1.1.3 Healthcare workers.  
Healthcare workers were recruited to take part in semi-structured interviews. This group 
consisted of registered nurses and medical doctors from the Helderberg Hospital. The 
healthcare workers were identified by the Head of the Infectious Diseases Clinic at 
Helderberg Hospital. After they were identified as viable candidates for the study, they were 
approached by one of the research team members, and were presented with the option to take 
part in the semi-structured interviews, or to decline if they so wished. 
3.1.2 Informed consent procedures 
The nature of the study was explained to all three groups of participants in a private room, 
either at the Infectious Diseases Clinic at Helderberg Hospital, or at the Phillipi Trust offices 
in Somerset West. All the participants were approached as prospective candidates, and 
invited to take part in this study. In this private room they were informed that: (1) their 
participation was entirely voluntary, that they could decline if they so wished, and that they 
had the right to withdraw from the study at any time; (2) that there were no foreseeable risks 
involved in participating in this study; (3) that they would not directly benefit from this study, 
but would receive a R50 grocery voucher and R20 for transportation, as appreciation for their 
participation in the project. Patient advocates were also provided with R20 as contribution 
towards their transportation fees; (4) All participants were informed that their input would be 
entirely confidential, and that the research team were the only ones who would have access to 
the interview material; (5) Patients were also informed of their anonymity once the data was 
processed, and that their names would not be made public in any way; (6) Their responsibility 
would be to take part in a semi-structured interview or focus group in the case of patient 
advocates, and that they would be encouraged to elaborate on their responses; (8) It was also 
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explained to them that there would be absolutely no consequences should they wish not to 
participate; (9) Lastly, they were informed about the intended use of a tape recorder to record 
the interviews or focus groups, in order for data to be transcribed and analysed. 
After the above was explained to them, they were asked to verbally confirm their 
participation. Once they confirmed that they wished to participate in the study, they were 
asked to sign an informed-consent form, indicating that they understood what had been 
explained to them, and that they formally acknowledge their participation.  
After the interviews or the focus groups, patients were presented with the opportunity 
to ask any questions they might have. Patients were then presented with a R50 grocery 
voucher and a R20 contribution towards their travelling expenses, as an expression of 
gratitude. Patient advocates were also presented with a R20 contribution towards their 
travelling expenses. 
3.2 Data collection methods 
Data was collected through semi-structured interviews conducted with patients and healthcare 
givers, as well as two focus group discussions conducted with patient advocates. The semi-
structured interviews involving patients were conducted at the Phillipi Trust offices, while 
interviews involving doctors and nurses were conducted at Helderberg Hospital, both 
locations in the vicinity of Somerset West. The semi-structured interviews were carried out 
by a research team, consisting of a project supervisor, two honours students from the 
Department of Psychology at Stellenbosch University, and the principal researcher. The 
interviews lasted an hour on average, and were recorded on tape, for the purposes of 
transcription and analysis of the data obtained. 
The focus group discussions involving patient advocates from the Phillipi Trust were 
conducted at Stellenbosch University. The focus groups were lead by the project supervisor. 
Both focus groups lasted an hour, and were also recorded on tape, for the purposes of 
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transcription and analysis of the data obtained. Interview schedules are presented in 
Appendix A and B.  
3.3 Data analysis 
The semi-structured interviews and focus group discussions were recorded digitally, with the 
consent of the participants. These digital recordings were then transcribed in a Microsoft 
Word document. The transcriptions were then saved in a plain text format in order to be 
entered into the Atlas.ti programme, which assisted with the thematic analysis of the 
transcriptions. 
A codebook was constructed in order to code transcriptions accurately. Transcriptions 
from patient interviews (n = 2), doctors (n = 1), nurses (n = 1), and FGD with patient 
advocates (n = 1) were used to create the codebook. The transcriptions were examined for 
codes that arose within the transcriptions. According to these codes, the codebook was 
established, consisting of the code, the definition of the code, as well as an example of a 
quotation matching the definition of the code. See Appendix C, D and E for the codebooks. 
Initially the transcriptions were divided into three groups, namely patients, patient 
advocates and clinicians, which consisted of the doctors and nurses. Each of these categories 
was coded according to two to three main headings, which has taken a similar format in the 
three categories. (1) Patients were coded in terms of two main headings of patient individual 
factors (PIF), and patient identified structural barriers (PISB). (2) Patient advocates were 
coded in terms of three main headings of patient advocate experiences (PAE), patient 
advocate-identified individual factors (PAIIF), and patient advocate-identified structural 
barriers (PAISB). (3) Lastly, the clinicians were also coded in terms of three main headings, 
consisting of clinician experiences (CE), clinician-identified individual factors (CIIF), and 
clinician-identified structural barriers (CISB). Underneath each main heading, the 
transcriptions were finally coded according to the sub-themes that had arisen in the 
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transcriptions. After coding each category individually, families were made of themes 
relating to one another, with the assistance of Atlas.ti. Networks were then established 
making a clear distinction between the different main headings and sub-themes that arose 
from the transcriptions. After the completion of families and networks, it was possible to do a 
codes output table and a quotations output table. The codes output table indicated the 
frequency the different codes had arisen in the different transcriptions, as well as the sum 
total of the frequency between all transcriptions. The quotations output table illustrated the 
quotations underneath each code individually. 
After the completion of the coding, the codebook was revised to ensure conceptual 
clarity, by making certain that all the codes, definitions and quotations correlate with each 
other as closely as possible. The quotations output table was then used to check the 
quotations against the codebook, to ensure they all satisfy the criteria set by the codebook. 
The three categories were then collapsed into one document, and coded again with the 
assistance of the codebook. Families were then established according to similar themes that 
had arisen in the transcriptions. Networks were established for a second time to make a clear 
distinction between the different main headings and sub-themes that arose from the 
transcriptions. The barriers identified through the coding of the transcriptions were then 
discussed in terms of General Systems Theory in Chapter 5. 
3.4 Ethical approval 
The ethical approval needed to conduct this study was obtained from the Committee for 
Human Research at Stellenbosch University, the Western Cape Department of Health, the 
superintendent of Helderberg Hospital, and the director of the Infectious Diseases Clinic at 
Helderberg Hospital. Ethical approval is presented in Appendix F and G. 
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CHAPTER FOUR: RESULTS 
Patient advocates and clinicians readily responded to the request to participate in the focus 
group discussions and semi-structured interviews respectively. None who was approached 
turned down the opportunity to participate in the study. At the onset, some patients appeared 
reluctant to participate in the study, as they thought it would take up their time and that they 
would be late for their transportation. This obstacle was overcome by asking patient 
advocates to schedule appointments with patients and accompany them to interviews. Patient 
advocates and clinicians keenly shared their perceptions about the barriers patients 
experienced in taking their ART. Patients on the other hand appeared to need more prompts 
and cues during the semi-structured interviews to share the difficulties they experienced in 
adhering to their medication and care. Codenames were used to ensure the anonymity of the 
participants. 
The following themes emerged from the interviews with patients, clinicians and focus 
group discussions with patient advocates: (1) individual barriers, (2) poverty-related barriers, 
(3) institution-related barriers, and (4) social and community-related barriers. Within these 
four themes, sub-themes were also identified. All the themes and sub-themes will be 
discussed in this chapter. Table of themes was attached in Appendix H. 
4.1 Individual barriers to ART adherence 
Focus group discussions with patient advocates, and semi-structured interviews conducted 
with patients and clinicians recognized five individual barriers that related to patients’ 
adherence behaviour. These barriers were: (1) forgetfulness, (2) health literacy, (3) literacy, 
(4) medication, and (5) mental health. 
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4.1.1 Forgetfulness 
Forgetfulness as a barrier to ARV treatment adherence was associated with patients’ inability 
to remember not only to take their medication, but also to do so at a scheduled time and 
according to prescribed directions. 
Clinicians. Forgetfulness as a barrier to adherent behaviour was identified by two of 
the nurses from the sample. Sisters Kabini and Kekaba, both registered nurses at the 
Infectious Diseases Clinic indicated that patients would often go without their medications 
for days due to their forgetfulness to take it or to obtain it from the hospital pharmacy during 
scheduled clinic visits. According to sisters Kabini and Kekaba, respectively: 
... some said they will, they forgot their tablets here then they just go without tablets. 
… people are tending to forget. We are human beings and we tend to forget. 
Discrepancies. It was clear that for the nurses, the patients’ forgetfulness was a salient 
theme. However, patient advocates and the patients themselves did not indicate forgetfulness 
as a barrier to adherent behaviour. The effect of forgetfulness identified by the nurses was 
concerned with actual pill-taking behaviour, and did not extend to the patient’s ability to 
remember to attend scheduled clinic visits. 
4.1.2 Health literacy 
Health literacy was associated with patients’ ability to understand information related to HIV 
and ART, and their ability to make decisions around adherence to ART treatment and care. 
These decisions were based on information and perceptions of the patients.  
Patient Advocates. Patient advocates from both focus group discussions testified to 
patients’ lack of knowledge and misguided perceptions about HIV and ART. The patient 
advocates indicated that these misguided perceptions caused patients significant distress. 
Misguided perceptions reported by the patient advocates included the perception that TB 
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would develop into HIV, or that they would definitely contract TB when they had been 
diagnosed as HIV positive, and that this would lead to an inevitable death. 
The patient advocates from both focus group discussions also indicated that patients 
displayed misguided perceptions and knowledge about ART and the use thereof. Many 
patients were under the impression that they should not take their medication on an empty 
stomach. And, although it was recommended that some should be taken after meals, it was 
preferred that patients take their medication on an empty stomach rather than skipping doses 
when they did not have any food. Some patients were considered to be ignorant about the 
importance of taking ARVs, as they were unaware of the indefinite duration of treatment and 
possible side-effects associated with ART. A patient advocate quoted one of her patients: 
I’m here because the doctor said to me my CD4 count is very low. I need to come but 
as soon as my immune system is strong, I stop the medication.  
Clinicians. Doctor Periam, a doctor from the United Kingdom, and Dr Smith, the 
head of the Infectitious Diseases Clinic at Helderberg Hospital indicated that patients may not 
always understand fully how their medication should be taken. This lack of understanding 
often occurred despite being counselled in their home language. Dr Smith is quoted: 
I think…um…the issues are from a practical point of view, some of the issues 
may…may be that they don’t understand a hundred percent how to take them, even 
though they do get counselled in their own language. 
Concurrences and discrepancies. Patient advocates and clinicians associated health 
literacy with adherent behaviour. However, these respondents provided different reasons for 
its importance. Both patient advocates and clinicians related health literacy to the patient’s 
ability to understand how to take ART, but patient advocates identified the patient’s 
knowledge and perceptions of HIV and ARTs as an additional barrier to ART adherence. 
Clinicians on the other hand regarded patients’ health literacy to be related to their level of 
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education. Misguided knowledge and perceptions around HIV and ARVs reinforced the 
crucial role of patient advocates and clinicians in providing patients with the correct 
guidelines and information around the disease and treatment thereof. 
4.1.3 Literacy  
Literacy as barrier to ART adherence was associated with their ability to correctly read or 
comprehend the medical instructions of their prescriptions. Barriers associated with literacy 
were also associated with the importance of literate friends or family members. 
Clinicians. From the experience of Dr Smith and Sister Kekana low literacy often 
acted as a barrier to ART adherence. Sister Kekana stressed the importance of patients’ 
ability to read their prescriptions in the absence of a literate friend or family member. It was 
often necessary for patients to revert back to the instructions of their prescriptions, as with 
certain medications such as NVPs the instructions did not remain the same for the duration of 
the prescription. She also indicated that barriers associated with literacy were intensified 
amongst patients who had missed their scheduled clinic visits, as these visits provided 
clinicians with the opportunity to remind them of any changes in prescriptions. 
Discrepancies. The effect of literacy on the patient’s adherence to ART was clearly 
indicated by clinicians. However, patient advocates and the patients did not express any 
difficulties in understanding the instructions set out by ART prescriptions. 
4.1.4 Medication 
Experiences with ART medication, and the consumption thereof were associated with the 
characteristics of the medication. It was also related to the patient’s experience of taking the 
medication.  
Patient Advocates. Patient advocates from the first focus group discussion stated that 
patients experienced discomfort and unpleasantness when taking ART medication. Side-
effects and physical characteristics of tablets, such as the size of the tablets, were seen as 
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contributing to these negative experiences. Patient advocates emphasized the importance of 
educating patients about the possible side-effects before initiating treatment. 
Patients. Three of the patients included in this sample stated that they have 
experienced one or more side-effects associated with ART medications. These side-effects 
were reported to have been worse after the initiation of ART, or when taken on an empty 
stomach. Patients reported nausea, vomiting, drowsiness and hypersomnia as some of the 
side-effects they experienced. Gerome, described his experience of taking ARV medication: 
When I take the pills on an empty stomach, then I am like a drunken person. I can’t 
take the medication on an empty stomach; the pills make me sleep a lot. 
Clinicians. All of the doctors indicated that patients experienced discomfort or 
unpleasantness associated with characteristics such as size, thickness and volume of tablets. 
However, the doctors disagreed on the effect this discomfort, unpleasantness and experience 
of side-effects had on the patient’s pill-taking behaviour. Dr Periam did not consider side-
effects to be a significant barrier to ART adherence, as the community from which the 
patients came were seen to be fairly resilient. Dr Smith on the other hand believed that ARVs 
did impede on the patient’s willingness to adhere to ART. 
... taking their pills, especially in the beginning, they may have side-effects that make 
them nauseous or make them start vomiting, they feel dizzy and they may not have 
been adequately prepared for those side-effects…um…and that may lead them to not 
take their pills. 
Concurrences and discrepancies. Patient advocates, patients and clinicians agreed 
that the experience of side-effects and consumption of ART medication to be unpleasant. 
There was however a disagreement between clinicians about how these negative experiences 
affected patients’ pill-taking behaviour. There was concurrence between patient advocates 
and clinicians, but not between patients on the effect the physical characteristics had on the 
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experience of consuming. The patients were the only group from the sample to stress the 
effect of taking medication on an empty stomach. 
4.1.5 Mental health 
Patient’s mental health was associated with the effect psychological well-being had on their 
ability to adhere to their ART. Additionally, the role of mental health on adherent behaviour 
was also associated with having received treatment for these conditions. 
Patients. From the entire sample, a single patient identified mental health to have 
been a barrier to ART medication adherence. Priscilla, a mother of one, often experienced 
episodes of depression. She had received treatment for this condition. She explained how her 
mental health contributed to her non-adherence to ARVs: 
When one feels de-motivated, you aren’t in the mood for anything, you don’t want 
anyone around you, and then at that stage I am not in the mood to take my 
medication. 
Discrepancies. Even though mental health was not mentioned by patient advocates or 
clinicians as barrier to ARV adherence, the quotation provided by Priscilla indicated the need 
for other aspects of the patient’s health to be considered when treating a person infected with 
HIV. These aspects of health should include mental health as a barrier to ART adherence. 
4.2 Poverty-related barriers 
Insufficient financial resources was a reality for the patients included in this sample. Day-to-
day living was a challenge for most. Although patients were provided with free ARV 
medications and services at the Infectious Diseases Clinic, their finances, or the lack thereof, 
appeared to be a significant barrier to their ability to adhere to ARV treatment and care. 
During this study several barriers to ART adherence were identified, which directly or 
indirectly related to the patient’s financial situation. The poverty-related barriers identified 
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were: (1) employment, (2) migration, (3) disability grants, (4) transportation, (5) living 
arrangements, (6) reminder tools, and (7) transportation. 
4.2.1 Employment 
Employment was associated with the effect treatment and scheduled clinic appointments had 
on the patient’s occupational circumstances and income. In addition, adherence also had an 
effect on their occupational circumstances.  
Patients. The effect of ART on the patient’s ability to participate in physical 
employment and to generate an income, was identified by two of the patients. The need to 
participate in these activities was described by Gerome: 
…I can’t, I can’t work in that heat. I wanted to go and to also make my contribution 
to our household, that we can at least have an income… 
The inability to participate in demanding work-related activities, which was possible 
prior to the initiation of ART, did not directly impact on ARV adherence. However, the lack 
of financial income indirectly impacted on patients’ ability to adhere to ARV treatment and 
care. This was owing to patients not being able to afford transport and food, and could also be 
associated with aspects such as disability grants and living arrangementss. 
Shaamiela, a mother of one, described how her employment impacted on her ability to 
adhere to scheduled clinic visits in the past. Employment made it difficult at times to organize 
the necessary leave in order to attend her scheduled clinic visits. 
Clinicians. Dr Periam and sister Bekaka identified scheduled clinic visits to impede 
on the patient’s ability to attend work, as these scheduled clinic visits often required that 
patients regularly take a full day’s leave. This was especially problematic when treatment was 
initiated as patients were required to attend scheduled clinic visits once a week or once every 
two weeks. Patients were often not prepared to disclose their HIV status to their employers 
which made it more difficult for them to explain to employers why they had to take leave on 
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such a regular basis. Sister Bekaka testified to one or two patients being dismissed by their 
employer, due to their inability to get the necessary leave to attend scheduled clinic visits. 
Patients consequently had to miss work on a regular basis. Missing a full day’s work often 
meant that patients had to forgo a day’s pay, even though they had a medical certificate. This 
meant that attending scheduled clinic visit often had an additional financial strain on patients, 
in addition to the expenses associated with travelling to the clinic. Dr Periam stated: 
If you don’t pitch, you don’t get paid if you don’t work. So…that has got a financial 
effect to get here. 
Three of the clinicians also identified that routines associated with shift work imposed on 
adherence to medication. Working irregular shifts often contributed to the patient’s inability 
to remember to take their medication or to do so at a set time. Sister Bekaka stated: 
The different shifts that people work…sometimes they work day-shift for a week, and 
then night-shift for a week and with the switch it is difficult for them, so they don’t 
drink their medication. They don’t take their medication at regular times. 
Although non-adherence was mostly attributed to forgetfulness associated with shift-work, 
clinicians indicated that some patients intentionally chose not to take their medication while 
they were at work. The decision not to adhere to ARV medication often stemmed from not 
wanting to make an issue of taking their tablets. 
Concurrences and discrepancies. Aspects surrounding employment as barrier to ARV 
treatment and care were identified by patients and clinicians. Patient advocates did not reveal 
any problems surrounding the issue. While patients mostly showed a greater concern for the 
indirect effect ARVs had on their ability to generate an income, clinicians were more 
concerned with the direct effect attending scheduled clinic visits had on their motivation to 
adhere to ARVs and to attend scheduled clinic visits. 
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4.2.2 Migration 
Non-adherence to ARV care was also associated with resettlement or the passage through 
provinces due to employment opportunities, holidays and significant events outside the area 
of the clinic where patients received ART. Significant events specifically included funerals 
and religious holidays. 
Clinicians. Four clinicians from the sample associated migration with the patient’s 
non-adherence to ART care. The clinicians stressed the importance of patients seeking out 
treatment in the event of migration. However, the clinicians indicated that this was often not 
the case. Dr Nkwali attributed reasons for non-adherence to patients not being aware of 
where they should seek treatment, or to the fact that many tend to put ARV treatment on the 
“backburner” until they have found employment. She also indicated that patients did not 
consider treatment to be a priority especially when they felt asymptomatic. Dr Periam added 
that patients often chose not to seek treatment when visiting friends or relatives, since 
patients perceived that they had to disclose their HIV positive status if they wanted to go for 
treatment in that area. 
In addition to the importance of obtaining treatment during temporary or permanent 
migration, it was also important that migrant patients had to obtain transfer letters when 
doing so. Sisters Kekana and Kabini stressed the significance of patients being transferred out 
to other clinics, to ensure that staff at those facilities “had something on paper” when treating 
patients. Clinicians felt that the inability to obtain a transfer letter in itself acted as a barrier to 
acquire the proper ARV treatment. 
Discrepancies. The effect of both temporary and permanent migration on the patient’s 
ability to adhere to ARV treatment was a prominent concern amongst clinicians. It was 
however not a concern amongst patients or patient advocates. The reason for the clinicians’ 
concern might be associated with their experience of patients returning to their local clinics, 
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and migrant patients arriving days or even weeks late for their scheduled clinic visits, which 
consequently resulted in inadequate adherence to care. 
4.2.3 Disability grants 
The majority of the patients included in this sample either had already applied for a disability 
grant, or were in the process of applying for it or were already receiving a disability grant. 
Patients were considered as dependent upon disability grants as their primary source of 
income and to maintain their daily living, which subsequently enabled adherent behaviour. 
However, disability grants were also identified as a barrier to ARV adherence, as it did not 
motivate patients to attain better health. Getting better often meant that they would forgo their 
primary source of income as they would not requalify for a grant.  
Patient advocates. Patient advocates from both focus group discussions expressed that 
patients experienced difficulties in obtaining a disability grant, due to complications in the 
administration. Patient advocates from the second focus group discussions perceived 
disability grants to be an enabler of ART adherence, as it mostly formed an essential part of 
the patient’s income, which enabled them to purchase food to take their tablets with. 
Although disability grants contributed to adherent behaviour, it was also a barrier to 
ARV adherence since patients stopped taking ARVs to have their grants continued. A patient 
advocate from the first focus group discussions stated: 
The other thing I experienced, I don’t know if I’m right or wrong is HIV positive 
people they make the HIV the government’s responsibility, because they want to get 
their grant, because if you are HIV positive you get the grant for the six months so 
when you are better you don’t want to take the medication because of that, because of 
the grant. 
Patients. Difficulties in obtaining a disability grant were expressed by one of the 
patients. Jacobus indicated that these difficulties were directly attributed to paperwork being 
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lost by the doctors and the lack of feedback on the progress of applications. Even though 
some of the patients included in this sample indicated that they were already receiving 
disability grants, their ability to cover all their expenses was still difficult. Priscilla was one 
of the patients who still struggled to sustain her daily-living. 
…it is actually a problem, sometimes there isn’t any food. It is a struggle. The grant 
we receive is not always…it does not always cover everything. 
Priscilla also indicated that she knew of patients receiving disability grants who intentionally 
did not take their medication, or spent the grant they received inappropriately. She stated: 
That people that receive the grant. They do not take their medication. They drink, they 
buy wine with the money. 
Clinicians. Dr Periam and Dr Smith indicated that patients often held a misconception 
around the continuation of their disability grant. These misconceptions contributed to non-
adherence to ARV medication among patients. Both clinicians indicated that patients were 
often unaware that grants were only temporary, and that they often showed an entitlement to 
money from the government because they were HIV positive. Dr Nkwali indicated that 
patients often did not requalify for a disability grant once they were well enough, which 
subsequently meant that they had to return to work to generate an income. Some of these 
patients expressed anger towards her because she could not ethically recommend their grants 
to be continued. She also indicated that patients had threatened to stop their medication as 
blackmail in an attempt to have their grants continued. However she did not report any 
patients actually stopping their ARV medication. She stated: 
And you want them to…to continue with their medication. So sometimes they can use 
it as blackmail, to say that, if you don’t give it to me, I am going to stop my 
medication. 
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Sister Bekaka testified to patients actually having stopped their medication when their 
CD4 count exceeded 500cells/mm³. These patients did so in an attempt to requalify for a 
disability grant after their six months duration elapsed, to generate some sort of income. 
…we found out a while back that patients who had taken their medication regularly 
grants got stopped after six months as their CD4 count exceeded 500, and they did not 
work, because it is difficult to get a job again when you have lost or left it. They would 
then stop their medication so that they would become ill again, and their CD4 count 
would stop so they would get a grant again. 
Concurrences and discrepancies. Difficulties in obtaining government grants were 
expressed by both the patient advocates and the patients. Disability grants as a motivation to 
discontinue treatment was a salient barrier raised by the patient advocates, patients, and the 
clinicians. Clinicians recalled some patients threatening to discontinue their ARV, but none 
actually doing so, while the patient advocates and patients indicated that patients really did do 
it. Clinicians, but not the patient advocates or patients, experienced patients illustrating 
misguided perceptions about the disability grants. A sense of entitlement and the belief of an 
indefinite grant were common concerns. A patient indicated that to her knowledge, patients 
who received the grants often abused it, rather than used it for appropriate or necessary 
causes. 
4.2.4 Food insecurity 
Precise adherence to ART medications not only required strict adherence to treatment and 
care but also required patients to adhere to dietary restrictions. However, clinicians indicated 
that in the event of food insecurity, taking ARVs on an empty stomach to be preferred to not 
taking it at all. However, hunger exacerbated the likelihood of patients experiencing side-
effects. 
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Patient advocates. Food insecurity as barrier to ARV adherence was emphasized by 
both focus group discussions. It often happened that patients did not have any food when it 
was time to take their pills. Patient advocates indicated that it was possible to take the ARVs 
on an empty stomach, but it was not advised for all the medications patients received. 
A patient advocate from the first focus group discussions indicated that certain 
community resources were available to patients experiencing food insecurity. However they 
often did not solve the problem of food insecurity completely, as resources such as soup 
kitchens provided patients with only one meal. Although this enabled them to take one dose 
of their ARVs on a full stomach they still did not have food at home to take the second dose 
with. 
Patients. The majority of the patients included in the sample perceived it as important 
to take their ARV on a full stomach. However, food insecurity meant that this was not always 
possible. Six of the patients from the sample regarded food insecurity as a barrier to their 
ARV adherence. Andrew, a 32 year old divorced man described the severity of the problem: 
Sometimes when there is nothing, then I get water, just to fill me up, so I can take my 
medication. 
Patients also indicated that they had to go to great lengths to take their ARVs on a full 
stomach. They often had to make debt, or ask family or neighbours for something to eat when 
they had nothing in the house. Other times they would just go days without eating. 
Clinicians. Dr Nkwali indicated that she had come in contact with a patient who 
indicated food insecurity to be a problem when she had to take her ARVs. According to Dr 
Periam food insecurity contributed to the patient’s reluctance to take medication. 
They don’t want to take their medicine without food, so they don’t take it. 
Concurrences and discrepancies. Food insecurity as barrier to ARV adherence was 
indicated by patient advocates, patients and clinicians. Patient advocates indicated that 
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despite the assistance of community programmes such as soup kitchens, patients were often 
left with limited solutions, as they still battled with food insecurity at home. Patients 
indicated the amount of effort it takes to take their medication. Both clinicians and patients 
associated food insecurity with patients’ reluctance to take their medication. 
4.2.5 Living arrangements 
Most of the patients attending the Infectious Diseases Clinic or Helderberg Hospital resided 
in either a rural or semirural community. Patients often shared accommodation with relatives 
or friends. The effect of their financial situation often left them with no alternative. 
Patients. One of the patients indicated that his living arrangementss affected his 
ability to adhere to his ARV medication, and that he had stopped his ARV treatment once 
before. Due to his financial situation he had to share his accommodation with four relatives, 
which consequently lead to a lack of privacy. Since privacy was a luxury he could not afford, 
his living arrangementss made it difficult for him to take his medication in private. Winston 
described what his living arrangements was like. 
We are at the moment five who live together in a bungalow, in a structure, it is a 
wooden structure. It is rather small and there is only one big bed in the room in the 
bungalow, and we all sleep on it. 
Clinicians. Dr Nksosi indicated that the patient’s ARV adherence may have a lot to do 
with their living arrangements, due to the close proximity patients lived in with others and 
that patients were often left with no privacy. She stated: 
It might also have a lot to do with the fact that everyone is just so…living so close 
together, that they are almost just like in each others’ space kind of thing. 
Dr Smith on the other hand associated the patient’s living arrangements with the changing of 
routine, which often impeded on their ability to remember taking their medication. 
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A lack of routine, or a change in routine, is a huge…I find is a huge thing. 
Um…weekends, unexpected visitors or unexpected things happening, they lose their 
routine, and then they…then they forget to take their pill. 
Concurrences and discrepancies. The lack of privacy as a result of a crowded living 
situation was a barrier to ARV adherence. This was mentioned by both clinicians and one 
patient. One clinician also attributed the lack of routine to patients’ living arrangements 
which often made them forget to take their medication. However, neither patient advocates 
nor the other patients regarded living arrangements as a barrier to ARV adherence. 
4.2.6 Reminder tools 
Part of adequate adherence to ART is the importance of taking medication according to a 
structured timeline. Depending on the patient’s particular regimen, prescriptions mostly 
indicated that ARVs be taken 12 hours apart.  
Clinicians. The lack of reminder tools as a barrier to precise ARV adherence was only 
raised by Dr Smith. She was concerned that patients who lived in poverty often did not have 
the resources to purchase the basic tools to indicated time, such as watches, cell phones, 
televisions, or radios. The lack of such reminder tools acted as a barrier to precise adherence, 
since patients had no way of telling what time they should take their scheduled doses of ARV 
medication. 
Discrepancies. Although patients from this sample lived in a state of poverty, neither 
the patient advocates nor the patients indicated that the lack of reminder tools was a problem 
in adhering to specific timelines when taking ARV medication. 
4.2.7 Transportation 
In addition to adherence to medication, the adherence to care was of equal importance. Due 
to the financial stance of patients, the access to private transportation was most often 
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restricted.Patients either had to rely on public transportation or travel by foot to attend 
scheduled clinic visits.  
Patient advocates. During both focus group discussions with patient advocates 
patients’ inability to afford public transportation to the clinic was identified as a barrier to 
care adherence. Patient advocates from the second focus group discussion indicated that due 
to the patient’s inability to afford transportation to get to the clinic, patients often had no 
other option but to travel long distances by foot. Due to natural elements this journey was 
often physically daunting and worsened by the physical state of their bodies. When patients 
had to weigh up walking to the clinic with attending scheduled clinic visits, they often 
decided not to attend. A patient advocate stated: 
Sometimes they, they got a problem because they don’t want to walk and they decide, 
no I’m going stay home, I’m not going to the, to the doctor. 
Patients. Six of the patients reported not having the resources to travel to the clinic by 
taxi, even an amount of R7 was more than they could afford. Matthew, who had stopped 
treatment once before, indicated that he discontinued his medication because he did not have 
travel fare to get to the clinic.  
Because I did not have money for transport each month that is why I stopped my 
medication. 
Six of the patients also indicated that because they did not have the funds to travel to 
the clinic by taxi, they had to travel to the clinic either hitch-hiking or on foot; sometimes 
walking up to three hours one way. Travelling by foot not only consumed a significant 
amount of time but also meant that patients had to start walking as early as four o’clock in the 
morning to be able to get to the clinic on time. Shaamiela indicated that she had to allow for 
additional time to walk to the clinic, because she had to take her young son to the clinic with 
her, and that the pace they walked at was determined by him. Gerome on the other hand 
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indicated that he had to pray for a safe journey, as travelling by foot meant that he had to pass 
through rough neighbourhoods in the dark to get to the clinic. In the event that patients were 
able to travel to the clinic by taxi, they were still required to travel to the clinic by foot from 
the taxi rank in town, since the taxis did not travel all the way to the clinic. 
Clinicians. All the clinicians identified transport to be a barrier to adherence to care. 
Sister Kekaba contributed the patient’s inability to adhere to care to the lack of necessary 
funds to make use of public transport. The costly nature of taking a taxi to the clinic were 
emphasised by Dr Periam. She indicated that trips to the clinic often meant having to take 
more than one taxi, and therefore patients had to get up early to get to the clinic on time. Dr 
Nkwali and sister Kabini indicated that patients who were not able to afford public 
transportation had no other option but to walk to the clinic to attend scheduled clinic visits. 
Sister Bekaka mentioned that patients, who were able to afford a taxi, still had to travel from 
the taxi rank to the clinic by foot, because the clinic was not part of the taxi routes. Dr Smith 
indicated that the location of the clinic contributed to extra strain on the patient’s ability to 
get to the clinic, as many of these clinics were not located within the patient’s community. Dr 
Periam and sister Kabini pointed out that strikes and riots by taxi owners, which often lasted 
days, impacted on patients’ ability to get to the clinic on a set date. 
Concurrences and discrepancies. Patient advocates, patients and clinicians indicated 
that patients’ inability to afford transport impacted on their adherence to care. They have all 
indicated that patients who did not have the funds to travel by public transport had to do so by 
foot. Patient advocates and patients indicated that due to having to walk to the clinic patients 
often chose to discontinue ARV medication and care. Patient advocates described the 
daunting effect of having to travel by foot, while patients described the effect of having to 
travel with a child and being concerned for their safety while travelling through rough 
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neighbourhoods. Clinicians on the other hand also associated the location of the clinic outside 
the patient’s community and the effects of taxi riots and strikes as barriers linked to transport. 
4.3 Institution-related barriers 
Institution-related barriers were associated with the: (1) healthcare system; (2) healthcare 
facility, and (3) the staff employed at the healthcare facility. 
4.3.1 Healthcare system 
Barriers related to the healthcare system were those barriers which patients did not have 
direct control over. Difficulties associated with the healthcare system were: (1) the patient’s 
access to the healthcare system, and (2) the open access of ART. 
4.3.1.1 Patients’ access to healthcare system. 
Clinicians. Difficulties patients had in accessing the healthcare system were associated with 
the patient’s ability to adhere to ARV treatment and care. Dr Smith indicated that patients 
might not find it particularly easy to access the healthcare system, and even when they 
managed to access the healthcare system, there was the possibility that they could be 
subjected to a rather unpleasant experience. 
Discrepancies. Although Dr Smith indicated that patients might find it difficult to 
access the healthcare system, she did not express what exactly these difficulties were. Neither 
the patient advocates nor the patients directly identified any difficulty in accessing the 
healthcare system. Patients did however concur with Dr Smith on having encountered an 
unpleasant experience after they had accessed the healthcare system. These unpleasant 
experiences were however related to the healthcare facility rather than the healthcare system 
per se. 
4.3.1.2 Open access of ART in the healthcare system.  
The open access of ART in the healthcare system was associated with the present availability 
of ARV drugs in comparison to the restricted availability during the years of rollout 
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programmes. During the rollout programmes, such as the Khayelitsha Programme, candidates 
for ART were subjected to the strict assessment of clinical and social conditions. Regular 
clinic attendance was used as a tool to assess the patient’s ability to adhere to ART. 
Programmes like the Khayelitsha Programme consequently showed high adherence rates due 
to patients being strictly selected for ART. However, in recent years ARV medication had 
become more widespread, going beyond the chosen few of the national rollout programme. 
Although there was still a criterion on which the selection of patients was based, some of the 
strict selection criteria of the rollout programme had fallen away. 
Clinicians. Dr Smith identified the implications of allowing open access to ART to 
patients as a barrier to ART adherence. Lower rates of adherence were reported among 
patients who had open access to ART when compared to those of the national rollout 
programme. She also indicated that clinicians had a more accurate picture of how it was to 
treat patients with ARVs since patients were being treated for longer periods of time. 
…obviously we are less selective, and we have more of an issue with adherence, 
people are falling off the programme, people being in ARV for longer, the side-effects 
are starting to manifest. One gets more of a realistic picture of what it is like to treat 
patients with ARVs really. 
Discrepancies Patient advocates, patients and clinicians did not implicate the effect of 
open access on ART as a hindrance to patients’ adherence to ART. This issue could be more 
apparent to Dr Smith as she had been involved with ART since it became available. 
4.3.2 Healthcare facility 
Barriers related to the healthcare facility were associated specifically with the Infectious 
Diseases Clinic and the Helderberg Hospital to which the former was connected. The barriers 
related to the healthcare facility were identified as: (1) administration and protocol followed 
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by staff, (2) language in which patients were attended to, (3) waiting times, (4) overcrowding, 
and (5) privacy. 
4.3.2.1 Administration and protocol followed by staff.  
Difficulties relating to the administration and the protocol followed by staff included the 
organization and management of patient files and medication. These difficulties were also 
associated with adherence checks at these facilities. 
Clinicians. The record keeping of patient files at the hospital was indicated as a 
concern by sister Kekana. The concern was however not related to the Infectious Diseases 
Clinic, but rather to the hospital where patients were admitted for in-patient treatment. She 
was alarmed by the fact that during the patient’s admittance to the hospital, their original files 
from the Infectious Diseases Clinic could often not be found, or that the hospital did not 
transfer the files from the Infectious Diseases Clinic to the wards. As a result, duplicate files 
were often opened for these patients. This procedure resulted in the absence of original notes 
concerning the patient’s condition and the treatment they received as out-patient at the 
Infectious Diseases Clinic. She also indicated that hospital staff was often unaware of the 
patient’s HIV status, which consequently left many patients without ARVs for the duration of 
their hospital stay. She was quoted as saying: 
Sometimes the patient’s HIV diagnosis is looked over, they do not know if he is on 
treatment or not, and sometimes the patient will lay for days, two three days without 
medication. Then I will find out when I go and work in the ward. I will go and have a 
look. 
The concerns on the protocol hospital staff followed with regard to the patient’s medication 
were also raised by sister Kekana. On admittance to hospital, patients often brought their own 
medication with, but staff would frequently not write down the particular information on the 
patient’s chart. Subsequently clinicians at this facility had no knowledge of whether the 
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patients had taken their medications or not, and whether they had done so as prescribed. This 
also complicated the staff’s ability to do pill counts or to assess the patients’ adherence. 
Discrepancies. Patients and other clinicians didn’t raise any concerns about the 
administration of the healthcare facility or the protocol the staff followed in admitting in-
patients. Sister Kekana was able to identify this barrier due to her experience in working in 
the wards. The lack of concern amongst clinicians about the administration and protocol of 
the hospital could be because all the clinicians included in this sample were employed at the 
Infectious Diseases Clinic, and patients’ original files and notes on their treatment were freely 
accessible to them, since this was where patients received out-patient treatment. Ensuring that 
patients received their medication and adherence checks was an integral part of the clinicians’ 
job at the Infectious Diseases Clinic.  
4.3.2.2 Language in which patients were attended to.  
Language as barrier to ART stemmed from the diverse population the Infectious Diseases 
Clinic provided services to. Patients were mostly Afrikaans-, English- and Xhosa-speaking, 
while the majority of the clinicians employed at the Infectious Diseases Clinic were 
proficient in either Afrikaans or English or they were bilingual. The barriers to ART 
adherence were associated with the inability or difficulties clinicians had in communicating 
with patients. 
Clinicians. Difficulties or the inability to communicate with patients were mostly 
reported in the interactions with Xhosa-speaking patients. Dr Smith indicated that although 
she did not speak a fluent Xhosa, she was able to obtain a basic medical history from Xhosa-
speaking patients. She and Dr Periam indicated that they occasionally had to make use of a 
translator when dealing with these patients. When they were not able to attend to these 
patients themselves, they were able to refer the patients to one particular doctor on the staff, 
who was a Xhosa. 
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The ability of clinicians to communicate or understand Afrikaans- or English-
speaking patients was not raised as a general concern. Dr Periam reported a difficulty in 
communicating with Afrikaans-speaking patients but this was not a great concern since most 
of the staff at the Infectious Diseases Clinic could speak both Afrikaans and English. 
The impact of language on the clinician’s ability to communicate especially with 
Xhosa-speaking patients created a possible barrier to adherence as it was considered 
important to gain an understanding of underlying psycho-social issues to adequately treat 
ARV patients. Dr Smith stated: 
…you don’t get the nuances or the complicated stories, especially the psycho-social 
issues that get lost completely. 
The inability to get the necessary information from patients was also reported to have added 
to the frustration the clinicians experienced when treating patients. 
Discrepancies. Although the clinicians reported some degree of difficulty in 
communicating with patients and obtaining a comprehensive medical history and psycho-
social background in order to adequately treat patients, patient advocates and the patients 
themselves did not express any concerns about their ability to communicate with clinicians or 
any impact of a language difficulty on the treatment they received. 
4.3.2.3 Overcrowding.  
In South Africa, a large number of patients seek out ART at public healthcare facilities, as 
financial hardship did not allow for the necessary resources to access private healthcare. As a 
result public healthcare facilities were most often overstretched in their capacity to 
accommodate everyone who needed ART. 
Patient advocates. The experience of congestion at the Infectious Diseases Clinic was 
expressed by patient advocates from the first focus group discussion. They also mentioned 
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that patients often had an “uncomfortable” experience when they attended this facility. 
Patients often did not “feel welcome” due to the overstretched capacity of the facility. 
Patients. Three of the patients indicated that overcrowding at the facility caused them 
inconvenience, often as a result of the influx of patients from other clinics. This resulted in 
extended waiting times and the lack of privacy when being attended to. 
Clinicians. Dr Smith indicated that the Infectious Diseases Clinic was not able to keep 
up with the growth in patients seeking ART at that facility, especially with the influx of 
patients from the Eastern Cape. She also expressed her concern for the overstretched capacity 
of the hospital when patients required in-patient treatment. The hospital had a 100% bed 
occupancy rate, and patients were often not able to get a bed for days. She also indicated that 
when patients were required to stay at the hospital they would often have to get onto a trolley. 
If the trolleys were full they would have to get onto a mattress on the floor. When the 
mattresses were full, the patients often ended up on a blanket on the floor. 
Concurrences and discrepancies. Both patient advocates and patients were concerned 
with the patients’ experiences when attending the Infectious Diseases Clinic. Patients and 
clinicians attributed the overstretched capacity in part to an influx from patients from other 
regions or clinics. One of the clinicians identified the effect an overstretched capacity had on 
in-patient treatment at the hospital. The patients have attributed the origin of other institution-
related barriers to the overcrowding at the facility. 
4.3.2.4 Waiting times. 
Patient advocates. The return of patients to the Infectious Diseases Clinic was indicated to be 
inevitable for some of the patients, as they might not be able to attend to everything in one 
day due to waiting times. Return was often necessary to have their prescriptions filled. 
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Patients. Seven of the patients from this sample expressed a degree of inconvenience 
due to lengthy waiting periods when being attended to by the nurses or doctors, and having 
their prescriptions filled at the pharmacy. Gerald stated: 
I get here at six thirty, and then there are already a lot of people. Then I have to wait, 
and then I have to see the doctor. I only see the doctor past eleven or past twelve. 
The importance of arriving early in the morning on the date of scheduled clinic visits was 
also emphasized by the patients, some having arrived at five or six in the morning to be able 
to go home early in the afternoon. Although they arrived early in the morning their visit could 
still be a lengthy one. Straight-forward activities, such as being weighed or to have blood 
pressure taken, in addition to waiting for the doctor, counsellor or at the pharmacy, were all 
considered to be time consuming activities. 
Clinicians. The three doctors regarded the patient’s visit to the clinic to be a lengthy 
one, which could often be a “whole day thing”. Patients did not particularly like coming to 
the clinic, because the wait was not “so nice”. According to Dr Periam 
…they will first wait for the sisters, and get their pill counts, and then if they need to 
see the doctor, they will wait for the doctor, and wait at the pharmacy. By that time, 
they have waited and waited and waited for hours. 
Dr Smith pointed out that the patients may have to wait wherever they choose to access the 
healthcare system, as it might be overcrowded, but patients receive a good service and 
generally get everything attended to. 
Concurrences and discrepancies. Patients and clinicians indicated that patients 
experienced prolonged waiting times at the healthcare facility. Having to wait long was 
inconvenient for patients as it had an effect on the time they had to arrive at the clinic and the 
time they were able to leave. The patient advocates added that the result of the waiting times 
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had an effect on patients having to return to the clinic to conclude aspects of treatment that 
were not previously attended to, such as having their prescriptions refilled 
4.3.2.5 Privacy.  
Due to congestion at the Infectious Diseases Clinic, the lack of privacy was inevitable. 
Private consultation rooms were not available for patients when being attended to by the 
nurses or counsellors. More than one patient at a time received treatment in one room. 
Patient advocates. The first focus group discussion identified uncomfortable 
experiences during scheduled clinic visits. These experiences were attributed to the lack of 
privacy patients experienced when being attended to by nurses or counsellors at the facility. 
Patient advocates also indicated that the lack of privacy at the facility contributed to the 
patients’ unwillingness to attend their scheduled clinic visits. 
Clinicians. Dr Nkwali and sister Kekana thought that the lack of privacy at the facility 
made it difficult for patients to share any concerns, problems or difficulties in adhering to 
ARV treatment or care. Dr Nkwali mentioned the following: 
And some may not even be able to comfortably say what their problem is, there is just 
no privacy. 
Concurrences and discrepancies. There was a discrepancy between what patient 
advocates and clinicians perceived the influence of the lack of privacy had on patients’ 
adherence to ART. Patient advocates considered the lack of privacy to have an effect on the 
patient’s motivation to attend scheduled clinic visits, while the clinicians were concerned that 
patients were not able to discuss any obstacles they experienced in adhering to ART. Patient 
advocates and clinicians, however, agreed about the lack of privacy at the facility, but 
patients themselves did not show any concerns about the lack of privacy at the healthcare 
facility. 
63 
 
4.3.2.6 Patients’ experiences of staff at the healthcare facility.  
Patient advocates. Patients’ negative experiences with staff in charge of ARV patients were a 
concern indicated by patient advocates from both focus group discussions. Hostility, 
unkindness, and a lack of empathy from staff members were reported by these participants. 
Patient advocates attributed these negative attitudes to certain biases staff members held 
about patients’ race or social class. One of the patients mentioned: 
…those coming from a good home, and they are white and rich haughty people, they 
are treated properly. But we underprivileged, we are treated hard for no reason, to 
say it straight, we are spoken to rudely. 
The above mentioned quotation emphasized why patient advocates thought that the under 
privileged patients attending the healthcare facility were treated differently than the patients 
perceived to be of a “higher” social standing.  
Patient advocates also attributed the ill-treatment of patients to the patients’ 
punctuality in attending scheduled clinic visits. Being late for appointments, missing 
appointments completely, or attending appointments on dates other than scheduled were also 
seen as a cause of negative interactions. Patients who frequently abused alcohol or substances 
were also reported to be more likely to have experienced negative interactions with staff. 
Patients. Three of the patients from the sample testified to have had a negative 
experience with staff members. They however attributed being ill-treated to their lack of 
punctuality with scheduled clinic visits. Winston explained one of his negative encounters 
with staff. 
I stay away for a day or two, and then I think I will be ok, it can do no harm. When I 
get there the next day they kick, rant and rave. 
Clinicians. Five of the clinicians from the sample indicated patients’ negative 
experiences with staff to be an issue. Dr Smith stated: 
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And I think you see…you see it often that the staff get short with the patient; say they 
come late to the clinic... 
Knowledge of staff members being short-tempered or raising their voices at patients was 
admitted by Dr Smith and sister Kabini. These occurrences were attributed to patients being 
seen as “not playing the game”. Patients perceived as “not playing the game” was not 
punctual with their scheduled clinic visits. This lack of punctuality caused disruption in the 
flow of proceedings in the clinic which consequently added to the clinician’s workload. 
These clinicians furthermore attributed the staff’s short-temperedness to stress created by the 
workload of the clinicians at the healthcare facility. Attending to large volumes of patients 
often also required having to work through lunch breaks.  
Dr Smith and sister Kabini revealed that the negative experiences patients had with 
staff contributed to the patients’ unwillingness to attend certain clinics. In some cases patients 
often chose to stay home, even though their condition warranted treatment or in-patient 
treatment. 
Concurrences and discrepancies. Patient advocates, patients and clinicians concurred 
about negative interactions or experiences patients had with staff at the healthcare facility. 
Participants agreed on some of the causes of these negative interactions or experiences and 
differed on others. Patients’ punctuality with their scheduled clinic visits was indicated as a 
contributing factor by the patient advocates, patients and clinicians. Patient advocates also 
attributed these negative interactions or experiences to biases staff held about patients’ race, 
social class and substance abuse. Clinicians furthermore indicated working conditions of the 
staff to be part of the reason for negative interactions. However, only clinicians indicated that 
some patients chose not to adhere to their scheduled clinic visits or in-patient treatment due to 
the negative interactions with staff. 
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4.3.3 Staff at the healthcare facility  
Institution-related barriers associated with the staff at the facility were mainly identified by 
the clinicians, and the concerns raised were: (1) experiences of staff working with patients 
receiving ART, (2) burnout, (3) the lack of resources to provide staff with psychological 
assistance, and (4) health literacy of staff. Although these barriers were not directly 
associated with the patients’ adherence to care, it impacted on the quality of treatment the 
patients received when attending the healthcare facility. 
4.3.3.1 Experiences of staff in working with patients receiving ART.  
Three of the clinicians from this sample expressed having experienced certain feelings and 
emotions when treating ART patients. The large number of patients, the observation of these 
patients, and their dealings with and the treatment of these patients were seen as contributors 
to these feelings and emotions. Feelings of being “scared”, “frightened”, “disconcerted” and 
being “overwhelmed” in reaction to these situations were described by Dr Nkwali and Dr 
Smith who stated: 
…but the sheer numbers are overwhelming and the pressure…the pressure never lets 
up, and the clinic always grows and continues to get bigger. 
The sense of “helplessness”, “hopelessness”, and “disempowerment” was also attributed to 
these circumstances. These feelings were provoked by the perceived inability to change the 
social circumstances of the patients, such as the community the patients came from, drug 
abuse and depression.  
Dr Smith described the stressful and demanding nature of dealing with patients who 
were once well and then became ill and required in-patient treatment. She indicated that the 
patient’s inability to adhere to scheduled clinic visits also contributed to feelings of 
“frustration” amongst staff. 
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4.3.3.2 Burnout.  
The burnout of staff was associated with being overworked and the emotional toll taken by 
treating ART patients. Dr Smith was the only clinician to indicate the issue of burnout 
amongst staff. This could possibly be because as head of the Infectious Diseases Clinic, she 
was the one to speak to staff members who showed signs of burnout, while informally 
attempting to assist in dealing with the situation. 
4.3.3.3 The lack of psychological support for the staff.  
Although the clinicians indicated that they experienced a range of feelings and emotions 
when treating ARV patients, Dr Smith indicated that the staff did not have any automatic 
psychological support to deal with these feelings and emotions. A social worker was assigned 
to the hospital, but she was not directly affiliated with the Infectious Diseases Clinic, and 
mainly assisted with difficult grant applications. Psychologists, or anyone with skills to 
provide support, were not available to refer staff to. The issue of burnout was a matter mainly 
treated in-house through a once-a-week meeting where the improvement of the hospital was 
discussed. This often resulted in a forum where staff members aired their frustrations. 
Although these meetings provided the staff with an opportunity to air their frustrations, the 
meetings were not done on a professional basis with the assistance of a mediator. These 
meetings, however, enabled Dr Smith to pick up on some of the issues the staff battled with. 
4.3.3.4 Health literacy of staff.  
Staff’s insufficient knowledge relating to the treatment of patients infected with HIV and 
AIDS was only raised by sister Kekana. The insufficient knowledge of staff was mainly 
associated with a barrier that had been experienced in the past. Past knowledge was the cause 
of fear amongst staff, as “everyone knew it was a disease, and that’s where it stopped”. She 
also indicated that staff in the hospital was more likely than those in the Infectious Diseases 
Clinic to have insufficient knowledge about the disease and treatment. However, she also 
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indicated that since the courses they had attended they had better understanding about the 
disease and treatment and that the sisters saw the patients in a different light. 
4.4 Social and community-related barriers 
Social and community-related barriers to ART adherence were associated with the collective 
beliefs or perceptions of the ART patient’s community, as well as the resources available in 
the community in which these patients resided. The barriers that were identified were: (1) 
stigma and disclosure, (2) patient advocates’ access to patients, (3) religion, (4) substance 
abuse (5) culture, and (4) treatment support programmes. 
4.4.1 Stigma and disclosure  
Stigma and the patient’s willingness to disclose to friends or family were negatively 
associated with adherence behaviour, because of the perceived effect it would have on how 
their communities would treat patients. 
Patient advocates. The association between stigma and disclosure and patient’s 
adherence to ART were highlighted by patient advocates from both focus group discussions. 
The patient’s willingness to disclose to family and friends was coupled with the fear of being 
stigmatized. These fears included being rejected, their family being ashamed of them, or a 
fear of what their community would have to say. The need to secretly take their tablets, 
collecting them from their clinic, or not wanting to see a doctor, was often fuelled by stigma. 
A patient advocate from the second focus group discussion said: 
He told me that he is shy, he did not want to talk, because he was afraid that everyone 
would reject him. It made that he did not want to collect his medication from the 
clinic, or go to the doctor, because he did not want to disclose. 
The set up at the facility was also considered to be a stigmatizing agent. A patient 
advocate indicated how just being referred to a certain room in the clinic for ARV treatment 
“automatically” identified patients as being HIV positive. 
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Patients. Patients described the effect stigma had on how they felt about themself. 
Andrew revealed that due to the stigma associated with being HIV positive, patients were 
often “considered to be less, not like a complete person”, like “someone who was inferior to 
others”. Stigma due to being HIV positive contributed to a fear of how their community 
would react towards the patients. Margaret was worried that her community would laugh at 
her if they found out that she was HIV positive. Mitch indicated that he was aware of patients 
being verbally assaulted in the streets for being HIV positive. 
Patients indicated a reluctance to disclose their HIV status to family and friends. Both 
Winston and Andrew indicated their reluctance, because the news of their status would travel 
through their neighbourhoods or communities. Winston described the result of disclosing. 
The neighbourhood is so small that it would go around everywhere, it is not only the 
nearby proximity, and it doesn’t matter where the people live. If a small fire is started 
then the whole field catches fire, the way that they go about. 
Two of the patients indicated that their reluctance to disclose their HIV positive status was 
exacerbated by friends or families who abused alcohol, since being intoxicated had an effect 
on their talkative nature. Some of the patients stated that their inability to disclose their HIV-
positive status required them to take their medication when no one else was around. to the 
need of having to take their medication when no one was around. 
Clinicians. Dr Nkwali and Dr Periam both indicated the significant amount of stigma 
associated with being HIV positive. When compared to having other illnesses patients 
infected with HIV were considered to be more prone to stigmatization by their communities. 
This was seen to have originated from misguided perceptions communities held around HIV. 
Many of these perceptions associated with being HIV positive were still attributed to the 
“promiscuous nature” of patients. 
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Dr Nkwali and Dr Smith indicated that patients generally did not refuse care because 
of the fear of communities acting violently towards them, but rather because of the fear of 
being laughed at, talked about, or being stigmatized due to their HIV positive status. This fear 
was considered to contribute to the patient’s refusal of home-based care or visits by patient 
advocates when their condition warranted it. The stigma which fuelled this refusal was often 
associated with the possibility of being identified as HIV positive or because they knew the 
person who was providing them with the service. According to Dr Nkwali  
…they might need home- based care, they are terminally ill, and they still don’t want 
it, because they are still scared that people are going to talk about them. Although we 
do explain the confidentiality issues, they still see the stigma around HIV as being bad 
in their communities. 
Dr Nkwali and Dr Smith indicated that patients often demonstrated a reluctance to attend 
scheduled clinic visits at certain clinics in the fear of knowing other patients, or staff 
employed at the clinic. This situation often contributed to patients seeking services at clinics 
outside their immediate area, in an attempt not to be identified as being infected with HIV. 
Sister Bokaka stated: 
A lot of the patients refuse to go there, because they know the people who work there, 
they know the patients who come there. 
The effect of stigma on the patient’s willingness to adhere to ARV drugs was also 
emphasised. Dr Periam indicated that some patients refused to take their tablets in the 
presence of others, because they did not want to reveal that they were HIV positive. 
The clinic was also identified as a prime stigmatizing agent by one of the clinicians, 
although the clinic did not intentionally create a stigmatizing environment. Sister Kekaba 
described an incident where a box containing patient cards was accidentally changed from the 
Infectious Diseases Clinic to the ARV clinic. This situation resulted in angered patients who 
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became verbally abusive towards staff, because they were under the impression that they 
would be identified as being HIV positive. 
Concurrences and discrepancies: Patient advocates, patients and clinicians concurred 
that patients demonstrated a reluctance to disclose due to fear instilled by stigma. Patients 
were the only participants who expressed how being stigmatized made them feel about 
themselves. They expressed a real fear that their HIV positive status would spread through 
their communities should they disclose, especially should they disclose to an intoxicated 
relative or friend. 
The patient advocates and clinicians emphasized the effect of stigma on the patient’s 
adherence to ARV treatment and care. Not having disclosed meant that they needed to take 
their tablets secretly. They also concurred about the role of the clinic as a stigmatizing agent. 
Clinicians were the only participants to indicate that stigma contributed to patients seeking 
treatment in areas where they did not know patients or staff. 
4.4.2 Patient advocates’ access to patients  
Home visits by patient advocates provided patients with assistance with difficulties they 
experienced in adhering to ART. Difficulty to get access to patients acted as a barrier to 
patients’ adherence, as patients often did not receive the additional assistance from the patient 
advocates. 
Patient advocates. Concern about the inability to access patients due to the 
communities the patients resided in was raised by patient advocates from both focus group 
discussions. Patient advocates indicated a fear for their safety when entering some of the 
patients’ communities. One of the patient advocates said: 
It is your greatest fear when you work in the field. And where you enter, in our area 
there is a lot of squatter camps, and it is dangerous, but we have to go through there, 
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because at the end of the day our patients remain important, so we have to go there 
every day. 
This patient advocate referred to the physical characteristics of the patients’ communities, the 
lack of protection, and often the type of client they had to visit. The risky nature of visiting 
patients was particularly applicable to those patients who were addicted to drugs. 
Clinicians. The difficulties patient advocates experienced in accessing their clients 
were a concern raised by one of the clinicians. Dr Smith attributed these difficulties to the 
inability to physically contact the patients. Patient advocates often had to return several times 
to a patient’s home due to patients not being at home at the time of the visit. Patients often 
missed a couple of visits before difficulties they experienced in adhering to ART were 
attended to. 
Concurrences and discrepancies. Patient advocates and one of the clinicians 
concurred that patient advocates found it difficult to access patients at their homes. The 
reasons for these difficulties were however attributed to different circumstances. While the 
patient advocates emphasised the characteristics of patients and their environment as well as 
their own experiences in having to travel through those communities, the clinician attributed 
difficulties to patients not being accessible or available. Although there was a discrepancy in 
the reasons for the difficulties given by the patient advocates and clinicians, all the reasons 
resulted in patients not receiving the essential support with their adherence. 
4.4.3 Religion  
The role of religion on patients’ ART adherence was associated with influence of religious 
beliefs and values of a religious institution on the patients’ willingness to take their ART 
medication. 
Patient advocates. The non-adherence or discontinuation of medication due to 
religious beliefs or church dogma was recognized by patient advocates from the first focus 
72 
 
group discussions. Some of the patients believed that due to their faith in God, it was not 
necessary for them to take their ARV medication. A particular religious institution was 
specifically identified as one that had instructed patients not to take their ARV medication. 
The reason for these instructions was that the “cure” for their condition was provided by their 
faith and a healing prayer. By taking ARV medication, patients challenged the way of God 
and they were ill because of their disobedience to God. A patient advocate from this group 
said: 
If you believe that you went out for prayer and you got your healing prayer there’s no 
need to doubt God, so you better not take you medication. 
Patients. The patients from this sample did not indicate that their religious beliefs or 
the religious institution of the church acted as a barrier to their ARV adherence. Some of the 
patients who were affiliated with one specific religious institutions indicated that they 
received messages encouraging them to take their ARV medication. 
Clinicians. The influence of religious beliefs or institutions on the patients’ ART was 
only mentioned by one clinician. Sister Kekaba indicated that she had treated a patient, who 
insisted on being retested because he believed that he was “cured” by the healing prayer he 
received. This patient felt severely dejected when he was informed that his second test was 
positive. 
Concurrences and discrepancies. Patient advocates and clinicians agreed that the 
influence of religious beliefs or religious institutions impacted on patients’ beliefs around the 
necessity of taking ARV medication and subsequently also impacted on their HIV positive 
status. They also agreed that patients believed that when they received a healing prayer they 
would be “cured” of HIV and that adherence to ARV would be disobedience to God. There 
was however a distinct discrepancy between the messages patients received surrounding ART 
adherence, and those reported by the clinicians and patient advocates. 
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4.4.4 Substance abuse  
The effect of substance abuse, and more specifically alcohol abuse, on ART adherence could 
be considered within both the individual and a social and community-related context. The 
lack of alcohol treatment programmes in this particular community prevented patients to 
adequately adhere to ARV medication. 
Patient advocates. Patient advocates from both focus group discussions mainly 
attributed patients’ non-adherence associated with substance abuse to individual barriers. 
They identified substance abuse as contributing to patients often forgetting to take their ARV 
medications when intoxicated. According to a patient advocate from the second focus group 
discussions 
You have to take it twice a day, twelve hours apart. Maybe you have to take your 
medication in the morning, now you take it. When you get up, you are sober, you 
drink your medication. As the day progress, you start to drink. Tonight you have 
to…especially if you are drunk, then you are not going to take it because you are 
under the influence of alcohol 
The patient advocates from the focus group discussions testified to being aware of 
patients who consume alcohol. It was however difficult for them to see the reasons why 
patients  abused alcohol. 
Patients. The effect of alcohol abuse on patient’s non-adherence to ARV medication 
was indicated by Priscilla, one of the patients. 
I also drank and I forgot to take my treatment, I didn’t worry. Look, when a person 
drank, you don’t worry. 
Several patients from the sample admitted to having abused alcohol in the past. However, 
none of the patients interviewed perceived terminating their alcohol consumption to be a 
problem. The consumption of alcohol was also not considered to have an effect on their ART 
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adherence. The achievement of sober habits was attributed to personal achievement, rather 
than to the assistance of social networks or treatment support programmes. 
Clinicians. Four of the clinicians attributed non-adherence and default of ART to 
substance abuse. The effect of being intoxicated often caused patients to forget to take their 
ARV medication, or it contributed to their reluctance to take their medication while drinking. 
Clinicians also indicated that it is necessary for patients to adequately address the 
reasons why they were abusing alcohol. Dr Smith suggested that even though patients may 
want to stop drinking, the treatment programmes were often inadequate in helping them to do 
so. The treatment programmes available within the patients’ communities such as AA and 
AlAnon, were often not ideal as they generally did not accommodate Xhosa-speaking 
patients. 
Concurrences and discrepancies. The effect of substance abuse on the patient’s 
ability to adequately adhere to ART was raised by both the patient advocates and the 
clinicians. However, only one patient attributed substance abuse to non-adherence. The rest 
of the patients denied that substance abuse had an effect on their adherence. The availability 
of treatment programmes to assist all patients to stop drinking was deemed necessary by both 
patient advocates and clinicians. Patients on the other hand indicated that they either had 
stopped or could stop drinking by themselves without outside assistance. 
4.4.5 Culture and tradition  
The influence of culture and tradition on patients’ ability to adhere to ART could be 
considered as a mutual influence; the influence of cultural beliefs, practices and traditions on 
adherence, and the influence of adhering to ART on cultural beliefs, practices and traditions. 
Patient advocates. The role of cultural beliefs, practices and traditions on the patient’s 
adherence to ART, and the effects of ART on cultural beliefs, practices and traditions were 
identified by patient advocates from both focus group discussions. Although both groups 
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discussed the role of traditional medications in ART adherence, they differed about how 
traditional medication contributed or influenced ART adherence. The first focus group 
discussion indicated that traditional medication was not an issue of concern to their patients’ 
ART adherence. They were not concerned because the Helderberg Hospital mainly provided 
treatment to the coloured community, rather than the black community where traditional 
medicine was regarded as playing a more prominent role. However, the second focus group 
discussion indicated that some patients treated at the clinic believed in the effect of traditional 
medicine, and that the ARVs would not be effective. The patient advocates from this focus 
group discussion nevertheless concurred with the first focus group discussion on race being a 
contributing factor to patients’ use of traditional medication. According to patient advocates 
from this group some of the patients who started ART indicated that they were not taking 
traditional medications. After baseline blood works were done, however, the opposite would 
happen eventually. 
Clinicians. Patients’ beliefs surrounding the efficacy of ART were identified by one 
of the clinicians. These beliefs were associated with patients’ race or cultural background. Dr 
Nkwali mentioned that patients from a coloured background were more likely to believe in 
the efficacy of ART, than patients from a Xhosa background. Coloured patients also showed 
a greater sense of eagerness to initiate ART. Xhosa patients showed grave concern about 
stigma in their communities, and the effect home visits from patient advocates and hospices 
would have on them. They demonstrated a greater reluctance to take their ARV medication 
due to these reasons. 
The influence of patients’ cultural background was also identified as having an effect 
on their ability to disclose their HIV positive status to family. The inability to disclose was 
closely associated with their expected cultural roles or traditional roles. These roles were 
often more problematic for female patients. Sister Kekana explained a situation she 
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frequently came in contact with in her dealings with patients. Pregnant mothers who had 
started on AZT and NVP were often expected to breastfeed their newborn infants, as bottle 
feeding was not an acceptable practice in their culture. Having received ARV treatment 
therefore made it difficult for these mothers to explain why they could not breastfeed their 
babies. 
Concurrences and discrepancies. Patient advocates and clinicians agreed that the 
patient’s cultural background acted as a barrier to ART adherence; however, there were some 
discrepancies in the opinions about which aspects of ART it had an effect on. Patient 
advocates were concerned that the patient’s cultural background contributed to the use of 
traditional medicine in conjunction with their ART. Patients were dishonest about the use of 
traditional medicine since ART should not be initiated while patients were using traditional 
medicine. Clinicians on the other hand attributed patients’ cultural background to their 
willingness to take their ARV medication and the patient’s perceived efficacy of these 
medications. The clinicians also indicated that treatment often impeded on the patient’s 
cultural and traditional beliefs and practices as it required doing what was expected of them. 
This often contributed to the patient’s reluctance to disclose to family. Patients themselves 
did not indicate the traditions of their culture as having an effect on their treatment or ability 
to adhere to medication. 
4.4.6 Support 
4.4.6.1 Social support.  
The actual or perceived support patients received from their social networks, such as family, 
friends or neighbours was identified as an important enabler of ART adherence. Social 
support enabled patients to adequately adhere to their medication, to do so on time, and 
boosted patients’ confidence and trust in the treatment. 
77 
 
Patient Advocates. Patient advocates from both focus group discussions considered 
patients who did not have any social support to be more likely to struggle with ART 
adherence. Support from social networks contributed to adherence by reminding patients to 
take their ARV medication, to do so at scheduled times and ensuring they “stick” to their 
ARV medication. A patient advocate from the second focus group discussion mentioned that 
reminding patients of the consequences of not properly adhering to ARV medication was also 
an essential part of social support. 
You need to have someone who is going to remind you, remember you need to take 
this for the rest of your life, if you don’t take this understand you’re not going to be 
okay. But if you’re alone sometimes you determined to deny it. 
Patients. The facilitating effect of social support on the patient’s ability to adhere to 
ART was raised by six of the patients from the sample. Patients indicated that their family 
often reminded them to take their ARV medication; they were even reminded by their young 
children. Encouragement to boost their moral and to collect their ART medication from the 
clinic was also reported by patients. Margaret said she was woken up by family in the 
mornings to be able to take her medication on time. Gerome described the social support he 
received from his family. 
 My mother tells me to drink my pills, and then she tells me ‘hey hey it is five to seven, 
take your pills and two slices of bread and drink them’. I have a good understanding 
with my family… 
Clinicians. The importance of having social support and the negative effect of the 
absence of social support on patients’ ability to adhere to ART were reported by two of the 
clinicians. Dr Smith indicated that patients who had a good treatment supporter, social 
support or a good family structure “really managed to take their pills”. 
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I think it depends on the family structure and the support structure of the patient. 
If…if there is really a good support…someone who really cares for that patient, they 
will somehow make them swallow their pills. 
The need for social support to vulnerable populations, such as the elderly or illiterate, 
was especially emphasised by sister Kekana. She also described how the lack of social 
support to vulnerable populations impact on their ability to adhere to their medication. 
They can’t read, they’re forgetful, they…they need to have that patient person with 
them to tell them here is your tablets, and come drink you tablets, and make sure that 
they drink it, don’t put it at the bed side or at the table when they have breakfast, or 
whatsoever they need to make sure that the patient take it. 
These people lack support systems at home, probably because care givers got tired of 
staying at home looking after them, and decided to look for a job, leaving these patients with 
no one to look after them. 
Concurrences and discrepancies. The importance of the involvement and support 
from social networks in ART adherence was emphasised by patient advocates, patients, and 
clinicians. Reminding patients about the implications of non-adherence was also considered a 
vital aspect of social support by the patient advocates. The negative effect of not having 
social support was expressed by patient advocates, while clinicians added that the effect was 
intensified amongst vulnerable populations. Although patient advocates and clinicians 
regarded the lack of social support as an important aspect , patients did not mention how the 
lack of social support impacted on their ability to adhere to their ARVs. 
4.4.6.2 Financial support.  
The financial support patients received from family, friends or neighbours was not only 
associated with money, but also physical support. This type of support included goods which 
particularly enabled patients to adequately adhere to treatment and care. 
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Patients. The importance of financial or physical support as an enabler to adhere to 
ART medication and care was raised by four of the patients from the sample. Financial 
support from relatives or neighbours enabled patients to take their ARV medications with 
food, or to travel to the clinic to attend their scheduled clinic visits. Patricia described the 
effect financial support from a family member had on her ability to adhere to her scheduled 
clinic visits. 
My mother spoke with me; she was able to help me at that moment. Because yesterday 
I was at the clinic, I took the taxi, she gave me the money, thirty rand, and I got to the 
clinic. 
Similarly, Shaamiela described how the financial or physical support she received from her 
family assisted her in taking her medication. 
There was a time I did not have food in my house, and I had to take my pills, then I 
couldn’t. But if I didn’t have, I could always go and ask my family next door, in order 
for me to just take my pills. 
Discrepancies. Although financial or physical support was a salient issue amongst 
patients, patient advocates and clinicians did not indicate the importance of obtaining this 
type of support from social networks. The reason why this was identified by patients could 
possibly be attributed to the fact that the conditions that necessitated physical or financial 
support concerned basic aspects of their everyday life such as food and transport. The basic 
needs created the need for obtaining financial or physical support. 
4.4.7 Treatment support programmes  
Treatment support programmes included the Treatment Action Campaign (TAC). The TAC 
was identified as a civil society force which aimed to provide comprehensive healthcare 
services to individuals infected with HIV. 
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Patient advocates. The direct effect of the TAC as an enabler of patients’ adherence 
to ART was not identified. Patient advocates from the first focus group discussions indicated 
the indirect effect it had on patients’ ability to adhere, by getting the patients to disclose their 
status. The approach of the TAC was regarded as a “militant way” of getting patients to 
disclose their status publicly. Patient advocates did not present other influences of the TAC. 
Discrepancies. The indirect effect of the TAC on disclosure was only identified by the 
first focus group. Neither the second focus group discussion, nor patients and clinicians 
indicated treatment support programmes to have a direct or indirect effect on the patient’s 
ability to adhere to ARV treatment and care. 
4.5 Conclusion 
Through focus group discussions with patient advocates and semi-structured interviews with 
patients and clinicians a range of barriers and facilitators to patients’ ART adherence were 
identified. The main barriers and facilitators were related to individual barriers, poverty-
related barriers, institution-related barriers, and social and community-related barriers. There 
were certain concurrences but also discrepancies between the patient advocates, patients and 
clinicians included in this sample about which of these barriers contributed to patients’ 
adherence or non-adherence to ART, how they contributed and why. These concurrences and 
discrepancies contributed to a unique view of the subject matter of adherence as they 
represented a triangular view of: (1) difficulties patients experienced in adhering to treatment 
and care, (2) what the doctors and nurses perceived the difficulties were that patients 
experienced in adhering to treatment and care, and (3) what the patient advocates perceived 
the difficulties to be. The collection of data from focus group discussion with patient 
advocates allowed for systematically and simultaneously getting patient advocates’ 
perceptions related to patients’ adherence to ART. Semi-structured interviews with clinicians 
and patients allowed the flexibility to explore themes that arose during these interviews. The 
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analysis and discussion which follows in Chapter 5 will consider the results of the study 
within the framework of Bronfenbrenner’s (1972) Ecological Systems Theory. 
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CHAPTER FIVE: DISCUSSION 
5.1 Adherence behaviours as the product of the patient’s environment 
The influence of the environment on health and illness has been known since the time of 
Hippocrates (Taylor, Repetti, & Seeman, 1997). Yet, predominant conventional theories such 
as the biomedical model still regard adherence behaviour as being influenced only by 
biological and psychological factors (O’Leary & Martins, 2000). Most psychological and 
medical research does not incorporate environmental factors in understanding adherence 
behaviour (Munro, Lewin, Swart, & Volmink, 2007; Williams & Patterson, 1996). 
The data presented in the previous chapter however indicate that adherence 
behaviours are more complex than suggested by biological and psychological barriers such as 
forgetfulness, mental health, health literacy and barriers associated with medication regimens. 
This complexity brings into focus the need to consider the patient’s environment either as a 
facilitator or as a barrier to adherent behaviour. Adherent behaviour may thus be better 
explained by Kurt Lewin’s classical equation B = f (PE) (Lewin, 1935, p. 73) as the product 
of the interplay between the patient and the environment. 
Bronfenbrenner’s (1972) Ecological Systems Theory provided a multilevelled 
conceptual framework within which the complex adherence behaviours associated with the 
individual barriers, poverty-related barriers, institution-related barriers, and social and 
community-related barriers could be broken down to the level of the patients’ environment in 
which they originated. This conceptual framework also provided some insight into how these 
structural barriers either restricted or facilitated adherence behaviours. Such an approach is 
often overlooked by conventional biological and psychological research (Cox & Meade, 
1975; Lambert & McKevitt, 2002; Van der Geest & Hardon, 2006). 
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5.2 Bronfenbrenner’s (1972) Ecological Systems Theory 
The Ecological Systems Theory extends beyond conventional research theory which mainly 
focuses on the individual, to a theory which, apart from individual barriers, addressed the 
patient’s adherence in a global context (Coday et al., 2002; DiClemente, Crosby, & Kegler, 
2002). The use of the Ecological Systems Theory as a multi-levelled framework made it 
possible to consider the patient’s environment as a complex conceptual map of the influences 
on adherence behaviours (Reppucci, Mulvey, & Kastner, 1983). 
This conceptual map considered adherence behaviours situated within the patient’s 
environment as a “set of nested structures” where one structure was fitted within the others 
like “Russian dolls” (Bronfenbrenner; 1979). As represented by the modified Ecological 
Systems Theory (included in Appendix I) the various systems operating within the patient’s 
ecological environment include the individual as its own system as well as the micro-, exo- 
and macrosystem, and will be discussed accordingly. 
5.2.1 The individual as a system  
According to Potgieter (1998), the individual patient could be regarded as a complete system 
which consisted of various emotional, cognitive and behavioural sub-systems. These sub-
systems were considered as individual psychological and behavioural barriers by both 
conventional research as well as the present study. Although the identification of these 
barriers may not have been the primary aim of the present study it was still included in the 
modified Ecological Systems theory as it was considered an important contributor to the 
context of barriers within the patient’s environment.  
Previous research regarding individual barriers to adherence was included, and the 
findings of the present study largely coincided with findings of previous research, such as: (1) 
Chesney (1997) and Chesney et al. (1999) on forgetfulness amongst patients; and (2) Gordillo 
et al. (1999) and Roberts and Mann (2000) on the problem of pill-burden to ART adherence. 
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The data obtained also agreed with studies done by: (3) Weiss et al. (2003) on health literacy; 
(4) Kalichman et al. (1999) and Schuman et al. (2001) on the effect of illiteracy on 
adherence; and (5) Catz et al. (1998) and Punjari et al. (2008) on the role of mental health in 
determining adherence. 
5.2.2 Microsystem  
Bronfenbrenner (1979) identified the microsystem as any context where a person has 
immediate experience and personal interaction with others. Interpersonal relationships within 
this setting include those with family, friends or neighbours within the patient’s immediate 
environment. According to the modified Ecological Systems Theory this microsystem 
included: (1) barriers associated with stigma and disclosure, and (2) the facilitative effect of 
tangible social support on adherence behaviour. 
5.2.2.1 Stigma and disclosure.  
As suggested by the modified Ecological Systems Theory, stigma could be located within 
both the micro- and macrosystem. It was essential to consider stigma and disclosure within 
both these systems in order to understand how it functioned as a barrier to adherence. While 
the macrosystem was more concerned with the origin of stigma, the microsystem considered 
the effect thereof on the patient’s interactions with individuals within their microsystem.   
The present study found that patients feared disclosure of their HIV positive status to 
others within their environment for several reasons. In keeping with the findings of Maskew 
et al. (2007) the present study found patients to be reluctant to disclose that they are HIV 
positive to employers for the fear of being dismissed. This reluctance to disclose their HIV 
positive status not only restricted their ability to obtain the necessary leave to adhere to 
scheduled clinic visits, but also affected their pill-taking behaviour. Similar to Davies et al. 
(2006) respondents indicated that due to the fear of their HIV positive status being discovered 
patients often hid medication bottles, and subsequently forgot to take their medication. 
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Additionally, both Hardon et al. (2006) and the present study found that patients would 
deliberately skip doses when privacy was not available at the scheduled dosing time. The 
present study also found that patients chose not to disclose their HIV positive status to certain 
friends due to the fact that these friends frequently abused alcohol. Patients indicated that 
disclosing to these friends would mean that the news of their HIV positive status would 
spread through their community like a wildfire. 
In agreement with Liu et al. (2006) the present study found that patients refused in-
patient treatment as well as home-based care when terminally ill. They also refused to receive 
home visits from patient advocates, in fear of inappropriate disclosure of their HIV positive 
status. Patients associated inappropriate disclosure with their social network discovering their 
HIV positive status through services provided at home, or at the public healthcare facilities. 
Thus, patients’ adherence to ART care was compromised by their fear of having to deal with 
stigma when accessing certain healthcare resources within their environment. 
5.2.2.2 Social and tangible support.  
The modified Ecological Systems Theory located social and tangible support within the 
microsystem of the patient’s environment. The reason for this was that social networks within 
their environment were found to be responsible for the facilitation of their adherence 
behaviours. Similar to Catz et al. (2003) the present study found that encouraging patients to 
co-operate with the prescriptions of clinicians facilitated adherence behaviours.  
In agreement with Singh et al. (1999) the present study found that family members 
and neighbours were typically the ones who either directly or indirectly reinforced adherent 
behaviours. Respondents indicated that direct reinforcement included reminding patients to 
take their medications at specific times and according to the instructions of their physicians. 
While indirect reinforcement included boosting the patient’s moral or their motivation to take 
ARVs, as well as reminding patients of the implications of non-adherence. 
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Waddell and Messeri (2006) ascribed the importance of social support to: (1) an 
enhanced access to resources; (2) an enhanced immune response; (3) the improvement in 
health-related behaviours; and the (4) improvement in mental and physical health by reducing 
levels of stress or buffering patients from stressors that diminish health and well-being 
(Turner & Turner, 1999). Additionally Ennett, Bailey, and Dederman (1999) and Resnick et 
al. (1997) indicated that social support (5) reduced risk behaviours and increased emotional 
bonding through the provision of information and advice, and positive peer influence. 
Similar to the findings of Waddell and Messeri (2006), the present study also found 
that social support enhanced the patient’s access to other resources. Despite coming from a 
context of poverty, social networks also contributed to adherent behaviour amongst patients 
through donating financial or tangible resources to patients. These resources included food to 
take their medication with, or money to acquire either food or transportation. These resources 
were considered as having a grave effect on adherence to ART treatment and care. 
5.2.3 Exo-system  
The exo-system was the second system in Bronfenbrenner’s (1979) multi-levelled Ecological 
Systems Theory. Visser (2006) described this system as the organizational level of the 
patient’s ecological environment. This system included the relationship between two or more 
settings in the patient’s ecological environment of which one setting did not include the 
patient, but rather the patient’s immediate environment.  
As indicated in the modified Ecological Systems Theory this system included 
institutional barriers, which were divided into three sub-barriers namely: (1) the public 
healthcare system; (2) the specific medical resources available to the patients at the Infectious 
Diseases Clinic and Helderberg Hospital; and (3) staff as a medical resource available to the 
patients. 
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5.2.3.1 Healthcare system. 
5.2.3.1.1 Inclusion criteria of patients to ART programmes.  
As indicated by the modified Ecological Systems Theory the first institution-related sub-
barrier ascribed the lack of strict adherence to the shift in the criteria for inclusion of patients 
to ART programmes. Dr Smith referred to this shift in the inclusion criteria as the “open 
access” to ART treatment. Concerns surrounding the “open access” to ART treatment were 
associated with the introduction of more lenient inclusion criteria by the National Department 
of Health in 2004 and then again in 2010, when compared to those first introduced by rollout 
programmes such as the Khayelitsha Project in 2003.  
Rollout programmes such as the Khayelitsha Project (2003) presented above average 
adherence amongst patients due to the strict inclusion criteria of these programmes. Patients 
were considered for ART according to: (1) a biological criteria of WHO stage III and IV 
(WHO stage criteria indicated in Appendix J) and a CD4 count of <200cells/mm³; (2) 
regularity, where patients had to attend HIV clinics for at least three months being on time for 
the last four visits; (3) meeting social and adherence criteria, including the evaluation of 
home environment, disclosure, family support and a treatment supporter. After having met 
these criteria patients were only selected by a community selection committee (Médecins 
Sans Frontières South Africa, 2003).  
After the introduction of the Standardized National Eligibility Criteria for Starting 
Regimens for Adults and Adolescents in 2004 patients were now considered for enrolment 
based upon a biological criteria of: (1) CD4 count of <200cells/mm³ irrespective of stage or 
(2) WHO stage IV AIDS-defining illness, irrespective of CD4 count and (3) patient’s 
expressed willingness and readiness to take ART adherently (Provincial Administration 
Western Cape, 2004). These guidelines included psycho-social considerations of: (1) 
demonstrated reliability, like having attended three or more scheduled clinic visits; (2) no 
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active alcohol or substance abuse; (3) no untreated active depression; (4) recommended 
disclosure or member of support group; (5) insight, demonstrated by acceptance of status, the 
consequences of infection and the role of treatment before commencing ART. However they 
were psycho-social considerations and did not serve as an exclusion criteria (Provincial 
Administration Western Cape, 2004).These considerations meant that more HIV positive 
patients were now able to access ART, but since the removal of the strict inclusion criteria 
adherence rates showed a significant decline. 
A further concern was associated with the possibility of an ever greater decline in 
adherence due to the introduction of a new Standardized National Eligibility Criteria for 
Starting Regimens for Adults and Adolescents in 2010. Even though these new guidelines 
were introduced after the data was collected, these guidelines contributed to an even greater 
“open access” to ART, as they completely excluded the psycho-social considerations of the 
2004 guidelines, and lowered the biological criteria. Eligibility for ART now solely depended 
upon either: (1) CD4 count <200cells/mm³ irrespective of clinical stage, (2) CD4 
<350cells/mm³ in patients with TB/HIV or pregnant women, (3) WHO stage IV irrespective 
of CD4 count, (4) MDR/XDR-TB (National Department of Health, 2010). Not only did the 
“open access treatment” raise concerns about the patient’s ability to adhere to ART, but also 
that the large number of patients now eligible for ART would contribute to an even greater 
patient load on an already overstretched public healthcare facility. 
5.2.3.2 Public healthcare facility.  
The second aspect associated with institutional barriers as indicated by the modified 
Ecological Systems Theory was related to the healthcare facility. The public healthcare 
facility in the present study was represented by the medical resources available at the 
Infectious Diseases Clinic and Helderberg Hospital, and the role it played as either facilitators 
or barriers to patients’ adherence to ART treatment and care. 
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5.2.3.2.1 Healthcare facility and the protocol staff followed when treating patients. 
In keeping with the findings of Maskew et al. (2007) the present study showed the 
importance of efficient administration of paper files at the public healthcare facility, to be 
able to provide patients with the essential treatment and assist them with adherent behaviours. 
In addition to the findings of Maskew et al. (2007) the present study also found that missing 
crucial information on patients’ treatment was often the result of lost or duplicated files. The 
importance of original patient files was stressed as duplicate files often did not contain 
information such as contact details, treatment history, past clinic visits and blood tests were 
not recorded in those files. Therefore, in the absence of original patient files, it was also 
difficult for clinicians to keep track of each individual patient’s progress. 
The absence of this information was considered to have compromised the quality of 
care patients received at these facilities. In 2004 the National Department of Health 
announced the development of a health information system. This system was designed to 
alleviate the operability in admissions, discharges and transfers, as well as maintenance of 
full patient records. However the implementation of such a system has yet to be realised. 
Apart from administrative difficulties, clinicians indicated that due to protocol 
followed by hospital staff when admitting patients the patients’ ability to adhere to ART 
treatment was gravely compromised when receiving in-patient treatment. The 
mismanagement of patients’ ARV medication meant that patients often went without ART 
for several days. In addition to that patients often spent whole days without receiving routine 
monitoring of their condition during their hospital stay. The above mentioned conditions 
experienced by patients in public healthcare facilities strongly contradict an environment 
where adherence should be facilitated and ensured. 
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5.2.3.2.2 Overcrowding, waiting times and privacy.  
In a context of limited financial resources private healthcare was a commodity patients could 
not afford. With even more patients becoming eligible for ART due to the open access to 
treatment, the demand for already limited public healthcare resources to accommodate 
patients was greatly restricted. These demands for public healthcare not only lead to a shift in 
infrastructure but also impacted on personnel and financial resources at the Infectious 
Diseases Clinic and Helderberg Hospital. Though more patients had access to treatment, they 
were now also exposed to conditions which impinged on their motivation to adhere to ART 
care.  
Despite limited literature on the barriers associated with public healthcare, 
respondents indicated that the large numbers of patients now utilizing public healthcare 
resources meant that patients had to wait for extended periods of time before being attended 
to by doctors, nurses, and counsellor as well as having their prescriptions filled at the hospital 
pharmacy. This demand contributed to the lack of privacy when being attended to, as the 
overstretched capacity meant that multiple patients were attended to at the same time. The 
overstretched capacity of the Infectious Diseases Clinic to accommodate out-patients 
extended to the hospital where patients were admitted for in-patient treatment. A 100% bed 
occupancy rate was not uncommon for these facilities and patients often ended up on the 
floor when waiting for a bed to become available. This overstretched capacity therefore 
negatively impacted on the quality care available to the patient.  
Not only did overcrowded public healthcare facilities compromise the quality of care 
available to the patients, but these experiences with facilities also obstructed the patient’s 
willingness to endure these circumstances when attending scheduled clinic appointments. 
Facing these overcrowded circumstances not only contributed to lengthy clinic visits and a 
lack of privacy, but also meant that patients had to leave as early as four o’clock in the 
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morning to get ahead of other patients to be able to leave the facility at a reasonable time in 
the afternoon.  
Having to leave in the early hours of the morning introduced a new set of barriers to 
ART adherence, as patients feared for their safety when having to travel through certain 
communities in the dark. Based on crime statistics of the South African Police Service (2010) 
Western Cape patients had to travel through communities where 2,274 counts of murder, 
1,707 counts of attempted murder, 34,410 counts of assault, and 12,543 counts of robbery 
with aggravated circumstances, have been reported within the past year. When considering 
the level of crime within the patients’ environment their hesitation to attend scheduled clinic 
appointments cannot be ignored  
5.2.3.2.3 Language.  
Limited language resources further impeded patient care. Afrikaans- and English-speaking 
patients could comfortably address their concerns in consultation. However Xhosa-speaking 
patients often had difficulty in communicating not only clinical concerns but deeper issues 
that were often lost in translation. This inability stemmed from staff mainly being Afrikaans- 
or English-speaking, with only one doctor being Xhosa-speaking, and another being able to 
take a basic medical history in Xhosa. Subsequently Xhosa-speaking patients were either 
referred to the Xhosa-speaking doctor, or had to use an interpreter. 
Swartz (1998) indicated that at an interpersonal level the use of an interpreter during 
consultation introduced a third person to a situation mainly designed for two. Subsequently 
such a situation carried certain risks regarding confidentiality and the inappropriate disclosure 
of a patient’s HIV positive status. It was suggested that the use of an interpreter should be 
avoided where possible. The clinician’s ability to adequately address adherence problems 
when using an interpreter could be greatly compromised as patients might be less 
forthcoming through a third party, especially when the patient knew the interpreter (South 
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African HIV Clinicians Society, 2007). Dr Smith emphasized the importance of good 
communication between patient and clinician in addressing problems surrounding adherence. 
This is imperative as an understanding of the patient’s psycho-social issues enabled staff to 
adequately address any difficulties the patients experienced with their adherence. 
Swartz (1998) indicated that the reasons for using an interpreter were related to the 
institution and its needs. The lack of Xhosa-speaking staff at the healthcare facility, as well as 
the absence of “official” interpreter positions raised the question of equal care for all patients. 
Both the present study and Swartz (1998) found that in hospitals without official interpreters 
cleaners or family members should be used as interpreters.  
Although there were no official interpreter positions at the Infectious Diseases Clinic 
the South African HIV Clinicians Society (2007) recommended that independent interpreters 
be trained on issues of confidentiality to be prepared for such a position. They would then 
have the ability to obtain vital information from patients and make it easier to reveal issues 
regarding their adherence within an environment where they felt comfortable. 
5.2.3.2.4 Patients’ relationship with healthcare workers.  
As indicated by the modified Ecological Systems Theory patients’ relationship with their 
healthcare workers was considered within the exo-system of their environment. This 
relationship was considered important since the staff were found to be a valuable medical 
resource available to patients at the Infectious Diseases Clinic. 
The Department of Health (2003) and Tzynka and Erlen (2004) considered a trusting 
and supportive relationship between patients and healthcare workers to be indispensible and 
an important facilitator of better adherent behaviour amongst patients. The importance of 
such a relationship was also stressed by Catz et al. (1998) who indicated that any interaction 
with a patient provided the clinicians with an opportunity to reinforce adherent behaviour. 
Additionally, a supportive and non-judgemental environment has the potential to enable 
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patients to honestly discuss and address any problems with their adherence (Department of 
Health, 2003). 
Even though literature such as Catz et al. (2000), Murphy, Roberts, Martin, Marelich 
and Hoffman (2000) and Murphy, Roberts, Hoffman, Monalina and Lu (2003) indicated that 
trusting and supportive relationships enabled adherent behaviour, the present study found that 
negative interactions with healthcare workers had the ability to act as a barrier. Respondents 
indicated that patients’ relationships with healthcare workers were influenced by negative 
interactions, which subsequently impeded on their willingness to adhere to ART care. 
Patients took responsibility for these negative experiences and the short-temperedness of 
staff, as they attributed these to their lack of punctuality with scheduled clinic appointments. 
Clinicians on the other hand attributed these negative experiences to nature and workload 
associated with their jobs. Whether experiences were deemed positive or negative, it had a 
definite effect on patients’ willingness to attend scheduled clinic appointments. 
5.2.3.3 Healthcare workers at the IDC.  
5.2.3.3.1 Experiences, burnout and lack of resources.  
The third aspect of institutional barriers as indicated by the modified Ecological Systems 
Theory in Appendix I was associated with the clinicians as a medical resource available to 
the patients seeking ART treatment. Attending to the acute needs of the ART patients they 
treat on a daily basis, the needs of the clinicians were often overlooked (National Department 
of Health, 2004). Clinicians encountered large numbers of patients in limited resource 
settings. They were often burdened with a severe workload and consequently faced burnout. 
However, the availability of services to address the psychological implications associated 
with such circumstances was not addressed adequately. 
The Department of Health (2003) announced the development of staff support 
programmes at healthcare facilities. These programmes included the provision of time and 
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structured staff support programmes for debriefing and grief management associated with the 
loss of patients, especially those well-known to staff. Although clinicians indicated a great 
need for such a programme, still no resources or professional services were available to them, 
which resulted in these matters being dealt with informally. 
Addressing the psychological needs of the clinician should be considered a priority, as 
their well-being contributed to the “type” and quality of medical resources available to ART 
patients. The importance of addressing these needs have already been indicated by the 
patient–healthcare provider relationships, and its effects on patients’ willingness to adhere to 
scheduled clinic appointments. 
5.2.3.3.2 Staff health literacy.  
The lack of adequate health literacy amongst staff in the past served as a barrier to ART 
treatment. In the years before the widespread knowledge of HIV and AIDS, some clinicians 
reported not knowing more than HIV being a disease, or the special challenges associated 
with treating ART patients. However, the National Department of Health indicated that from 
2003 onwards, healthcare workers had to receive specific training regarding ART treatment 
and adherence and that the training should be updated periodically (Department of Health, 
2003). Such educational courses and the progress made in ART contributed to better health 
literacy amongst staff, translating into better care and assistance with adherence amongst 
patients. 
5.2.4 Macrosystem 
The third system of Bronfenbrenner’s (1972) Ecological Systems Theory included the 
macrosystem. This system was considered the “blue print” of the patient’s specific society, 
culture and sub-culture (Bronfenbrenner, 1994). As indicated by the modified Ecological 
Systems Theory, adherence behaviours within this system were understood by: (1) poverty-
related barriers associated with a specific economic system; (2) social and community-related 
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barriers related to wider systems of ideology operative within the patient’s society, and (3) 
the availability of social resources within their communities. 
5.2.4.1 The influence of poverty on ART adherence to treatment and care.  
Bronfenbrenner (1979) located the origin of poverty-related barriers within the macrosystem 
of the patient’s environment, as the effect of poverty was a function of a specific economic 
system. According to the Gini coefficient, a commonly used measure of social inequality, 
South Africa was classified within the category of “very high levels of social inequality” with 
a score of 0.578 (United Nations, 2009), along with countries such as Haiti or Brazil. This 
number was based on a score of which the value 1.00 represented a situation of perfect 
equality and 0.00 a situation of perfect inequality. In other words a country with a Gini 
coefficient of 0.00 wealth was divided equally amongst everyone, and a Gini coefficient of 
1.00 represented a situation where only one person had all the wealth and everyone else had 
nothing (United Nations; 2009). 
A level of very high social inequality inevitably contributed towards an environment 
with limited financial resources. Similar to Hicks et al. (2007), Tegger et al. (2008) and Ware 
et al. (2009), the present study found that even though these patients received free ARVs, 
their limited financial resources still negatively impacted on their ability to adhere to ART 
treatment and care. The effect of limited financial resources on patients’ adherence behaviour 
was found to be similar to that in a study conducted by Nguyen and Stovel in Botswana 
(2004). The present study found that the limited resources associated with poverty affected 
the patient’s ability to afford basic commodities such as food, “reminder tools” and transport 
which could facilitate better adhere to ART treatment and care. Poverty limited the patient’s 
adherence by impeding on the ability to expend. Adequate adherence also impacted on their 
vocational abilities and interfered with their current working conditions. 
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5.2.4.2 Restricted vocational abilities and conditions of employment.  
South Africa has an official unemployment rate of 25.3%. Speculations are that this rate 
could actually be as high as 30% (Statistics South Africa; 2010). With 4.3 million 
unemployed South Africans, concerns about patients’ ability to remain part of an 
economically viable workforce continue to be legitimate. Patients taking part in this study 
were concerned that due to the physical effect ART had on their body they would not be able 
to perform previously feasible tasks and be able to generate a sufficient income. It is evident 
from the perspective of patients that the inability to generate a sufficient income posed a 
barrier to ART treatment and care. 
As in the study of Weiser et al. (2003) clinicians indicated that in some cases the 
nature of patients’ employment conditions negatively impacted on their adherence, 
particularly the lack of health benefits. Furthermore the timely nature of scheduled clinic 
appointments, the frequency of these visits, and especially when treatment was initiated, 
meant that patients had to forgo a day’s pay each time they had to attend the clinic. Failure to 
disclose their HIV status to their employers further restricted patients’ ability to attend the 
clinic. In the context of widespread unemployment rates, many patients were reluctant to risk 
taking leave for scheduled clinic appointments as they did not want to risk possible dismissal. 
Clinicians also reported that patients who worked shifts were continually burdened by 
having to remember to take their medication, and by being confronted by their inability to 
take their medications in private without being questioned by colleagues. The nature of 
working irregular shifts and facing possible exposure therefore contributed to non-adherent 
behaviour. 
5.2.4.3 Disability grants.  
With the unemployment rate speculated to be as high as 30%, being HIV positive in itself 
became a source of income amongst patients (Nattrass, 2006). Qualifying for a disability 
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grant also meant that patients became reliant upon disability benefits as their primary source 
of income. Disability grants facilitated better adherence amongst patients by alleviating 
poverty (Lund, 1999), however it also became a barrier to adherence and good health. 
Disability grants were indicated as difficult to obtain, and being HIV positive alone 
did not automatically qualify a patient to receive a grant. In addition to the administrative 
difficulties patients experienced in applying for a disability grant, patients had to qualify for 
the biological criterion of a CD4 count of <200cells/mm³. This biological criterion meant that 
patients had to be ill enough to meet the criteria for an AIDS diagnosis to be able to obtain a 
disability grant of R1010, in 2009 (Nattrass, 2006; South African Social Security Agency, 
2009).   
In agreement with Ravallion (2003) the present study found that patients did not 
perceive the amount of R1010 to be sufficient to support day-to-day living. However, based 
upon the international poverty line of R9.10 ($1.25) per patient per day the World Bank 
(2010) indicated that people should be able to meet their most basic needs on the amount of 
R430.70 ($60) per month. Keeping in mind the high unemployment rate these disability 
grants were often the single source of household income for patients. TB studies conducted in 
the Western Cape Nattrass (2006), found that when a disability grant was regarded as a 
source of income it compromised the patient’s need or motivation to maintain adherent 
behaviour and good health. Patients therefore compromised their adherent behaviour by 
deliberately forgoing ART in an attempt to maintain a CD4 count below 200cells/mm³. In 
doing so, these patients would become eligible to apply for an extension of their grant. 
Clinicians furthermore indicated that even though patients became non-adherent to ART, 
there were also times when patients used the threat of non-adherence in an attempt to have 
their disability grant continued. 
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The effect of disability grants on adherence behaviour however still remains 
controversial. Despite this controversy the present study, in agreement with Nattras (2006), 
concluded that patients obtained access to a disability grants through an act of desperation. 
These acts of desperation compromised patients’ health, as they limit much needed healthcare 
in order to be able to afford basic commodities 
5.2.4.4 Food insecurity as a function of poverty.  
Food insecurity was considered a macrosystem barrier to ART adherence. The inability to 
afford certain foods is associated with high levels of poverty. Available literature on food 
insecurity, such as studies done by Baylies (2002), De Waal (2002) and Du Guerny (2002), 
associated an increased level of food insecurity with the HIV positive patient’s inability to 
adhere to special diets. However, the present study found that food insecurity resulted in an 
inability to afford even the most basic foods. 
In keeping with the findings of Ware et al. (2009) the present study found that in most 
cases patients made use of available social resources within their environment when 
experiencing food insecurity. These social resources included soup kitchens or obtaining food 
from family members or neighbours to take their medication with. There were however times 
when patients simply did not have a choice but to “do without” when their social resources 
were exhausted. The inability to purchase these most basic foods made patients reluctant to 
take their ART medication. They would often dismiss the clinician’s recommendations, to 
take ART medication on an empty stomach rather than skipping doses completely, as the 
hunger-induced side-effects of the treatment were too difficult to overcome. 
Marson and De Cock (2004) stressed the importance of food security, as hungry or 
undernourished patients found it difficult or sometimes impossible to adhere to complex ART 
regimens. Being well-nourished was essential to the survival and functional recovery of the 
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patient while on ART (Ware et al., 2009), and medications were considered to be more 
effective when patients were well nourished.  
5.2.4.5 Living arrangements as a function of poverty. 
 Limited financial resources restricted patients’ options regarding their living arrangements. 
Moralejo et al. (2006) found barriers related to living conditions, to be associated with the 
type of relationship the patient had with the person they lived with. The present study, 
however, found that these barriers were rather associated with an overcrowded living 
situation. Such a living situation had a negative impact on the patient’s willingness to take 
ART medication in the presence of others. Such living arrangements also meant an 
environment with regularly disrupted daily routines, which subsequently contributed to 
forgetfulness when taking ART medication. 
5.2.4.6 Reminder tools as a function of poverty.  
As indicated by the Modified Ecological Systems Theory, the absence of reminder tools 
within the patients’ environment was ascribed to poverty. This came as clinicians associated 
the lack of these reminder tools with the patient’s restricted ability to purchase items such as 
watches, cell phones or television sets to assist them with precise adherence to the scheduled 
dosing times. In agreement with Golin et al. (2002) the clinicians confirmed that patients who 
used more adherence aids had been more likely to be adherent. Supported by Golin et al. 
(2002), clinicians stressed the importance of reminder tools. However, neither the patient 
advocates nor the patients showed any concerns about the patient being able to afford 
reminder tools. 
5.2.4.7 Transportation as a function of poverty.  
As indicated by the Modified Ecological Systems Theory, the present study found the 
inability to afford transportation to be a function of poverty. It was found that public 
transportation was an expenditure most patients struggled to afford, which confirmed the 
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findings of Mukerjee et al. (2006). Similar to studies conducted in Nigeria and Tanzania this 
study found that obtaining money for transportation to attend scheduled clinic visits was 
rarely as easy as “dipping into a ready supply of cash” (Ware et al., 2009). For patients who 
were seeking out-patient treatment, an amount as little as R7 was more than some could 
afford. In the absence of financial resources for transportations, patients either did not adhere 
to their scheduled clinic appointments, or they travelled to the clinic by foot. Some hitch-
hiked, sometimes travelling up to three hours at a time, while enduring harsh elements. 
Patients who were able to afford public transportation faced additional barriers in 
adhering to scheduled clinic appointments, such as a poor public transportation system in the 
area of the Infectious Diseases Clinic. Taxi routes were itinerant to the Somerset West CBD 
and the patients who were able to afford public transportation were still required to complete 
the rest of their journey by foot. Additionally, taxi strikes negatively impacted on the 
patients’ ability to get to the Infectious Diseases Clinic on time. Subsequently patients were 
often left without transportation for several days at a time. The public transportation system 
also left patients without alternative means of transportation, such as buses. Maintaining 
scheduled clinic appointments were directly related to the patient’s ability to remain adherent 
to ART (Stout, Leon, & Niccolai, 2004). 
5.2.4.8 Migration.  
The present study, in agreement with studies by Lima et al. (2009) found migration amongst 
HIV positive patients to be a common occurrence. The decision to migrate was most often 
associated with patients’ socio-economic status and resulted from the inability to generate an 
income within their present environment (Lima et al., 2009). Consequently, during permanent 
migration the patient’s need to seek out ART treatment and care was often outweighed by the 
need to obtain employment, or to acquire some sort of income, especially when the migrant 
patient was asymptomatic.  
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Additionally respondents indicated that adherence was also compromised by 
insufficient knowledge as to where they could seek out ART treatment and care within their 
new environment. Respondents furthermore associated non-adherent behaviour with certain 
beliefs around having to disclose their HIV positive status to their family before being able to 
access ART treatment and care. “Having to disclose” often outweighed the perceived need or 
importance of accessing much needed care. 
Respondents indicated temporary migration to have a negative effect on adherent 
behaviours amongst patients. Similar to permanent migration, temporary migration resulted 
in patients from other regions of the country resettling in the Western Cape in search of 
employment, often leaving their families behind. Returning to those regions during holidays 
or for specific events such as funerals was identified as a barrier to adherent behaviour. 
During both permanent and temporary migration patients travelled without a sufficient supply 
of ART medication. Despite not having a sufficient supply of ART medication, migrant 
patients still chose not to seek ART care in the area where they had settled, and subsequently 
went without it. 
Clinicians expressed grave concern about both permanent and temporary migration, 
as in both cases patients often travelled without the necessary transfer letters. The lack of this 
necessary documentation compromised the quality of care amongst migrant patients 
accessing treatment at other public health facilities. Clinicians at those facilities were 
required to treat patients without the necessary information on their medical history, blood 
tests or current treatments.  
5.2.5 The effect of social and community-related barriers on adherence 
The effect of social and community-related barriers present within the macrosystem was 
associated with the barriers posed by wider systems of ideology within the patient’s society 
or community (Bronfenbrenner, 1994). Within this system adherent behaviour was facilitated 
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or restricted by the beliefs, knowledge, attitudes and values of the patient’s society or 
community. As suggested by the modified Ecological Systems Theory barriers associated 
with the patient’s particular society or community included: (1) stigma associated with HIV 
and AIDS; (2) attitudes and values of religious standings or institutions; and (3) cultural 
values and practices. 
5.2.5.1 Stigma and disclosure.  
Though the effect of stigma and disclosure was previously noted as a microsystem barrier due 
to its effect on the patient’s interaction with others, it was also deemed a macrosystem barrier 
since stigma was considered to have originated within this system. The origin of stigma was 
derived from two sources, the first being the fear of contagion, and secondly from the 
negatively based assumption about people living with HIV (UNAIDS/WHO Working Group 
on Global HIV/AIDS and STI Surveilance, 2008). Like Ritamaki et al. (2006) the present 
study attributed negatively based assumptions to stigma which included the attitude of the 
community towards and understanding of HIV and HIV positive individuals.  
Goffman (1963) associated stigma with the shared meanings or schemas of the 
patient’s community. The present study indicated that stigma associated with being HIV 
positive to have evolved from the faulty schemas or beliefs of the community around the 
transmission of HIV. Patients indicated that stigma resulted in being treated differently by 
their social networks or communities. Patients also indicated that their decision to disclose 
their HIV status to others was greatly influenced by their fear that they would become a 
source of ridicule in their communities or, what Goffman (1963) referred to as “being 
inferior”.  
The collective beliefs, values and attitudes of the patients’ community not only played 
a part in their decision to disclose their HIV positive status to others, but also contributed to 
the reluctance amongst patients to utilize the medical resources within their communities. In 
103 
 
accordance with Liu et al. (2006) this reluctance was illustrated by the patient’s refusal to 
attend healthcare facilities, utilize home-based care when terminally ill, or to receive visits 
from patient advocates to assist with difficulties in adherence. However, in agreement with 
the findings of Reis et al. (2005), the healthcare facility itself was also a prime stigmatizing 
agent, and contributed to an already reluctant patient’s unwillingness to attend scheduled 
clinic visits. 
Studies such as Ritamaki et al. (2006) suggested that the negative effect of stigma on 
adherence behaviours could be addressed within the exo-system of the patient’s environment. 
Ritamaki et al. (2006) concluded that this could be done by doctors at public healthcare 
facilities attending to stigma-related issues when counselling patients prior to their ART 
initiation. 
5.2.5.2 Religion.  
Based on patient advocates’ reports rather than patients’ reports it was found that the beliefs 
and values of a specific religious institution prevented patients to adhere to ART. When 
patients affiliated with this religious institution chose to receive a healing prayer, their 
adherent behaviours were considered as deviant from God’s will, because their adherent 
behaviour would then “indicate” that they did not believe in God. It was believed that these 
healing prayers served as a cure for their HIV or AIDS. Although this specific religious 
institution placed great restrictions upon adherent behaviour, patients affiliated with other 
religious institutions only indicated to have received facilitative messages from their various 
religious affiliations. 
5.2.5.3 Cultural and traditional background of patients.  
The role of cultural and traditional background had a dual effect on the ART adherence 
behaviours amongst patients. Firstly, the collective beliefs, practices and traditions impeded 
on patients' willingness to adhere to their ART medications. Studies conducted amongst 
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African American and ethnic minorities indicated adherence amongst these groups to be 
poorer than Caucasian participants (Metha et al., 1997). Reasons for these differences could 
however not be found (Kalichman, 1999). 
The present study on the other hand did not consider race alone when determining 
adherent behaviour, but also considered the collective beliefs, practices and traditions of 
racial groups. These collective beliefs, practices and traditions were largely associated with 
the beliefs or perceptions of the effectiveness of ART, which subsequently contributed to 
their willingness to adhere. Cultural practices also had some bearing on whether patients took 
traditional medications in conjunction with their ART regimens. 
The second finding related to cultural and traditional background was the effect of 
ART on cultural expectations. The study presented the example of a black mother who could 
not breastfeed her infant due to the risk associated with ART. Bottle-feeding an infant was 
frowned upon by her culture. Additionally, such cultural expectations meant that patients had 
to disclose their HIV status as an explanation why they could not conform to cultural 
practices.   
5.2.5.4 Resources available to patients within their communities.  
As indicated by the modified Ecological Systems Theory, the third system operating within 
the macrosystem identified barriers associated with the availability of certain resources 
within the patient’s community. The resources identified were: (1) the patient advocates’ 
access to patients and (2) the availability of substance abuse programmes. 
5.2.5.4.1 Patient advocates’ access to patients.  
Patient advocates proved to be a valuable resource within the patient’s community, as they 
assisted patients with any difficulties in their adherence, as well as serving as a link between 
the clinic and the community. However, the enabling effect of patient advocates as a social 
resource was often limited by the physical structures of the communities the patients resided 
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in. Respondents indicated that the neighbourhoods within the patient’s community and 
certain townships instilled a fear amongst patient advocates when they had to do home visits. 
This fear was partly fuelled by certain groups of people residing in the area, such as those 
abusing substances. Respondents indicated that the characteristics of the neighbourhood often 
made it difficult to contact patients, therefore patient advocates often had to return several 
times to the patient’s residence. 
5.2.5.4.2 Substance abuse.  
The importance of substance abuse as a barrier to ART treatment and care has changed over 
the last seven years. In 2003 during the Khayelitsha Project, substance abuse excluded 
patients from the rollout programmes. In 2004 the Standardized National Eligibility Criteria 
for Starting Regimens for Adults and Adolescents, substance abuse was a consideration when 
ART was initiated. However, since the new guidelines for initiating ART, substance abuse 
has not been a consideration for selecting patients for ART. 
Substance abuse however remained of great importance to clinicians and researchers 
as it was still considered to be a barrier to ART adherence (Garcia & Cote, 2003; Parsons et 
al., 2008; Trzynka & Erlen, 2004). Literature on this subject of substance abuse locate non-
adherent behaviour within individual-system of the patient’s environment, as it mainly 
explained non-adherence as the result of substance-induced forgetfulness (Trzynka & Erlen, 
2004).  
The present study on the other hand identified substance abuse as a macrosystem 
barrier to adherence, since the select resources available within the patients’ communities 
limited their ability to address substance abuse through treatment support programmes. This 
was especially limited amongst certain language groups. Clinicians indicated that the lack of 
treatment programmes amongst Xhosa-speaking patients was of particular concern. 
Clinicians also indicated that patients could greatly benefit from the establishment of such 
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programmes within their communities to further facilitate adherence. Patients themselves did 
not feel that substance abuse was a problem or that it interfered with their adherence, despite 
having admitted to substance abuse prior to initiating ART. 
5.3 Conclusion 
Upon examination of the data included in the previous chapter several barriers to adherence 
as a product of the patient’s environment were identified. The examination of adherence 
behaviours moved beyond the conventional individual psychological and behavioural 
research on this matter. However the present study did not disregard these barriers, but rather 
included them into the patient’s multi-structural environment, which proved the importance 
of also considering poverty-, institutional-, and community-related barriers to ART 
adherence. Although these barriers were analytically distinct, the various systems in the 
patient’s environment were interrelated. The need for interventions were emphasised by 
research, as the change in any of the systems would subsequently lead to distinct change in 
the patient’s adherence behaviour. 
5.4 Significance of study 
The present study presented an original perspective on ART adherence behaviour. Through 
the triangulation of the perspectives of patients, clinicians (doctors and nurses) and patient 
advocates this study was able to identify structural barriers through using a specific 
framework. This framework considered ART adherence as a product of the patient’s 
environment, as well as the interplay between the systems operating within this environment. 
By including different groups of respondents it was also possible to identify the different 
systems within the patient’s environment, and how these systems contributed to non-
adherence. Lastly, considering the patient’s environment as barrier to or facilitator of the 
patient’s adherence, several original barriers were identified, which were not yet identified in 
other studies on ART adherence.  
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5.5 Limitations of study 
A limitation posed by this study could be attributed to the data collection stage. The presence 
of two to four interviewers, may have affected the responses obtained from patients included 
in the sample. Patients were reassured that their responses would be kept confidential and 
anonymous. However the number of interviewers present may have contributed to discomfort 
amongst patients when sharing information on sensitive issues. The number of interviewers 
may also have contributed to patients not being as forthcoming as they possibly would have 
been in a one-on-one situation. This possible discomfort may have been intensified by the 
difference in race and social class of the respondents and the interviewers.  
5.6 Suggestions for future research 
The present study did not present immediate solutions to the barriers to ART adherence 
within the patient’s environment. However, it provided a solid foundation for research to 
address how patients could be assisted in developing the necessary skills to cope with their 
environment more effectively in order to improve adherence behaviours.  
An investigation into how the new inclusion criteria could be considered in 
determining how adherence behaviours amongst HIV positive patients were affected. By 
doing so strategies could be developed to support newly enrolled patients to adhere to ART 
treatment and care. 
Effective ways of enhancing social support from the patient’s social networks should 
also be explored, as they provide a rich source of social and tangible support. This could be 
done by examining ways of how disclosure could be enhanced or how social networks could 
be included in the treatment programmes to improve patients’ ability to adhere. Lastly, the 
present study also invited the investigation of the political factors operating within the 
patient’s environment, as no political barriers to ART adherence were reported by the 
respondents. 
108 
 
REFERENCES 
Ajzen, I. (1985). From intentions to actions: A theory of planned behaviour. In J. Kuhl, & J. 
Beckmann (Eds.), Springer series in social psychology (pp. 11-39). Berlin: Springer. 
Ajzen, I., & Fishbein, M. (1980). Understanding attitudes and predicting social behaviour.  
New Jersey: Prentice Hall. 
Altice, F., & Friedland, G. (1998). The era of adherence to HIV therapy. Annals of Internal 
Medicine , 129(6), 503-505. Retrieved from  
http://www.annals.org/content/129/6/ 503.extract.  
Antiretroviral therapy coverage among people with advanced HIV infections (percentage). 
(2008). Retrieved from http://www.who.int/whosis/indicators/2007ARV/en/idex.html.  
Bangsberg, D. R., Hecht, F., Charlebois, E., Zolopa, A., Holodniy, M., Sheiner, L., . . . Moss, 
A. (2000). Adherence to protease inhibitors, HIV-1 viral load, and the development of 
drug resistance in an indigent population. AIDS, 14(4), 357-366. Retrieved from 
http://journals.lww.com/aidsonline/Fulltext/2000/03100/Adherence_to_protease_inhi
bitors,_HIV_1_viral.8.aspx.  
Bangsberg, D., Charlebois, E., Robert, G., Holdniy, M., Deeks, S., Perry, S., . . . Federick, M.  
(2003). High levels of adherence do not prevent accumulation of HIV drug resistance 
mutations. AIDS, 17(13), 1925-1932. Retrieved from  
http://journals.lww.com/aidsonline/Fulltext/2003/09050/High_levels_of_adherence_d
o_not_prevent.11.aspx.  
Bangsberg, D., Hecht, F., Clague, H., Charlebois, E., Ciccarone, D., Chesney, M., . . . Moss, 
A. (2002). Provider assessment of adherence to HIV antiretroviral therapy. Journal of 
Acquired Immune Deficiency Syndromes, 26(5), 435-442. Retrieved from 
http://journals.lww.com/jaids/Abstract/2001/04150/Provider_Assessment_of_Adhere
nce_to_HIV.5.aspx.  
109 
 
Bangsberg, D., & Moss, A. (1999). When should we delay highly active antiretroviral 
therapy? Journal of General Internal Medicine, 14(7), 446-448.  doi: 10.1046/j.1525-
1497.1999.05109.x. 
Baylies, C. (2002). The impact of AIDS on rural households in Africa: A shock like any 
other? Development and Change, 33(4), 611-632. doi: 10.1111/1467-7660.00272. 
Berg, C., Michelson, S., & Safren, S. (2007). Behavioural aspects of HIV care: Adherence, 
depression, substance use, and HIV-transmission behaviours. Infectious Disease 
Clinics of North America, 21(1), 181-200. Retrieved from 
http://www.id.theclinics.com/article/S0891-5520(07)00007-4/abstract.  
Boulle, A., Bock, P., Osler, M., Cohen, K., Channing, L., Hildebrand, K., . . . Abdullah, F. 
(2008). Antiretroviral therapy and early mortality in South Africa. Bulletin of the 
World Health Organization , 86(9), 657 - 746. doi: 10.1590/S0042-
96862008000900011. 
Bova, C. (2000). Women with HIV infection: The three waves of scientific inquiry. Journal 
of the Association of Nurses in AIDS Care, 11(5), 19-28. doi:10.1016/S1055-
3290(06)60381-6. 
Bronfenbrenner, U. (1975). Influences on human development. Dryden Press: Fort Worth. 
Bronfenbrenner, U. (1979). The ecology of human development, experiments by nature and 
design. Cambridge: Harvard University Press. 
Bronfenbrenner, U. (1994). Ecological models in human development. In M. Gauvain, & M. 
Cole (Eds.), Readings on the development of children (pp. 37-43). New York: 
Freeman. 
Burden of Disease Research Unit. (2007). What is the impact of HIV/AIDS in South Africa? 
Retrieved from http://www.mrc.ac.za//bod/faqaids.htm.  
110 
 
Burke, L., Dunbar-Jacob, J., & Hill, M. (1997). Compliance with cardiovascular disease 
prevention strategies: A review of research. Annals of Behavioural Medicine, 19(3), 
239-263. doi: 10.1007/BF02892289. 
Burke, L., & Ockene, I. (2001). Compliance in healthcare and research. Armonk, NY: 
Futura. 
Carpenter, C., Cooper, D., Fischl, M., Gatell, J. G., Gazzard, B.G., Hammer, S., . . . 
Volberding, P.A. (2000). Antiretroviral therapy in adults: Updated recommendations 
of the international AIDS society-USA panel. Journal of the American Medical 
Association, 283(3), 381-390. Retrieved from http://jama.ama-assn.org/cgi/content/ 
abstract/283/3/381.  
Catz, S., Kelly, J., Bogart, L., Benotsch, E., & McAuliffe, T. (2000). Patterns, correlates, and 
barriers to medication adherence among persons prescribed new treatments for HIV 
disease. Health Psychology, 19(2), 124-135. Retrieved from 
http://psycnet.apa.org/index.cfm?fa=buy.optionToBuy&id=2000-13978-003. 
Centers for Disease Control and Prevention. (1998). Report of the NIH panel to define 
principles of therapy of HIV infection and guidelines for the use of antiretroviral 
agents in HIV-infected adults and adolescents. Retrieved from 
http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL04241998014.pdf.  
Centers for Disease Control and Prevention. (2001a). HIV/AIDS Surveilence Report. 
Retrieved from http://www.cdc.gov/hiv/surveillance/resources/reports/ 
2001report_no2/.   
Centers for Disease Control and Prevention. (2001b). Revised recommendations for HIV 
screening of pregnant women: Perinatal counseling and guidelines consultation. 59-
65: Morbidity and Mortality Weekly Report, U.S. Department of Health and Human 
111 
 
Services/Public Health Services. Retrieved from http://www.cdc.gov/mmwr/ 
preview/mmwrhtml/rr5019a2.htm.  
Chesney, M. (1997). New antiretroviral therapies: Adherence challenges and strategies. 
Evolving HIV treatments: Advances and challenges of adherence, 37th ICAAC 
Symposium. Toronto, Canada. 
Chesney, M. (2000). Factors affecting adherence to antiretroviral therapy. Clinical Infectious 
Diseases, 30(Suppl 2), S171-S176. doi: 10.1086/313849.  
Chesney, M. (2006). The elusive gold standard. Further perspectives for HIV adherence and 
intervention. Journal of Acquired Immune Deficiency Syndromes, 43(Suppl 1), S149-
S155. doi: 10.1097/01.qai.0000243112.91293.26. 
Chesney, M., Ickovics, J., Chambers, D., Gifford, A., Neidig, J., Zwickl, B., . . . Wu, A.W. 
(2000). Self-reported adherence to antiretroviral medications among participants in 
HIV clinical trials: The AACTG Adherence Instruments. AIDS Care, 12(3), 255-266. 
doi: 10.1080/09540120050042891. 
Chesney, M., Ickovics, J., Hecht, F., Sikipa, G., & Rabkin, J. (1999). Adherence: A necessity 
for successful HIV combination therapy. AIDS, 13(Suppl A), S271-S278. Retrieved 
from http://www.researchgate.net/publication/12432900_Adherence_a_necessity_for 
_successful_HIV_combination_therapy.  
Chesney, M., Morin, M., & Sherr, L. (2000). Adherence to HIV combination therapy. Social 
Science and Medicine, 50(11), 1599-1605. doi:10.1016/S0277-9536(99)00468-2.  
Cleemput, I., & Kestleloot, K. (2002). Economic implications of non-compliance in 
healthcare. Lancet, 359(9324), 2129-2130. doi:10.1016/S0140-6736(02)09114-6. 
Coday, M., Klesges, L. M., Garrison, R. J., Johnson, C., O’Toole, M., & Morris, G. S. (2002). 
Health opportunities with physical exercise (HOPE): Social contextual interventions 
112 
 
to reduce sedentary behaviour in urban settings. Health Education Research, 17(5), 
637-647. doi:10.1093/her/17.5.637. 
Continuing antiretroviral treatment. (2008). Retrieved from http://mwww.avert.org/ 
conttrt.htm.  
Cook, J., Grey, D., Burke, J., Gurtman, A., Richardson, J., Wilson, T., . . . Hessol, N.A. 
(2004). Depressive symptoms and AIDS-related mortality among multisite cohort of 
HIV positive women. American Journal of Public Health, 94(7), 1133-1140. 
Retrieved from http://ajph.aphapublications.org/cgi/content/abstract/94/7/1133.  
Cox, C., & Meade, A. (1975). A sociology of medical practice. New York: The Macmilan 
Publishing Co. Inc. 
Cramer, J., Mattson, R., Prevey, M., Scheyer, R., & Ouellette, V. (1989). How often is 
medication taken as prescribed? A novel assessment technique. Journal of the 
American Medical Association, 261(22), 3273-3277. Retrieved from http://jama.ama-
assn.org/cgi/content/abstract/261/22/3273?ck=nck.  
Darnell, J., Murry, M. D., Martz, B. L., & Weinberger, M. (1986). Medical use by 
ambulatory elderly: An in-home survey. Journal of the American Geriatric Society, 
34(1), 1-4. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/3941238.   
Davies, G., Koenig, L., Stratford, D., Palmore, M., Bush, T., Golde, M., . . . Ellerbrock, T.V. 
(2006). Overview and implementation of an intervention to prevent adherence failure 
among HIV-infected adults initiating antiretroviral therapy: Lessons learned from 
Project HEART. AIDS Care, 18(8), 895-903. doi: 10.1080/09540120500329556. 
Deeks, S., Smith, M., Holodniy, M. K., & Kahn, J.O. (1997). HIV-1 protease inhitiors: A 
review for clinicians. Journal of the American Medical Association, 277(2), 145-153. 
Retrieved from http://jama.ama-assn.org/cgi/reprint/277/2/145.  
113 
 
Department of Health and Human Services. (2008). Guidelines for the use of antiretroviral 
agents in HIV-1-infected adults and adolescents. Retrieved from 
http://www.aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf.  
Department of Health South Africa. (2007). National HIV and syphilis prevalence survey, 
South Africa, 2006. Retrieved from http://www.doh.gov.za/docs/reports/2007/ 
hiv/part1.pdf.  
De Waal, A. (2002). AIDS-related national crises in Africa: Food security, governance and 
development partnerships. Institute of Development Studies Bulletin, 33(4), 120-126. 
doi: 10.1111/j.1759-5436.2002.tb00052.x. 
Dick, J., Schoeman, J., Mohammed, A., & Lombard, C. (1996). Tuberculosis in the 
community: 1. Evaluation of a volunteer health worker programme to enhance 
adherence to anti-tuberculosis treatment. Tuberculosis and Lung Disease, 77(3), 274-
279. doi: 10.1016/S0962-8479(96)90013-1. 
DiClemente, R. J., Crosby, R. A., & Kegler, M. C. (2002). Emerging theories in health 
promotion practice and research. San Fransisco: Jossey Bass. 
Dorrington, R., Bourne, D., Bradshaw, D., Laubscher, R., & Timaeus, I. (2001). The impact 
of HIV/AIDS on adult mortality in South Africa. Retrieved from 
http://www.mrc.ac.za/bod/.  
Dorrington, R., Bradshaw, D., Johnson, L., & Budlender, D. (2004). The demographic impact 
of HIV/AIDS in South Africa. National indicators for 2004. Retrieved from 
http://www.mrc.ac.za/bod/demographic.pdf.  
Dorrington, R., Johnson, L., Bradshaw, D., & Daniel, T. (2006). The democratic impact of 
HIV/AIDS in South Africa: National and provincial indicators for 2006. Retrieved 
from http://www.mrc.ac.za/bod/DemographicImpactHIVIndicators.pdf.   
114 
 
Eccles, M., Grimshaw, J., Walker, A., Johnson, M., & Pitts, N. (2005). Changing the 
behaviour of healthcare professionals: The use of theory in promoting the uptake of 
research findings. Journal of Clinical Epidemiology, 58(2), 107-112. Retrieved from 
http://www.jclinepi.com/article/S0895-4356(04)00256-2/fulltext. 
Ennett, S. T., Bailey, S. L., & Dederman, E. B. (1999). Social network characteristics 
associated with risky behaviours among runaway and homeless. Journal of Health 
and Social Behaviour, 40, 63-78. Retrieved from http://www.jstor.org/pss/2676379. 
Ewart, C. K. (1991). Social action theory for public health psychology. The American 
Psychologist, 46(9), 931-946. Retrieved from 
http://psycnet.apa.org/index.cfm?fa=buy.optionToBuy&id=1992-06593-001.   
Farmer, P., Leandre, F., Mukherjee, J., Claude, M., Nevil, P., Smith-Fawzi, M., . . . Kim, J.Y. 
(2001). Community-based approaches to HIV treatment in resource-poor settings. The 
Lancet, 358(9279), 404-409. doi: 10.1016/S0140-6736(01)05550-7. 
Finzi, D., Blankson, J., Siliciano, J., Margolick, K., Chadwick, T., Pierson, K., . . . Siliciano, 
R.F. (1999). Latent infection of CD4+ T cells provides a mechanism for lifelong 
persistence of HIV-1, even in patients on effective combination therapy. Natural 
Medicine, 5, 512-517. doi: 10.1038/8394.  
Fogarty, L., Roter, D., Larson, S., Burke, J., Gillespie, J., & Levy, R. (2002). Patient 
adherence to HIV medication regimens: A review of published and abstract reports. 
Patient Education and Counselling, 46(2), 93-108. Retrieved from  
http://www.pec-journal.com/article/S0738-3991(01)00219-1/abstract.  
Forsyth, A., & Carey, M. (1998). Measuring self-efficacy in the context of HIV risk 
reduction: Research challenges and recommendations. Health Psychology, 17(6) 559-
568. doi: 10.1037/0278-6133.17.6.559. 
115 
 
Gallant, J. (2000). Strategies for long-term success in treatment of HIV infection. Journal of 
the American Medical Association, 283(10), 1329-1334. Retrieved from 
http://jama.ama-assn.org/cgi/content/abstract/283/10/1329.  
García, P., & Côte, J. (2003). Factors affecting adherence to antiretroviral therapy in people 
living with HIV/AIDS. Journal of the Association of Nurses and AIDS Care, 14(4), 
37-45. doi: 10.1177/1055329003252424.  
Gore-Felton, C., Rotheram-Borus, M. J., Weinhardt, L. S., Kelly, J. A., Lightfoot, M., 
Kirshembaum, S. B., . . . Morin, S.F. (2005). The healthy living project: An 
individually tailored, multidimensional intervention for HIV-infected persons. AIDS 
Education and Prevention, 17, 21-21. doi: 10.1521/aeap.17.2.21.58691. 
Glor, J., & Smith, C. (2005). Direct to the consumer: HIV and adherence. Pharmacuetical 
Executive, 106-107. Retrieved from 
http://pharmexec.findpharma.com/pharmexec/Marketing/Direct-to-Consumer-HIV-
and-Adherence/ArticleStandard/Article/detail/146964.  
Goffman, E. (1963). Stigma: Notes on the management of spoiled identity.  New Jersey: 
Prentice-Hall. 
Golin, C. E., Liu, H., Hays, R. D., Miller, L. G., Beck, C. K., Ickovics, J., . . Wenger, N.S. 
(2002). A prospective study of predictors of adherence to combination antiretroviral 
medication. Journal of General Internal Medicine, 17, 756-765. doi: 10.1046/j.1525-
1497.2002.11214.  
Gordillo, V., Del Amo, J., Soriano, V., & Gonzalez-Lahoz, J. (1999). Sociodemographic and 
psychological variables influencing adherence to antiretroviral therapy. AIDS, 13(13), 
1763-1769. Retrieved from 
http://journals.lww.com/aidsonline/Fulltext/1999/09100/Sociodemographic_and_psyc
hological_variables.21.aspx.   
116 
 
Graham, J., Bennett, I., Holmes, W., & Gross, R. (2007). Medication beliefs as medications 
as mediators of the health literacy - antiretroviral adherence relationship in HIV-
infected individuals. AIDS Behavior, 11(3), 385-392. doi: 10.1007/s10461-006-9164-
9. 
Gulick, R. (2006). Adherence to antiretroviral therapy: How much is enough? Clinical 
Infectious Diseases, 43(7), 942-944. doi: 10.1086/507549. 
Haubrich, R.F (1999). The value of patient-reported adherence to antiretroviral therapy in 
predicting virologic and immunilogic response. AIDS, 13, 1099-1107. Retrieved from 
http://journals.lww.com/aidsonline/Fulltext/1999/06180/The_value_of_patient_report
ed_adherence_to.14.aspx.  
Haynes, R. (1979). Determinants of compliance: the disease and mechanics of treatment. In 
R. Haynes, D. Taylor, & D. Sackett (Eds.), Compliance in Healthcare (pp. 49-62). 
Baltimore: John Hopkins University Press. 
Haynes, R., Sackett, D., & Taylor, D. (1980). How to detect and manage low patient 
compliance in chronic illness. Geriatrics, 35(1), 96-97. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/7350072.  
Heiden. D., Ford, N., Wilson, D., Rodriques, W. R., Margolis, T., Janssens, B., . . . Drew, 
W.L. (2007). Cytomegalovirus Retinitis: The neglected disease of the AIDS 
pandemic. PLoS Med, 4(12), e334. doi: 10.1371/journal.pmed.0040334.  
Hicks, P. L., Mulvey, K. P., Chander, G., Fleisman, J. A., Josephs, J. S., Korthuis, P. T., . . . 
Gebo, K.A. (2007). The impact of illicit drug use and substance abuse treatment on 
adherence to HAART. AIDS Care, 19(9), 1134-1140. doi: 10.1080/ 
09540120701351888.  
Hoggs, R., Health, K., Yip, B., Craib, K., O'Shaugnessy, M., Schechter, M., . . . Montaner, 
J.S.G. (1998). Improved survival among HIV-infected individuals following initiation 
117 
 
of antiretroviral therapy. Journal of the American Medical Association, 279(6), 450-
454. doi: 10.1001/jama.279.6.450. 
Hope, C., Wu, J., Tu, W., Young, J., & Murray, M. (2004). Association of medical 
adherence, knowledge, and skills with emergency department visits by adults 50 years 
or older with congestive heart failure. American Journal of Health System Pharmacy, 
61(19), 2043-2049. Retrieved from 
http://www.ajhp.org/cgi/content/abstract/61/19/2043.  
Ickovics, J. (1997). Measures of adherence. Adherence to New HIV Therapies: A research 
Conference. Washington. 
Ickovics, J., & Meade, C. (2002). Adherence to HAART among patients with HIV: 
Breakthroughs and barriers. AIDS Care, 14, 309-318. doi: 
10.1080/09540120220123685. 
Ilongo, I. (2004). Tuberculosis health belief gaps of tuberculosis and suspected tuberculosis 
cases in New York. International Journal of Clinical and Health Psychology, 4(1), 
69-90. Retrieved from http://www.aepc.es/ijchp/articulos.php?coid=English&id=96.  
Imrie, A., Beveridge, A., Genn, W., Vizzard, J., & Cooper, D. (1997). Transmission of HIV-1 
resistant to nevirapine and zidovudine: Sydney primary HIV infection study group. 
Journal of Infectious Diseases, 175(6), 1502-1506. Retrieved from 
http://www.journals.uchicago.edu/doi/abs/10.1086/516487.   
Introduction to HIV and AIDS treatment. (2008). Averting HIV and AIDS. Retrieved 
September, from http://www.avert.org/introtrt.htm.  
Janz, N., & Becker, M. (1984). The health belief model: A decade later. Health Education 
Quarterly, 11(1), 1-47. doi:10.1177/109019818401100101. 
Johnson, M.O., Catz, S.L., Remien, R.M., Rotherham, M.J., Morin, S.F., Charlebois, E., . . . 
Chesney, M.A. (2003). Theory guided, empirically supported avenues for intervention 
118 
 
on HIV medication nonadherence: Findings from the healthy living project. AIDS 
Patient Care and STDs, 17(12), 645-656. doi:10.1089/108729103771928708. 
Johnson, M., & Neilands, T. (2007). Coping with HIV treatment side-effects: 
Conceptualization, measurement, and linkages. AIDS Behaviour, 11(4), 575-585. doi: 
10.1007/s10461-007-9229-4.  
Joint United Nations Programme on HIV/AIDS (UNAIDS). (2008). Report on the global 
AIDS epidemic. Retrieved from 
http://www.unaids.org/en/KnowledgeCentre/HIVData/GlobalReport/2008/default.asp.  
Kagee, A. (2004). Treatment adherence in South African primary healthcare. South African 
Family Practice, 46(1), 26-30. Retrieved from http://www.safpj.co.za/index.php/safpj/ 
article/viewFile/143/143.  
Kagee, A. (2008). Adherence to antiretroviral therapy in the context of the national rollout in 
South Africa: Defining a research agenda for psychology. South African Journal of 
Psychology, 38(2), 413-428. Retrieved from 
http://www.sabinet.co.za/abstracts/sapsyc/sapsyc_v38_n2_a11.html.  
Kagee, A., Le Roux, M., & Dick, J. (2007). Treatment adherence among primary care 
patients in a historically disadvantaged community in South Africa. Journal of Health 
Psychology , 12(3), 444-460. doi: 10.1177/1359105307076232.  
Kagee, A., Remien, R. H., Berkman, A., Hoffman, S., Campos, L., & Swartz, L. (2010). 
Structural barriers to ART adherence: Challenges and potential ways forward. Global 
Public Health: An International Journal for Research, Policy and Practice, 26, 1-15. 
doi: 10.1080/17441691003796387. 
Kalichman, S. (1998). Understanding AIDS, Advances in research and treatment. 
Washingtom: American Psychological Association. 
119 
 
Kalichman, S., Catz, S., & Ramachandran, B. (1999). Barriers to HIV treatment adherence 
among African-American adults with disadvantaged education. Journal of the 
National Medication Association, 91(8), 439. Retrieved from 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2608436/pdf/jnma00353-0017.pdf.  
Kalichman, S., Rompa, D., DiFonzo, K., Simpson, D., Austen, J., Luke, W., . . . Buckles, J. 
(2001). HIV treatment adherence in women living with HIV/AIDS: Research based 
on the information-motivation-behavioural skills model of health. Journal of the 
Association of Nurses in AIDS Care, 12(4), 58-67. doi: 10.1016/S1055-
3290(06)60217-3. 
Kitahata, M., Reed, S., Dillingham, P., Van Rompaeu, S., Young, A., Harrington, R., . . . 
Holmes, K.K. (2004). Pharmacy-based assessment of adherence to HAART predicts 
virologic and immunologic treatment response and clinical progression to AIDS and 
death. International Journal of STDs and AIDS, 15, 803-810. doi: 
10.1258/0956462042563666. 
Lambert, H., & McKevitt, C. (2002). Anthropolohy in health research: From qualitative 
methods to multidiscipliniarity. British Medical Journal, 325, 210-213. doi: 
10.1136/bmj.325.7357.210v. 
Lange, J. (2003). Efficacy and durability of nevirapine in antiretroviral drug naive patients. 
Journal of Acquired Immune Deficiency Syndromes, 34, S40-S52. Retrieved from 
http://journals.lww.com/jaids/Fulltext/2003/09011/Efficacy_and_Durability_of_Nevir
apine_in.7.aspx.  
Ledergerber, B., Egger, M., Opravil, M., Telenti, A., Hirschel, B., & Battegay, M., . . . 
Weber, R. (1999). Clinical progression and virological failure on highly active 
antiretroviral therapy in HIV-1 patients: A prospective cohort study. Lancet, 
353(9156), 863-868. doi: 10.1016/S0140-6736(99)01122-8.  
120 
 
Lewin, K. (1935). A dynamic theory of personality. New York: McGraw-Hill. 
Lima, V., Fernandes, K., Rachlis, B., Druyts, E., Montaner, J., & Hogg, R. (2009). Migration 
adversely affects antiretroviral adherence in a population-based cohort of HIV/AIDS 
patients. Social Science and Medicine, 68(6), 1044-1049. doi: 
10.1016/j.socscimed.2008.12.043. 
Liu, H., Golin, C., Miller, L., Hays, R., Beck, K., Sanandaji, S., . . . Wenger, N.S. (2001). A 
comparison study of multiple measure of adherence to HIV protease inhibitors. 
Annals of Internal Medicine, 134(10), 968-977. Retrieved from 
http://www.annals.org/content/134/10/968.short.  
Lund, F. (1999). Understanding South African social security through recent household 
surveys: New opportunities and continuing gaps. Development Southern Africa, 16(1), 
55-69. doi: 10.1080/0376359908440061.  
Makoul, G., & Roloff, M. (1998). The role of efficacy and outcome expectations in the 
decision to withhold relational complaints. Communication Research, 25(1), 5-29. 
doi: 10.1177/009365098025001001. 
Mainman, L. A., & Becker, M.H. (1974). The health belief model: Origins and correlates in 
psychological theory. In M. H. Becker (Ed.), The health belief model and personal 
health behaviour (pp. 9-26), New Jersey: Charles B. Slack. 
Mannheimer, S., Matts, J., Telzak, E., Chesney, M., Child, C., Wu, A., . . . Friedland, G. 
(2005). Quality of life in HIV-infected individuals receiving antiretroviral therapy is 
related to adherence. AIDS Care, 17(1), 10-22. doi: 10.1080/09540120412331305098. 
Maskew, M., MacPhail, P., Menezes, C., & Rubel, D. (2007). Lost to follow up, contributing 
factors and challenges in South African patients on antiretroviral therapy. South 
African Medical Journal, 97(9), 853-857. Retrieved from 
http://www.samj.org.za/index.php/samj/article/view/524/87.  
121 
 
Medecins Sans Frontieres South Africa; Department of Public Health at the University of 
Cape Town; Provincial Administration of the Western Cape, South Africa. (2003). 
Perspectives and practice in antiretroviral treatment. Antiretroviral therapy in 
primary healthcare: Experience of Khayelitsha programme in South Africa. A case 
study. Retrieved from http://www.who.int/hiv/amds/case8.pdf.  
Mellors, M., Riley, T., & Erlen, J. (1997). HIV self transcendence, and quality of life. 
Journal of the Association of Nurses in AIDS Care, 8(2), 59-69. doi: 10.1016/S1055-
3290(97)80018-0.  
Metha, S., Moore, R., & Graham, N. (1997). Potential factors affecting adherence with HIV 
therapy. AIDS, 11(14), 1665-1670. Retrieved from http://journals.lww.com/ 
aidsonline/Fulltext/1997/14000/Potential_factors_affecting_adherence_with_HIV.2.as
px.  
Michelet, C. (1998). Opportunistic infections occuring during highly active antiretroviral 
treatment. AIDS, 12(14), 1815-1822. Retrieved from 
http://journals.lww.com/aidsonline/Fulltext/1998/14000/Opportunistic_infections_occ
urring_during_highly.13.aspx.  
Montaner, J., Hoggs, R., Raboud, J., Harrigan, R., & O'Shaughnessy, M. (1998). 
Antiretroviral treatment in 1998. Lancet, 352(9144), 1919-1922. doi:10.1016/S0140-
6736(98)07532-1.  
Moralejo, L., Ines, S., Marcos, M., Fuertes, A., & Luna, G. (2006). Factors influencing 
adherence to highly active antiretroviral therapy in Spain. Current HIV Research, 
4(2), 221-227. Retrieved from 
http://www.researchgate.net/publication/7169251_Factors_influencing_adherence_to
_highly_active_antiretroviral_therapy_in_Spain.  
122 
 
Moyer, T., Temesgen, Z., Enger, R., Estes, L., Charlson, J., Oliver, L., & Wright, A. (1999). 
Drug monitoring of antiretroviral therapy for HIV-1 infection: Method validation and 
results of a pilot study. Clinical Chemistry, 45, 1465-1476. Retrieved from 
http://www.clinchem.org/cgi/content/full/45/9/1465.  
Mukherjee, J., Ivers, L., Leandre, F., & Farmer, P. B. (2006). Antiretroviral therapy in 
resource-poor settings: Decreasing barriers and promoting adherence. Journal of 
Acquired Immune Deficiency Syndromes, 43(Suppl 1), S123-126. doi: 
10.1097/01.qai.0000248348.25630.74. 
Munro, S., Lewin, S., Swart, T., & Volmink, J. (2007). A review of health behaviour theories: 
How useful are these for developing interventions to promote long-term medication 
adherence for TB and HIV/AIDS? BMC Public Health, 7, 104. doi:10.1186/1471-
2458-7-104. 
Murphy, D. A., Roberts, K. J., Hoffman, D., Monalina, A., & Lu, M. C. (2003). Barriers and 
successful strategies to antiretroviral adherence among HIV-infected monolingual 
Spanish-speaking patients. AIDS Care, 15(2), 217-230. doi: 10.1186/1471-2458-7-
104. 
Murphy, D. A., Roberts, K. J., Martin, D. J., Marelich, W., & Hoffman, D. (2000). Barriers to 
antiretroviral adherence amongst HIV-infected adults. AIDS Patient Care and STDs, 
14(1), 47-58. doi:10.1089/108729100318127. 
Murri, R., Ammassari, A., Gallicano, K., De Luca, A., Cingolani, A., Jacobson, D., . . . 
Antinori, A. (2000). Patient-reported non-adherence to HAART is related to protease 
inhibitor levels. Journal of Acuired Immune Deficiency Syndromes, 24(2), 123-128. 
Retrieved from 
http://journals.lww.com/jaids/Fulltext/2000/06010/Patient_Reported_Non-
adherence_to_HAART_Is_Related.6.aspx.  
123 
 
National Department of Health. (2004). National antiretroviral treatment guidelines. 
Retrieved from 
http://www.doh.gov.za/docs/factsheets/guidelines/artguidelines04/index.html.  
National Department of Health. (2007). HIV, AIDS and STI Strategic Plan for South Africa, 
2007 - 2011. National Consultation Conference. Boksburg. 
National Department of Health. (2010). Clinical guidelines for the management of HIV & 
AIDS in adults and adolescents. Retrieved from 
http://www.sanac.org.za/documents/2010%20Adult%20ART%20Guidelines.pdf.  
Nguyen, V., & Stovel, K. (2004). The social science of HIV/AIDS: A critical review and 
priorities for action. Social science research council working group on HIV/AIDS: 
Washington DC. 
Nattrass, N. (2006). Disability and welfare in South Africa’s era of unemployment and AIDS. 
(CSSR Working Paper N0. 147). Retrieved from 
http://www.sarpn.org.za/documents/d0001936/index.php.  
Nicolay, N., & Kotze, J. (2008). ASSA2003 (Provincial) AIDS and Demographic Projections 
for 2009. Retrieved from 
http://www.metam.co.za/documents_v2/File/RedRibbon_2009/Provincial%20HIV%2
0and%20AIDS%20statistics%20for%202008.pdf.   
Nischal, K., Khopkar, U., & Saple, D. (2005). Improving adherence to antiretroviral therapy. 
Indian Journal of Dermatology, Venereology and Leprology, 71(5), 316-320. 
doi:10.4103/0378-6323.16780. 
O'Leary, A., & Martins, P. (2000). Structural factors affecting women's HIV risk: A life-
course example. AIDS, 14(Suppl 1), S68-S72. Retrieved from 
http://journals.lww.com/aidsonline/Fulltext/2000/06001/Structural_factors_affecting_
women_s_HIV_risk__a.11.aspx.  
124 
 
Osterberg, L., & Blaschke, T. (2005). Adherence to medication. New England Journal of 
Medicine, 353(5), 487-497. Retrieved from 
http://www.nejm.org/doi/pdf/10.1056/NEJMra050100.  
Parker, R., & Easton, D. K. (2000). Structural barriers and faciliators in HIV prevention: A 
review of international research. AIDS, 14(Suppl 1), S22-S32. Retrieved from 
http://journals.lww.com/aidsonline/Fulltext/2000/06001/Structural_barriers_and_facil
itators_in_HIV.4.aspx.  
Parsons, J., Rosof, E., & Mustanski, B. (2008). Medication adherence mediates the 
relationship between adherence self-efficacy and biological assessments of HIV 
health among those with alcohol use disorders. AIDS Behavior, 21(1), 95-103. doi: 
10.1007/s10461-007-9241-8. 
Paterson, D. L., Swindells, S., Mohr, J., Brester, M., Vergis, E. N., Squier, C. W., . . . Singh, 
N. (2000). Adherence to protease inhibitor therapy and outcomes in patients with HIV 
infection. Annals of Internal Medicine, 131, 21-30. Retrieved from 
http://www.annals.org/content/133/1/21.1.abstract.  
Penna, N., & Treisman, G. (2005). HIV/AIDS. Washington, DC: American Psychiatric 
Publishing. 
Plipat, N., Kottapat, U., Komoltri, C, Voradilokkul, J., Anansakunwatt, W., Chearskul, P., . . . 
Vamprapar, N. (2007). Evaluation of a practical method to assess antiretroviral 
adherence in HIV-infected Thai children. Southeastern Asian Journal of Tropical 
Medicine and Public Health, 38(5), 828. Retrieved 
http://www.tm.mahidol.ac.th/seameo/2007_38_5/06-3997.pdf.   
Potgieter, M. C. (1998). The social work process: Development to empower people. Pretoria: 
Prentice Hall South Africa (Pty) LTD. 
125 
 
Resnick, M. D., Bearnan, P. S., Blum, R. W., Bauman, K. E., Harris, K. M., Jones, J., . . . 
Udry, J.R. (1997). Protecting adolescents from harm: Findings from the National 
Longitudinal Study of adolecent health. Journal of the American Medical Association, 
278(10), 823-832. Retrieved from  
http://jama.ama-assn.org/cgi/content/abstract/278/10/823.  
Powderly, W., Landay, A., & Lederman, M. (1998). Recovery of the immune system with 
antiretroviral therapy: The end of opportunism? Jounral of the American Medical 
Association, 280, 72-77. Retrieved from  
http://jama.ama-assn.org/cgi/content/abstract/280/1/72.  
Prochaska, J. O., & Velicer, W. F. (1997). The transtheoretical model of behaviour change. 
American Journal of Health Promotion, 12, 38-48. Retrieved from 
http://healthpromotionjournal.com/mm5/merchant.mvc?Screen=PROD&Store_Code=
AJHP&Product_Code=JV12I138&Category_Code=.  
Provincial Government of the Western Cape. (2004). Antiretroviral treatment protocol: 
Provincial administration Western Cape. Retrieved from 
http://www.doh.gov.za/docs/index.html.  
Rabkin, J., & Chesney, M. (1999). Treatment adherence to HIV medications: The Achilles 
level of new therapies. In D. Ostrow & S. Kallichman (Eds.), Behavioral and mental 
health impacts of new HIV therapies (pp. 61-79). New York: Plenum Press. 
Ravallion, M. (2003). Targeted transfers in poor countries: Revisiting the trade-offs and 
policy options. Paper presented at international conference on chronic poverty and 
development policy. 7-9 April. Chronic Poverty Centre. University of Manchester. 
Reis, C., Heisler, M., Amowitz, L. L., Moreland, R. S., Mafeni, J. O., Anyamele, C., . . . 
Iacopino, V. (2005). Discriminatory attitudes and practices by healthcare workers 
126 
 
towards patients with HIV/AIDS in Nigeria. PLoS Med, 2(8), e246. 
doi:10.1371/journal.pmed.0020246. 
Remien, R., Hirky, A. J., Johnson, M. O., Weinhardt, D., & Le, G. M. (2003). Adherence to 
medication treatment: A qualitative study of facilitators and barriers among a diverse 
sample of HIV + men and women in four U.S. cities. AIDS and Behavior, 7(1), 61-72. 
doi: 10.1023/A:1022513507669. 
Remien, R. H., Stirratt, M. J., Dognin, J., Day, E., El-Bassel, N., & Warne, P. (2006). Moving 
from theory to research to practice: Implementing an effective dyadic intervention to 
improve antiretroviral adherence for clinic patients. Journal of Acquired Immune 
Deficiency Syndromes, 43, S69-S78. doi: 10.1097/01.qai.0000248340.20685.7d. 
Reppucci, N. D., Mulvey, E. P., & Kastner, L. (1983). Prevention and interdisciplinary 
perspective: A framework and case analysis. In R. D. Felner, L. A. Jason, J. N 
Moritsugu, & S. S. Faber (Eds.), Preventative psychology: Theory, research, and 
practice. (pp. 234-244). New York: Peragamon Press. 
Reynolds, N. R. (2004). Adherence to antiretroviral therapies: State of science. Current HIV 
Research, 2(3), 207-214. doi: 10.2174/1570162043351309. 
Reynolds, N., Testa, M., Su, M., Chesney, M., & Robbins, C. (2003). Baseline predictors of 
adherence and regimen failure in treatment naive HIV+ subjects (ACTG 384). 2nd 
IAS Conference on HIV Pathogenesis and Treatment. Paris. 
Roberts, K., & Mann, T. (2000). Barriers to antiretroviral medication adherence in HIV-
infected women. AIDS Care, 12(4), 377-386. doi: 10.1080/09540120050123774. 
Rosenstock, I., Strecher, V., & Becker, M. (1988). Social learning theory and the health 
belief model. Health Education Quarterly, 15(2), 171-183. 
doi:10.1177/109019818801500203. 
127 
 
Sackett, D., & Haynes, R. (1976). Compliance with therapeutic regimens. Baltimore: John 
Hopkins University Press. 
Safren, S., Radomsky, A., Otto, M., & Solomon, E. (2002). Predictors of psychological well-
being in a diverse sample of HIV positive patients receiving highly active 
antiretroviral therapy. Psychosomatics, 43(3), 478. Retrieved from 
http://psy.psychiatryonline.org/cgi/content/full/43/6/478.  
Sarna, A., Pujari, A., Sengar, A., Garg, R., Gupta, G., & Van Dam, J. (2008). Adherence to 
antiretroviral therapy and its determinants amongst HIV patients in India. Indian 
Journal of Medical Research, 127, 28-36. Retrieved from 
www.icmr.nic.in/ijmr/2008/january/0101.pdf.  
Schuman, P., Ohmit, S., Cohen, M., Sacks, H., Richardson, J., Young, M., . . . Gardner, L. 
(2001). Prescription of and adherence to antiretroviral therapy among women with 
AIDS. AIDS and Behaviour, 5(4), 371-378. doi: 10.1023/A:1013143024686. 
Shisana, O., Rehle, T., Simbayi, L. C., Zuma, K., Jooste, S., Pillay-van Wyk,V., . . . Van Zyl, 
J. (2009). South African national HIV prevalence, incidence, behaviour and 
communication survey 2008: A turning tide among teenagers. Cape Town: HSRC 
Press.  
Shriver, M., Everett, C., & Stephen, S. (2000). Structural interventions to encourage primary 
HIV prevention among people living with HIV. AIDS, 14(Suppl 1), S57-S62. 
Retrieved from 
http://journals.lww.com/aidsonline/Fulltext/2000/06001/Structural_interventions_to_e
ncourage_primary_HIV.9.aspx.  
Simoni, J. M., Kurth, A. E., Pearson, C. R., Pantalone, D. W., Merrill, J. O., & Frick, P. A. 
(2006). Self-report measures of antiretroviral therapy adherence: A review with 
128 
 
recommendations for HIV research and clinical management. AIDS Behaviour, 10(3), 
227-245. doi: 10.1007/s10461-006-9078-6. 
Singh, N., Berman, S., Swindells, S., Mohr, J., & Squire, C. (1999). Adherence of human 
immunodeficiency virus-infected patients to antiretroviral therapy. Clinical Infectious 
Diseases, 29(4), 824-830. Retrieved from 
http://www.journals.uchicago.edu/doi/pdf/10.1086/520443.  
South African HIV Clinicians Society. (2007). Clinical guidelines on antiretroviral 
management for displaced populations. Retrieved from 
http://www.unhcr.org/4683b0522.pdf. 
South African Police Service. (2010). Crime in the Western Cape Total from April to March 
2003/2004-2009/2010. Retrieved from 
http://www.saps.gov.za/statistics/reports/crimestats/2010/crime_situation_sa.pdf.  
South African Social Security Agency. (2009). You and your grant 2009/2010. Retrieved 
from http://www.sassa.gov.za/ABOUT-SOCIAL-GRANTS/INFORMATION-ON-
GRANTS-BROCHURE-2009-641.aspx. 
Spring, B. (2008). Health decision making: Lynchpin of evidence-based practice. Medical 
Decision Making, 28(6), 866-874. doi: 10.1177/027298908326146.   
Starting antiretroviral treatment. (2008). Averting HIV and AIDS. Retrieved from: 
http://www.avert.org/starttrt.htm.  
Statistics South Africa. (2010). Quarterly labour force survey. Retrieved from 
https://www.statssa.gov.za/Publications/P0211/P02112ndQuarter2010.pdf.  
Stone, V., Hogan, J., Schuman, P., Rompalo, A. M., Howard, A. A., Korkontzelou, C, & 
Smith, D. K. (2001). Antiretroviral regimen complexity, self-reported adherence, and 
HIV patients' understanding of their regimens. Journal of Acquired Immune 
Deficiency Syndromes, 28(2), 124-131. Retrieved from 
129 
 
http://journals.lww.com/jaids/Fulltext/2001/10010/Antiretroviral_Regimen_Complexi
ty,_Self_Reported.3.aspx.  
Stout, B. D., Leon, M. P., & Niccolai, L. M. (2004). Non-adherence to antiretroviral therapy 
in HIV positive patients in Costa Rica. AIDS Care and STDs, 18(5), 297-304. 
doi:10.1089/108729104323076034. 
Sullivan, L., Dukes, K., Harris, L., & Dittus, R. (1995). A comparison of various methods of 
self-reported health outcomes data among low income and minority patients. Medical 
Care, 33(4), 183-194. Retrieved from http://www.jstor.org/pss/3766625.  
Sumartojo, E. (2000). Structural factors in HIV prevention: Concepts, examples, and 
implications for research. AIDS, 14(Suppl 1), S3-S10. Retrieved from 
http://journals.lww.com/aidsonline/Fulltext/2000/06001/Structural_factors_in_HIV_p
revention__concepts,.2.aspx.  
Sutton, S. (1997). Theory of planned behaviour. In A. Baum, S. Newman, J. Weinman, R. 
West, & C. McManus (Eds.), Cambridge handbook of psychology, health and 
medicine (pp. 177-179). Cambridge: Cambridge University Press. 
Swartz, L. (1998). Culture and mental health: A Southern African view. Cape Town: Oxford 
University Press. 
Taylor, S. E., Repetti, R. L., & Seeman, T. (1997). Health psychology: What is an unhealthy 
environment and how does it get under the skin? Annual Review of Psychology, 48, 
411-447. Retrieved from 
http://www.annualreviews.org/doi/abs/10.1146/annurev.psych.48.1.411.  
Tegger, M. K., Crane, H. M., Tapia, K. A., Uldall, K. K., Holte, S. E., & Kitahata, M. M. 
(2008). The effect of mental illness, substance use, and treatment for depression on 
the initiation of highly active antiretroviral therapy among HIV-infected individuals. 
AIDS Patient Care and STDs, 22(3), 233-243. doi:10.1089/apc.2007.0092. 
130 
 
Trzynka, S., & Erlen, J. (2004). HIV disease susceptibility in women and barriers to 
adherence. Medsurg Nursing, 13(2), 97-104. Retrieved from 
http://findarticles.com/p/articles/mi_m0FSS/is_2_13/ai_n17206923/.  
Turkoski, B. (2006). Unraveling the mystery of HIV medications. Orthopedic Nursing, 25(1), 
51. Retrieved from 
http://journals.lww.com/orthopaedicnursing/Abstract/2006/01000/Unraveling_the_M
ystery_of_HIV_Medications.13.aspx.  
Turner, R. J., & Turner, J. B. (1999). Social intergration and support. In C. S. Aneshensel & 
J. C. Phelan (Eds.), Handbook on the sociology of mental health (pp. 301-320). New 
York: Kluwer. 
UNAIDS. (2007). AIDS epidemic update 2007. Retrieved from 
http://www.unaids.org/en/KnowledgeCentre/HIVData/EpiUpdate/EpiUpdArchive/20
07/default.asp.  
UNAIDS/WHO Working Group on Global HIV/AIDS and STI Surveilance. (2008). 
Epidemiological fact sheet on HIV and AIDS: core data on epidemiology and 
response. Retrieved from 
http://apps.who.int/globalatlas/predefinedReports/EFS2008/full/EFS2008_ZA.pdf.  
United Nations. (2009). Human development report. Retrieved from 
http://hdr.undp.org/en/reports/global/hdr2009/.  
Valdez, L., Lederman, M., Woolley, I., Walker, C., Vernon, L., Hise, A., . . . Gripshover, 
B.M. (1999). Human immunodeficiency virus 1 protease inhibitors in clinical 
practice: Predictors of virological outcome. Archieves of Internal Medicine, 159, 
1771-1776. Retrieved from http://archinte.ama-assn.org/cgi/reprint/159/15/1771.pdf.  
131 
 
Van der Geest, S., & Hardon, A. (2006). Social and cultural efficacies of medicines: 
Complications for antiretroviral therapy. Journal of Ethnobiology and Ethnomedicine, 
2, 48-53. doi:10.1186/1746-4269-2-48. 
Van Dulmen, S., Sluijs, E., Van Dijk, L., De Ridder, D., Heerdink, R., & Bensing, J. (2007). 
Patient adherence to medical treatment: A review of reviews. British Medical Counsil 
Health Service Research, 7, 55. doi:10.1186/1472-6963-7-55. 
Vanhove, G., Schapiro, J., Winters, M., Merigan, T., & Blanschke, T. (1996). Patient 
complience and drug failure in protease inhibitor monotherapy. Journal of the 
American Medical Association, 276, 1955-1956. Retrieved from http://jama.ama-
assn.org/cgi/content/summary/276/24/1955. 
Visser, M. (2006). Introduction to community psychology. Pretoria: Van Schaik Publishers. 
Waddell, E. N., & Messeri, P. A. (2006). Social support, disclosure, and use of antiretroviral 
therapy. AIDS and Behaviour, 10(3), 263-272. doi: 10.1007/s10461-005-9042-x. 
Wagner, G., & Rabkin, J. (2000). Measuring medication adherence: Are missed doses 
reported more accurately than perfect adherence? AIDS Care, 12(4), 405-408. doi: 
10.1080/09540120050123800. 
Wainberg, M., & Friedland, G. (1998). Public health implications of antiretroviral therapy 
and HIV drug resistance. Journal of the American Medical Association, 279, 1977-
1983. Retrieved from http://jama.ama-assn.org/cgi/content/abstract/279/24/1977. 
Wall, T., Sorensen, J., Batki, S., Delucci, K., Lodon, J., & Chesney, M. (1995). Adherence to 
zidovudine (AZT) among HIV-infected methadone patients: A pilot study of 
supervised therapy and dispensing compared to usual care. Drug and Alcohol 
Dependence, 37(3), 261-269. doi: 10.1016/0376-8716(94)01080-5.  
132 
 
Walsh, J., Horne, R., Dalton, M., Burgess, A., & Gazzard, B. (2001). Reasons for non-
adhernce to antiretroviral therapy: Patients' perspectives provide evidence of multiple 
causes. AIDS Care, 13, 709-720. doi: 10.1080/09540120120076878. 
Ware, N., Wyatt, M., & Tugenberg, T. (2006). Social relationships, stigma and adherence to 
antiretroviral tharapy for HIV/AIDS. AIDS Care, 18, 904-910. 
doi:10.1080/09540120500330554. 
Ware, N. C., Idoko, J., Kaaya, S., Biraro, I. A., Wyatt, M. A., Agbaji, O., . . . Bangsberg, 
D.R. (2009). Explaining adherence success in sub-Saharan Africa: An ethnographic 
study. PLos Medicine, 6(1), e1000011. doi:10.1371/journal.pmed.1000011. 
Waterhouse, D., Calzone, K., Mele, C., & Brenner, D. (1993). Adherence to oral taxoxifen: A 
comparison of patient self-report, pill counts, and microelectronic monitoring. Journal 
of Clinical Oncology , 11, 1189-1197. Retrieved from 
http://jco.ascopubs.org/content/11/6/1189.short. 
Weiser, S., Wolfe, W., Bangsberg, D., Thior, I., Gilbert, P., Makhema, J., . . . Marlink, R. 
(2003). Barriers to antiretroviral adherence for patients living with HIV infection and 
AIDS in Botswana. Journal of Acquired Immune Deficiency Syndromes, 33(3), 281-
288. Retrieved from 
http://journals.lww.com/jaids/Fulltext/2003/11010/Barriers_to_Antiretroviral_Adhere
nce_for_Patients.4.aspx. 
Weiss, L., French, T., Finkelstein, R., Waters, M., Mukherjee, R., & Agins, B. (2003). HIV-
related knowledge and adherence to HAART. AIDS Care, 15, 673-679. doi: 
10.1080/09540120310001595159. 
White, H. (2005). Adherence outcomes: It's more than taking pills. The Lancet, 366, 1989-
1991. doi:10.1016/S0140-6736(05)67761-6. 
133 
 
Williams, K., & Bond, M. (2002). The roles of self-efficacy outcome expectancies and social 
support in the self-care behaviours of diabetics. Psychological Health and 
Medication, 7(2), 127-141. doi: 10.1080/13548500120116076. 
Williams, D. R., & Patterson, M. E. (1996). Environmental meaning and ecosystem 
management: Perspectives from environmental psychology and human geography. 
Society and Natural Resources, 9, 507-521. doi: 10.1080/08941929609380990. 
Wolf, M., Davis, T., Arozullah, A., Penn, R., Arnold, C., Sugar, M., . . . Bennett, C.L. (2005). 
Relationship between literacy and HIV treatment knowledge among patients on 
HAART regimens. AIDS Care, 17, 863-873. doi: 10.1080/09540120500038660. 
Wolf, M., Davis, T., Osborn, C., Skripkauskas, S., Bennett, C., & Makoul, G. (2007). 
Literacy, self-efficacy, and HIV medication adherence. Patient Education and 
Counselling , 65, 253-260. doi:10.1016/j.pec.2006.08.006. 
World Bank. (2010). World Bank updates poverty estimates for the developing world. 
Retrieved from 
http://econ.worldbank.org/WBSITE/EXTERNAL/EXTDEC/EXTRESEARCH/0,,cont
entMDK:21882162~pagePK:64165401~piPK:64165026~theSitePK:469382,00.html. 
World Health Organization. (2006). HIV/AIDS Programme. Antiretroviral therapy for HIV 
infection in adults and adolescents: Recommendations for public health approach. 
Retrieved from http://www.who.int/hiv/pub/arv/adult/en/index.html.  
World Health Organization. (2007). AIDS epidemic update. Retrieved from 
http://data.unaids.org/pub/epislides/2007/2007_epiupdate_en.pdf.  
Yeni, P., Hammer, S., Carpenter, C., Cooper, D., Fischl, M., Gatell, J., . . . Volberding, P.A. 
(2002). Antiretroviral treatment for adult HIV infection in 2002: Updated 
recommendations of the Internationl AIDS Society-USA Panel. Journal of the 
134 
 
American Medical Association, 288, 222-235. Retrieved from http://jama.ama-
assn.org/cgi/content/abstract/288/2/222. 
  
135 
 
APPENDIX A 
INTERVIEW SCHEDULE: CLINICIANS 
1. What is your position? (Clinician, nurse, doctor) 
2. Please tell me about your experience in treating AIDS patients. (Probe: What is it like for 
you) 
3. What do you think are patient’s experiences of the healthcare system in general? 
4. What do you think is the hardest part for patients in taking their medication? 
5. What do you think is the patient’s experience of the clinic in particular? 
6. How would you describe your patient’s relationship with you? 
7. What do you think are patient’s main problems that make it difficult for them to attend 
clinic appointments? 
8. Are there any aspects of the clinic, the way things are set up or organized, that you think 
make it difficult for patients to come for their appointments? 
9. What aspects about the clinic or the healthcare system do you think can be changed to 
make it easier for patients to come for their appointments? 
10. If these changes were made, can you tell me how it would be different or better for 
patients in terms of attending clinic appointments? 
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APPENDIX B 
INTERVIEW SCHEDULE: PATIENTS 
1. What do you see as the most important factors that act as barriers to your attending your 
clinic appointments as you are required to?  
Potential probes:  
a. Do you generally think you attend your appointments the way you are expected to? 
b. Why do you think you don’t attend your appointments the way you are expected 
to? 
c. Tell me about the difficulties you face in your life that make it difficult to attend the 
clinic regularly? 
2. We are interested in the kinds of things you think would stop you from attending your 
appointments regularly. Can you think of all the things in your life that you think make it 
difficult for you to attend the clinic? 
3. Please tell me about your experience with the medicine you are taking? What is it like? 
4. What is your experience of the healthcare system in general? 
5. What is your experience with the clinic in particular? 
6. How would you describe your relationship with your doctor or nurse? 
7. What are the main problems that you have in your life that make it difficult for you to 
attend your clinic appointments? 
8. Are there any aspects of the clinic, the way things are set up or organized, that make it 
difficult for you to come for appointments? 
9. What aspects about the clinic or the healthcare system can be changed to make it easier for 
you to come for your appointments? 
10. If these changes were made (mention the suggestions the patient gave in above), can you 
tell me how it would be different or better for you in terms of attending clinic appointments? 
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11. Is there anything that we haven’t talked about that you want to say about any of these 
issues? 
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APPENDIX C 
CODEBOOK FOR CLINICIANS 
Codebook for Clinicians 
Code Definition Example of quotation 
CE  The clinician's experience, or 
feelings and emotions related to 
treating patients on antiretroviral 
therapy. 
 
“…we look at the actual 
absolute numbers…the 
numbers…that need to be on 
treatment…uhm…it can be very 
overwhelming…” 
“…if you just look at the 
numbers, I think the numbers are 
overwhelming.” 
“…one often feels very helpless, 
in terms of improving social 
circumstances. I mean the whole 
thing around adherence…” 
CIIF 
 
 
Clinicians' identification of 
individual behavioural and 
psychological factors related to the 
patients' treatment adherence. 
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Codebook for Clinicians (continued) 
Code Definition Example of quotation 
CIIF – 
Forgetfulness 
Individual factor related to the 
patients' forgetfulness in taking 
medication. 
“…omdat people are tending to 
forget. We are human beings and 
we are we tend to forget…” 
CIIF –  Health 
literacy 
 
Individual factor related to the 
patients knowledge and information 
pertaining to HIV/AIDS and 
antiretroviral therapy. 
“…some of the issues 
may…may be that they 
understand a 100% how to take 
them, even though they do get 
counselled in their own 
language…” 
CIIF –  Literacy Individual factor related to the 
patients' level of education. 
“They may not be…may not be 
literate.” 
CIIF – Medication 
characteristics 
Difficulties experienced in the 
actual taking of medication. 
“The volume of the pills. That is 
the biggest barrier…” 
CIIF – Side-effects 
 
Individual factor related to the side-
effects patients experience in taking 
antiretroviral medication. 
“Then the other issues than 
taking their pills, especially in 
the beginning, they may have 
side-effects that make them 
nauseous or make them start 
vomiting, they feel dizzy and 
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Codebook for Clinicians (continued) 
Code Definition Example of quotation 
  they may not have been 
adequately prepared for those 
side-effects…” 
CISB Clinician identification of structural 
barriers. 
 
CISB – Access to 
mental healthcare 
Patients’ ability to access adequate 
mental health services. 
 
“I think that, on the whole, they 
would probably find it a difficult 
system to access. 
Um…um…first of all…um…the 
clinics, and generally the 
casualty, or generally where ever 
they access the healthcare 
system they have to wait and it 
is overcrowded…” 
CISB – Burnout 
 
Burnout relating to overworked 
healthcare professionals. 
 
“…I think…I think…burnout is 
an issue. And also seeing your 
patients die, who are doing well, 
or have put so much effort into,  
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Codebook for Clinicians (continued) 
Code Definition Example of quotation 
  and then they don’t do 
well…and I think that is also 
hard.” 
CISB – Clinic – 
Administration 
 
Administration relating to the 
organization or management of 
patient files and medication, and 
the taking of medication. 
 
“…cause what happen in the 
hospital is there’s a problem 
with the files. Files have been 
duplicated and stuff so the 
original notes is not in there to 
say that the patient is known 
with us and that the patient is 
positive and is on this 
treatment.” 
CISB – Clinic - 
Overcrowding 
Volumes and numbers of patients 
seeking treatment at clinic. 
“Basically…um…the beds are 
always full. We have a 100% 
bed occupancy. So you have to 
wait for a discharge before you 
can admit a patient. So they all 
go to casualty, and if they are 
sick enough to stay there they 
get onto a trolley. If the trolleys 
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Codebook for Clinicians (continued) 
Code Definition Example of quotation 
  are full they get onto a mattress 
on the floor. If the mattresses are 
full, they sometimes end up with 
a blanket on the floor.” 
CISB – Clinic  - 
Privacy 
Issues related to privacy due to a 
lack of resources. 
 
“…with privacy sometimes in 
that corner where they do the pill 
counts and the adherence check, 
because there is some patients 
that are chronic when they come 
for the pill count, before 
they…they or if…if…if they 
have problems and  they need to 
see the doctor then the sister 
would have to find out, is there a 
problem that needs to be seen by 
the doctor 
CISB – Clinic - 
Waiting 
Amount of time elapsed before 
treatment is provided to patient. 
 
“That it is a very long visit to the 
doctor (laugh) in one day. I 
mean, some people wake up at 
four to come to the clinic, and  
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Codebook for Clinicians (continued) 
Code Definition Example of quotation 
  they only leave at four in the 
evening.” 
CISB - Difficulty 
accessing 
healthcare system 
Difficulties patients' experience in 
attaining access to healthcare 
system. 
“I think that, on the whole, they 
would probably find it a difficult 
system to access.” 
CISB - Disability 
grant – 
Misconceptions 
 
Patients fail to understand the 
purpose of the grant. 
“…he disability grant issue is a 
huge issue…um…because 
patients initially aren’t often 
aware of the fact that it is a 
temporary grant.” 
CISB – Disability 
grant – Patient 
factor 
Factors affecting a criterion 
specified attainment and use 
disability grant by patients. 
And I have met a couple of 
patients they have ones, because 
it is a short term thing for most 
until they get reassessed at what 
ever level intervals, if they are 
better and they don’t have any 
other conditions going on, they 
won’t requalify.” 
 
144 
 
Codebook for Clinicians (continued) 
Code Definition Example of quotation 
CISB - Disability 
grant – Poverty 
 
Poverty-related issues associated 
with attainment of a disability 
grant. 
“…but a problem lots of the 
patients have is that they have 
been sick, been out of the labour 
market or they may have never 
been employed. Um…they 
might look after kids who are 
HIV positive, and now their 
grant get stopped, or can’t 
reapply again. And they…the 
patients find it very frustrating, 
because there obviously isn’t an 
income support for them…” 
CISB – Disclosure 
 
Difficulties patients have in 
revealing status to others. 
“…non-disclosure at the home 
or the workplace is an issue, 
because they hide their tablets, 
they may not have them in their 
face right there, and that may 
lead to them forgetting to take 
their doses 
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Codebook for Clinicians (continued) 
Code Definition Example of quotation 
CISB - 
Employment 
The effect of being HIV positive, 
and the implications of adhering to 
treatment on patients’ employment. 
“Um…I think it’s…um…it 
interferes with their ability to 
work that is quite an important 
thing. They don’t want to tell 
their employers they are HIV 
positive…um…so, equally their 
employers get sick of them, 
especially in the beginning 
where they come in once a 
week, once in every two weeks.” 
CISB - 
Employment – 
Routine 
Lack of routine due to employment, 
resulting in missed dosages. 
“People who work shifts, it can 
be a problem…it could be a big 
problem…because they need to 
take to take their medication at 
eight o’clock, they don’t want to 
make an issue of leaving work, 
or taking some tablets, and 
getting questioned about it. They 
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Codebook for Clinicians (continued) 
Code Definition Example of quotation 
 
 
might not remember to take their 
tablets with them…um…they 
have left them at home. 
They…that kind of…um…their 
lifestyle doesn’t fit in with being 
home for both those doses that 
could be a problem.” 
CISB - 
Experiences with 
healthcare 
professionals  
Interactions experienced between 
patients and healthcare 
professionals. 
“A patient told me the other day 
that they don’t want to go to a 
certain clinic because they staff 
was actually being rude to them, 
and being sort of stigmatizing 
them.” 
CISB - Healthcare 
facility - Lack of 
counsellors 
Lack of counsellors for debriefing 
healthcare workers involved with 
treating HIV patients 
 
“We don’t have a social…we 
have a social worker attached to 
the hospital and not of the ARV 
team, she doesn’t play a big role 
 
,  
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Codebook for Clinicians (continued) 
Code Definition Example of quotation 
 
 
except for maybe difficult grants 
or something. We don’t have a 
psychologist, access to 
psychologist… 
CISB - Healthcare 
facility - limited 
resources 
Lack of resources that limit 
adequate treatment of patients 
within the healthcare facility. 
“And we as the sisters, you’ve 
seen that little corner in which 
we were the other day, and we 
have to see two patients at a 
time. Two sisters and a nurse in 
that corner works in doing the 
weights and the temperatures 
and stuff.” 
CISB - Health 
literacy – Staff 
 
Staffs' insufficient knowledge 
related to the treatment of 
HIV/AIDS patients. 
 
“Ja if they don’t have the 
knowledge, or the info or what 
they just doing the job because 
they..it’s paying and...they can 
meet a nice doctor…” 
CISB - Lack of 
routine 
The change in patient’s daily 
routine that disrupts the patients'  
“…weekends, unexpected 
visitors or unexpected things  
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Codebook for Clinicians (continued) 
Code Definition Example of quotation 
 ability to take medication on time. happening, they lose their 
routine, and then they…then 
they forget to take their pill…” 
CISB – Language 
 
 
Difficulties experienced by 
clinicians or patients' in 
communicating or understanding 
one another. 
 
“But you don’t get the nuances 
or the complicated stories, 
especially the psycho-social 
issues that get lost 
completely…” 
“…a lot of thing are lost in 
translation.” 
CISB - Lay 
counsellors - 
ineffective training 
Informal training prohibits proper 
counselling of patients.  
“We have the councillors, who 
are more lay counsellors, and 
they often do not have the skills 
to deal with…(inaudible speech) 
they don’t really have the skills 
to deal with…um…many of the 
psycho-social issues…” 
CISB – Living 
arrangements 
Discomfort patients experience 
related to living conditions. 
“It might also have a lot to do 
with the fact that everyone is just 
so…living so close together, that 
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Codebook for Clinicians (continued) 
Code Definition Example of quotation 
  they are almost just like in each 
others’ space kind of thing.” 
CISB – Migration Failure to seek out medical care in 
areas outside their local clinic. 
“Or some patients have moved 
from another province to another 
province. And they are informed 
that they need to be transformed 
out. But then they just get that 
break where they stop, or they 
are moving over. They just don’t 
seek help at…at the next stop. 
Or maybe they didn’t know. It 
all just stops, for no apparent 
reason.” 
CISB - Migration - 
Transfer letters 
 
Failure to attain transfer letter when 
areas outside their local clinic. 
“…without having their 
treatment  is another issue for 
patients non adherent raak 
mense want hulle trek weg trek 
van een gebied na ‘n ander 
gebied toe, verstaan,then hulle 
kom nie om te kom vra vir a  
150 
 
Codebook for Clinicians (continued) 
Code Definition Example of quotation 
 
 
 transfer letter nie. Hulle 
gaan.”net, cause they don’t 
know they could do that come 
andask for a transfer letter. Hulle 
gaan net na daai area toe, dan 
gaan meld hulle by die kliniek 
en dan bel die kliniek daarvan af 
om te se sister hier het so an so 
meneer opgedaag, hy se hy is a 
pasient by hulle klinieken hy se 
hy’s op die an die behandeling 
hy’t die potjies gebring daar van 
die hospital, en a good thing- 
that he did cause the files 
number stays the same, so then 
we fax the stuff to them at the 
clinic there 
CISB - Open 
access to treatment 
The open selection criteria of 
patients of patients receiving  
“Because we had initially 
had…had funding from ARC,  
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Codebook for Clinicians (continued) 
Code Definition Example of quotation 
 
 
which is a NGO, and you were 
only allowed to treat parents and 
we very very limited. And, all 
those patients did very well, 
because we were very highly 
selective. Now there is more 
open…pretty open access, 
and…uhm…obviously we are 
less selective, and we have more 
of an issue with adherence, 
people falling off the program, 
people having, as…as they are 
on ARVs for longer, the side-
effects are starting to manifest, 
and…um…one gets more of a 
realistic picture of what it is like 
to treat patients with ARVs 
really.” 
CISB - Patient 
advocates - Lack  
Difficulties patient advocates 
experience in getting hold of  
“We find it frequently that they 
go there a few times and the  
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Codebook for Clinicians (continued) 
Code Definition Example of quotation 
of access to 
patients 
patients. patients aren’t at home and they 
miss quite a few…quite a few 
visits” 
CISB – Poverty – 
Finances 
Patient’s financial situation due to 
poverty. 
“Some patients just don’t have 
money.” 
CISB – Poverty – 
Food insecurity 
Poverty-related factors resulting in 
limited availability of food, in order 
to medication. 
“And there was another lady as 
well who came in and said that 
she didn’t have food for three 
days either. And it was very 
difficult for her to take…to take 
her medication.” 
CISB - Poverty - 
Reminder tools 
 
The lack of tools to aid patient in 
remembering to take medication, 
due to poverty.  
 
 
“The there are people who don’t 
have clocks don’t have alarms 
no nothing. Maybe they have a 
radio at a certain time of the day 
that news count up, and ok that’s 
the time that I must take my 
tablets. 
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Codebook for Clinicians (continued) 
Code Definition Example of quotation 
  But what if the battery is flat? 
What if there’s no power? How 
do they go about remembering 
the time?” 
CISB - Poverty – 
Transport 
 
Difficulties patients experiences in 
getting to the clinic due to the lack 
of financial resources. 
 
“… lots of the ARV clinics that 
are not in the patients’ 
community, so there are 
transport issues, and that is a 
great barrier to care.” 
CISB - Staff 
protocol 
 
Ineffective ways of managing the 
treatment of patients. 
“ It is still very…HIV care, and 
especially antiretroviral, is still 
very separate. They 
are…um…they are seen separate 
and different and lots of the 
medical staff don’t want to get 
involved, and therefore don’t, 
you know…people get their 
averted, and that is there, and 
you have to go there, and I don’t 
want to get involved…” 
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Codebook for Clinicians (continued) 
Code Definition Example of quotation 
CISB – Religion Beliefs and practices' effect on 
the patients' adherence to 
treatment. 
“The church does have an 
influence, cause I had this 
patient…um…who came to me” 
 
 doctor saw him, doctor told him 
that there it was and she asked 
me in to do a finger prick so that 
he can see both the test that was 
he said to me, sister I come 
today to have a test, an HIV test, 
and I asked him why? You are 
mos positive..why do you want.. 
said cause I’m not positive, I 
was prayed for and I believe I 
am no more positive. So I said to 
him ok, we gonna do the test 
again and give him a date to 
come back for the results, and 
when he came back I said to 
him, umm doctor...I made a little 
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 note for doctor not note actually 
I told her that I just like to not 
that the patient believed that he’s 
HIV positive free and required a 
test to be done and so when done 
and the test that was done now 
afterwards is the same. So then 
he, but he was so so depressed.” 
CISB – Stigma 
 
Bias or discrimination experienced 
or perceived by patients due to their 
HIV status. 
 
“But I think stigma, to me 
stigma is the biggest…the 
biggest issue.” 
“…the stigma patients, people, 
patients experience in the 
clinics. They do not want to be 
identified as being HIV 
positive.” 
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CISB - Substance 
abuse 
The misuse of certain substances 
that interferes with the patient’s 
ability to adequately adhere to 
treatment regimen. 
“…You know the patient cant 
stop drinking that it probably 
will affect their adherence." 
CISB - Substance 
abuse - lack of 
treatment 
programme 
Lack of proper treatment 
programmes for patients who abuse 
certain substances. 
 
“…it very frustrating…um… 
because there aren’t particularly 
good programs, even if the 
patients want want to stop, there 
aren’t particular programmes.” 
CISB - Support – 
Social 
 
Perceived or actual support attained 
through social networks. 
“…as long as they have a good 
patient treatment supporter, 
someone of the family who 
really cares for them, they seem 
to really manage to take their 
pills.” 
CISB - Tradition Traditional practices and beliefs 
effect on patients' adherence to 
treatment. 
“Well the culture is, especially 
when a girl is pregnant and she 
found out  that she’s positive, ,   
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 and her CD4 is below 200 and 
she has start using the AZT and 
the Niverapine and then go on full 
HAART after some time then 
they need to (sneeze, sneeze) 
disclose their problem. And that 
is a problem for them really cause 
when they are among their fathers 
and parent and have this child is 
now born then they, how do they 
present themselves bottle feeding 
the child…cause it’s not in their 
culture. Their culture relies that 
every mother breast feed their 
children. How do you explain to 
your mum, that I can’t breast feed 
…well enough stuffed breast with 
milk in it and you can’t breast 
feed your child. How do you  
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 explain it? How do you go around 
that? I’ve had this problem with 
patients all the time…” 
CISB – Transport 
– Distance 
Difficulties patients experience in 
getting to the clinic due to the 
distance they need to travel. 
“For some it could be the 
distance.” 
CISB - Transport – 
Riots 
Instability and reliability of the 
public transport system on the 
patient’s ability to get to the clinic. 
“…die taxi’s riot en hulle kan 
nie vervoer om hie uit te kom 
nie, soos nou onlangs almal se 
verskoning was, en die volgende 
dag toe’s die hele lot hier , 
en…sommige…” 
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Codebook for Patients 
Code Definition Example of quotation 
PIF 
 
Individual factors affecting 
patients 
 
PIF - Emotional 
wellbeing  
The contribution of patients’ 
emotional wellbeing to their 
ability to adhere to their 
medication. 
“ Daar is baie tye agterna wat ek 
ook besef dit is, ek moet my 
medikasie drink. As mens so 
musmoedig voel, jy voel jy is so 
lus vir niks nie, jy wil niemand 
rondom jou hê nie, dan voel jy 
net op daai stadium, ek is nie lus 
om my medikasie te drink nie…” 
PIF– Medication Patients’ experience with 
medication 
“Vanaf ek die eerste keer op die 
medikasie gegaan het, dit het my 
net baie laat slaaip. Ek het net 
baie lomerig gevoel, maar toe ek 
nou nader aan verder begin drink 
toe begin dit nou met my begin 
werk.” 
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PSB 
 
Structural barriers identified 
by patients 
 
PSB - Access to mental 
health services 
Difficulties patients' 
experience in accessing 
services related to mental 
health. 
“...Ja, hulle stuur vir jou Denova 
toe, daai is ‘n plek waar hulle vir jou 
uit droog om vir jou te help...die 
dokter wou nou vir my gestuur het, 
toe sê ek ek wil nie gaan nie...” 
PSB - Clinic – 
Overcrowding 
Volumes and numbers of 
patients seeking treatment at 
clinic. 
“Ja, dit is, dit is 'n bietjie van 'n 
probleem ja, dit is um, ek meen dit 
is 'n, daar is te veel mense daarso, 
dit is 'n, hulle moet natuurlik ook 
almal kans gee, daar is partykere 
wat jy drie, vier ure sit en dan vat 
hulle net jou gewig, ek meen dis, 
dis, dis um..” 
PSB - Clinic – Waiting Amount of time elapsed 
before treatment is provided 
to patient. 
 
“…daar is te veel mense daarso, dit 
is 'n, hulle moet natuurlik ook almal 
kans gee, daar is partykere wat jy 
drie, vier ure sit en dan vat hulle net 
jou gewig...” 
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PSB – Clinic – Waiting 
– Food 
Lack of food when 
attending clinic 
“…as jy nie geld in jou sak het nie 
of kos saam neem nie, dan raak jy 
maar honger daar en dit is nie lekker 
om so heeldag te sit nie…” 
PSB – Disability grant 
- Difficulties  
Problems patients may 
experience when applying 
for disability grant 
“…toe sê hulle vir my dat my 
papiere daar weg geraak het, by die 
hospitaal, nou moet ek weer 
aansoek doen…” 
PSB - Disability grant - 
Patient factor 
Factors affecting a criterion 
specified attainment and use 
of disability grant by 
patients 
“...daai mense wat kry die grant, 
hulle drink nie hulle medikasie nie, 
hulle drink, hulle koop wyn 
daarvan...” 
PSB - Disability grant 
– Poverty 
Poverty-related issues 
associated with attainment 
of a disability grant. 
“Dis nie altyd wat die dissability 
alles dek nie. Ons kan nie met daai 
R900 alles cover nie, want dis 
klomp dinge wat ons moet doen met 
daai R960.” 
PSB – Employment – 
Capability 
The effect of physical 
wellbeing on employment 
capabilities 
“…omdat ek in so 'n toestand is, 
daai warmte, ek kan nie, ek kan nie 
in daai warmte gaan werk nie. Ek  
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 wou graag gegaan het, en ook maar 
my bydra gedoen het vir die huis, 
dat ons dam 'n onkomste kry, maar 
ek kan nie in daai warmte gaan pars 
nie.” 
PSB - Experiences with 
healthcare 
professionals  
The nature of interactions 
experienced  between 
patients and healthcare 
professionals 
“Ek sal sê, baie susters wat nors is, 
hulle attitude is nie lekker nie…” 
PSB – Mobility 
(Migration) 
Factors relating to the 
movement of patients from 
one place to another, due to 
socio-economic 
circumstances. 
“...ek het ‘n begrafnis en volgende 
week, dat hulle dit vir my uitstel tot 
volgende week...hulle het 
ingestem....” 
PSB - Poverty - Food 
insecurity 
Poverty-related factors 
resulting in limited 
availability of food. 
“Vir my is dit nie eintlik, dit is 
eintlik 'n probleem, partykeer is daar 
nie eintlik kos nie. Dis eintlik 'n 
struggling. Ja, en hierdie geld wat 
ek nou kry is maar basies net vir die 
huur en die elektrisiteit, dan is daar  
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 miskien nou honderd rand oor vir 
kos…” 
PSB – Poverty – 
Housing 
The effect of poverty on 
housing conditions 
“…dit verg biekie baie stabiele 
huisvesting…” 
PSB – Stigma – 
Disclosure 
The effect of stigma on the 
patients’ ability to disclose 
“Ek weet nie, miskien sal hulle 
miskien nou wil vra, hoe en waar en 
wat, ek is nog nie seker nie, ek voel 
ek is nog nie reg om vir hulle te sê 
nie.” 
PSB - Substance abuse The misuse of certain 
substances that interferes 
with the patients’ ability to 
adequately adhere to 
treatment regimen. 
“Ek het ook gedrink, ek het ook 
gedrink en vergeet van my 
behandeling, ek het nie geworry 
nie.” 
PSB - Poverty – 
Transport 
Difficulties patients 
experiences in getting to the 
clinic due to the lack of 
financial resources. 
“Om by die hospitaal uit te kom nie, 
want ons ry per taxi. Soos ek reeds 
voorheen gesê het, met die 
dissability moet ek baie dinge dek 
en dan is daar nie partykeers geld 
vir die taxi nie.” 
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PSB - Support – 
Financial 
Necessary financial support 
from social networks in 
order to obtain access to 
treatment 
“Wat ek daar in kan sit, my ma het 
saam met my gepraat, sy is instaat 
om my nou te help, want ek was 
gister by die hospitaal, ek het met 
die taxi gery. Sy het vir my geld 
gegee, ‘n dertig rand, en ek het daar 
uit gekom, en hulle is instaat om vir 
my te ondersteun…” 
PSB - Support – Social Perceived or actual support 
attained through social 
networks. 
“Mense wat groter as ek is, ouer as 
ek, wat ek al vertel het, wat ek in 
my vertroue kan neem, wat nie vir 
my sal skel teen die pad nie, of wat 
sal sê, het jy gehoor Patricia het 
HIV, of het julle gesien sy hou vir 
haar kwaai, sy het daai siekte. O, 
nee, nee glad nie, dit is mense wat 
saam met my die pad stap, wat vir 
my ondersteun. As ek so mismoedig 
voel, dan kan ek na hulle toe gaan 
en dan kan hulle weer vir my 
opbeur, weer mooi met my praat,  
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 goeie woordjie en so aan. Wat my 
hand vat en wat lief is vir my, nie 
mense wat vir my seer maak en 
afkraak nie…” 
PSB – Stigma Bias or discrimination 
experienced or perceived by 
patients due to their HIV 
status. 
“…as jy HIV positief is, jy is 'n 
minder, jy is nie 'n volle persoon 
nie, jy is 'n minderwaardige 
persoon.” 
PSB - Transport – 
Distance 
Difficulties patients 
experience in getting to the 
clinic safely due to the 
distance needed to travelled. 
“ …en ek moet in die oggende, dan 
stap ek van die huis af, ek stap four 
o' clock van die huis af, dan kom ek 
mooi, half sewe dan kom ek hier bo 
by die dokter...” 
PSB – Transport – 
Taxi’s – Routes 
The effect of routes taxi’s 
travel on the patients’ ability 
to access care 
“…ek dink nie die taxi ry daai, daai 
roete nie…” 
PSB – Work – Leave The effect of employment 
conditions or  
 
“gewoontlik dan moet...toe ek nog 
gewerk het, dan is ek altyd as ek vir  
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 responsibilities on a 
patients’ ability to access 
care. 
 
die afspraak gaan vir die kliniek of 
so, het ek altyd gevra of ek die dag 
kan af kry en dan gaan ek nou die 
dag soon toe.” 
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Codebook for Patients Advocates 
Code Definition Example of quotation 
PAIISF Individual factors as 
identified by patient 
advocates 
 
PAIISF – Dislike of  
medication  
Patient advocate’s 
identification of patients’ 
dislike of the medication 
“Yeah and also something 
that now comes to my mind, 
it’s simply not nice to take 
medication.” 
PAIISF - Medication 
characteristics 
 
Difficulties experienced in 
the actual taking of 
medication. 
“I mean some of those tablets 
are so big. 
 
PAISB  Structural barriers as 
identified by patient 
advocates 
 
PAISB – Lack of access to 
mental health services, due to 
limited resources 
Difficulties patients' 
experience in accessing 
services related to mental  
“Maybe they do, because 
most of them are people who 
use alcohol and drugs. It’s a  
 
168 
 
Codebook for Patients Advocates (continued) 
Code Definition Example of quotation 
 health due to limited 
resources. 
very big problem, I mean, 
every Monday with our 
meeting, that would be the 
main problem… (speech in 
backround) …yes, substance 
abuse, yes but, then we don’t 
have the resources where you 
can actually send the people, 
but you can’t even send 
them, because if they don’t 
have to go, how will you get 
them there. So, it’s a problem 
that it seems that there’s no 
solution…” 
PAISB - Access of patient 
advocates to patients – Safety 
Threatening circumstances 
experienced by patient 
advocates when accessing 
patients in certain areas 
“Dit is jou grootste vrees as 
jy in die veld werk. En waar 
jy ingaan, daar by ons is daar 
baie plakkers kampe, en dis 
gevaarlik, maar ons moet 
daar deur gaan, want op die 
einde van die dag is ons  
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  kliente die belangrikste, so 
ons moet daar deurgaan, elke 
dag.” 
PAISB – Clinic – Hospital - 
Administration 
Difficulties with clinic and 
hospital administration when 
it comes to admitting of 
patients. 
“ARV pasiënte word nie 
dadelik gehaal van die 
ambulance om vir hulle op, 
of ‘n mens kan nie vir hulle 
dadelik opneem. Hulle moet 
eerste na die dag hospitaal 
toe gaan om die folder te 
sien, om die folder te kry om 
op te gaan hospitaal toe…” 
PAISB - Clinic – 
Overcrowding 
 
Volumes and numbers of 
patients seeking treatment at 
clinic. 
“… but at the moment their 
space… their very cramped.” 
PAISB - Clinic – Privacy Issues related to privacy due 
to a lack of resources. 
“There is not enough rooms 
to see the counsellor in 
private. So that’s also very 
uncomfortable for most of 
them…” 
170 
 
Codebook for Patients Advocates (continued) 
Code Definition Example of quotation 
PAISB – Clinic -  Waiting Amount of time elapsed 
before treatment is provided 
to patient. 
“…but sometimes they sit in 
the queue, and they will have 
to wait until four for an 
appointment.” 
PAISB - Clinic structure – 
Discomfort 
Patients' experiences of clinic 
due to unaccommodating 
clinical structure. 
“I think they do not feel 
unwelcome, but at the 
moment their space… their 
very cramped. So it’s a very 
uncomfortable experience. 
There is not enough rooms to 
see the counsellor in private. 
So that’s also very 
uncomfortable for most of 
them…” 
PAISB – Denial The non-acceptance of the 
patients' HIV status 
contributes to patients' non-
adherence to antiretroviral 
therapy. 
“Party mense is in denial. 
Die pille is daar, hulle sien 
pille daar, maar hulle is nog 
al die tyd in denial. Hulle 
weet die dokter het nou gesê 
hulle is positive, die pille,  
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  moet nog gedrink word maar 
iets in hulle brein sê vir hulle 
hulle is nog nie positive nie, 
that’s why, gaan ek nie die 
pille gebruik nie.” 
PAISB – Disability grant – 
Difficulties administration 
Difficulties patients 
experience in attaining a 
disability grant, and its effect 
on adherence to medication. 
“…baie van die mense het 
aansoek gedoen vir ‘n 
disability grant…um…dit vat 
‘n tyd want jy kry nou ‘n 
datum dan gee hulle vir jou 
drie dan moet jy weer na die 
dokter toe gaan en die dokter 
het nie reg ingevul nie dan 
moet daai mense weer vir so 
‘n maand of so wag vir ‘n 
appointment met ‘n 
dokter…um… toe het ons 
besluit, toe het ek vir hulle 
gesê ‘n mens kan klein begin 
want kyk daai mense gaan 
nou vir hulle medikasie nou,  
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  hulle is nou commited hulle 
gaan nou hulle medikasie 
drink, maar jy kan iemand 
ook nie nou, jy gee solank 
die pille, drink die pille en jy 
weet daar is niks wat daai 
persoon kan eet nie.” 
PAISB - Disability grant - 
patient factor 
Factors affecting a criterion 
specified attainment and use 
of disability grant by patients 
“I don’t know if I’m right or 
wrong is HIV positive people 
they make the HIV the 
government responsibility, 
because they want to get their 
grant, because if you are HIV 
positive you get mos the 
grant for the six months so 
when you are better you 
don’t want to take the 
medication because of that, 
because of the grant.” 
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PAISB - Experiences with 
healthcare professionals – 
Negative 
Negative interactions 
experienced between patients 
and healthcare professionals. 
“Hostility from the staff. 
They would er…let me also 
say maybe unkindness and 
impatience from the nursing 
staff…” 
“Nurses, nurses yes, and 
they’re very impatient when 
they do not do as they are 
told. So I think that for them 
is a very uncomfortable place 
to be.” 
PAISB - Health literacy Factors related to the patients 
knowledge, understanding 
and information pertaining to 
HIV/AIDS and antiretroviral 
therapy. 
 
“…somtyds, um, gebeur dit 
dat hulle verstaan nie lekker 
waaroor HIV gaan nie, en ek 
is nogal bly dat ons daar is 
om vir hulle die regte riglyne 
te gee oor HIV, en somtyds 
het mense baie verkeerde 
aspekte oor HIV, ne. Want as 
die mense praat oor HIV dan  
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  sal ek daar staan om te luister 
waar kom hulle aan hulle 
kennis wat hulle het…” 
PAISF – Implementation of 
treatment support 
programmes 
Patients’ experience as 
identified by patient 
advocates in the 
implementation of treatment 
support programmes 
“Treatment Action 
Campaign, the people that 
you worked with, has this, 
almost, militant way of 
getting their people to 
disclose, and that for us 
we’ve experienced it with 
one of our counsellors who 
has (?),disclose publicly, but 
then they accepted it, 
personally, and that was quite 
some…” 
PAISB - Non-disclosure Difficulties patients have in 
revealing status to others. 
“So dit het ‘n hele, die feit 
dat hulle nie hulle status 
bekend maak nie, they don’t 
disclose, dit het another 
effect on their body, it puts  
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  more stress on the, more 
strain, and even that makes 
them even go quicker to you 
know to the stage of full 
blown AIDS and that and 
also how they take the 
medication, and the root 
would I agree with (name) 
that they don’t want to be 
rejected, because when you 
work with…” 
PAISB – Poverty – Disability 
grant 
The effect of not having a 
disability grant on patients’ 
ability sustain day to day 
living. 
“…it’s not very nice to see 
that kind of thing because 
you go to the clinic, some of 
them are very hungry, they 
don’t get disability grants.” 
PAISB - Poverty - Food 
insecurity 
Poverty-related factors 
resulting in limited 
availability of food. 
“I had a client, we have a 
client, and we go and visit 
him, his mother always say, 
but their not working, and all 
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  the children is now HIV 
positive. So the one they go 
to the soup kitchen, now only 
in the mornings they have the 
soup kitchen, and what do 
they do maybe if you have to 
take the tablets at night, 
where do they get food?” 
PAISB – Poverty – Transport The effect of poverty on 
patients’ ability to adhere to 
treatment visits. 
“Die taxi’s is daar maar die 
taxi’s is… kyk net, van my af 
tot in die dorp is die taxi 
klaar vir jou R6, maar jy wat 
nou ook nie… unemployed is 
en jy werk nie, jy’t nie geld 
nie en jy is klaar ‘n moeder 
en al die, hoe gaan jy daar 
uitkom, om in die dorp te 
kom? In baie van ons gevalle 
is daar ‘n probleem saam met 
ons, maar jy ka nook nie, 
maar die mense wil net daar  
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  uitkom vir hulle 
appointments. Even die 
hospitaal daar van die village 
af, die taxi ry nie hospitaal 
toe nie, die taxi ry nie uit ons 
community uit hospitaal toe 
nie, daai mense moet stap 
van Gardens af regop om by 
die hospitaal uit te kom…” 
PAISB – Religion Beliefs and practices' effect 
on the patients' adherence to 
treatment. 
“…van ‘n godsdienstige 
ookpunt af, hulle medikasie 
sal los dat hulle glo die Here 
het vir hulle gesê, en daai 
mense het baie sterk invloed 
op hulle kerkmense, dat jy dit 
nie hoef te drink nie.” 
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“…die Universal Church, 
hulle is baie daarop dat as jy 
geneesing by hulle gekry het 
maak dit dat jy nie jou 
medikasie kan neem nie.” 
PAISB - Substance abuse The misuse of certain 
substances that interferes 
with the patients’ ability to 
adequately adhere to 
treatment regimen. 
“I know about…how many 
patient, two patients, or three 
patients is still struggling 
with drinking, with going to 
the point where they want to 
put them on the ARVs, 
because their struggling with 
alcohol…” 
PAISB - Support – Social Perceived or actual support 
attained through social 
networks. 
“We, they had to bring the 
family, and just the impact 
knowing the person, because 
sometimes they come with 
the person to the ARV site 
not knowing that the person 
is HIV positive, not knowing  
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  what it’s all about. So only  
that they may find out that 
the person is about to you 
know prepare to go on 
ARVs, and with a family that 
also has this fear of what is 
the community going to say, 
what are the other family 
members gonna say about it.”
PAISB – Stigma Bias or discrimination 
experienced or perceived by 
patients due to their HIV 
status. 
“…stigma, because some 
people know that we’re 
working in this field.” 
“So if your very near with 
those people, or seen with 
them, then it simply means 
that they’re also positive. So 
that might be the reason…” 
PAISB – Stigma – 
Disclosure 
The effect of stigma on 
patients’ ability to disclose to 
others. 
“…baie van hulle is afraid to 
disclose to their families, 
um… because now, in some  
180 
 
Codebook for Patients Advocates (continued) 
Code Definition Example of quotation 
  
of the communities now you 
are HIV and they don’t want 
to be involve with you, dis 
amper hulle is doodskaam vir 
die mense, in jou eie familie 
wil hulle nie disclose nie…” 
PAISB – Tradition and 
culture 
Traditional practices and 
beliefs effect on patients' 
adherence to treatment. 
“For instance, you know it, 
the people are very different 
race, some of them they do 
live internationally (…um…) 
because most of them they 
know if you tell the doctor 
that you’re use it , the doctor 
is not going to give you 
antiretrovirals and they 
sommer said no I’m not 
taking any traditional 
medication  and that will 
come out four months down 
the line after you started the 
ARVs because you’re going  
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to start ARVs and then 
you’re not going to stop 
taking medication and when 
you go back for the baseline 
blood it will eventually 
show.” 
PAISB - Transport – 
Distance 
Difficulties patients 
experience in getting to the 
clinic due to the distance 
needed to travelled. 
“Daar was een pasient by 
my, sy het haar ARVs gekry, 
en dan het sy nie geld gehad 
om huistoe te gaan nie.” 
PAISB – Transport – Taxi’s 
routes 
Difficulties patients’ 
experience in getting to the 
clinic due to taxi routes that 
do not include the clinic in 
their travel schedule. 
“‘n Uur van die taxi rank tot 
by die hospitaal, so ‘n uur, 
dit vat so ‘n halfuur om te 
loop (…ja dis baie vêr… ). 
Dis hoekom die volk, die 
mense as hulle swak is dan… 
hulle het nie taxi geld nie (Is 
daar taxi’s wat ry hospitaal 
toe?) Daar is nie taxi’s wat ry 
nie, daar het altyd vantevore  
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  ‘n bus gestaan wat elf uur ry, 
twee uur ry, wat ons op 
hospitaal wat die buste nog 
daar gewees het maar nou dat 
daar nie meer buste is nie ry 
die taxi’s nie soontoe nie.” 
“Busse wat hospitaal toe 
gegaan het dan het die mense 
noe gegaan, okay, vanoggend 
sewe uur is daar ‘n buste 
hospitaal toe, hulle gaat nou 
hulle pille haal, hul 
medikasie haal.” 
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APPENDIX F 
ETHICAL APPROVAL: HUMAN RESEARCH COMMITTEE 
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APPENDIX G 
ETHICAL APPROVAL: WESTERN CAPE DEPARTMENT OF HEALTH 
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APPENDIX H 
THEMES 
1. Individual barriers 
Sub themes Codes included in the sub-theme 
(a) Health Literacy CIIF-Health literacy; PAIIF-Health literacy. 
(b) Literacy CIIF-Literacy. 
(c) Medication CIIF-Medication-Characteristics; CIIF-Medication-Side-
effects; PAIIF-dislike of medication; PAIIF- medication 
characteristics; PIF-Medication. 
(d) Mental health PIF-Emotional well-being. 
(e) Forgetfulness CIIF-Forgetfulness. 
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2. Poverty-related barriers 
Sub themes Codes included in the sub-theme 
 (a) Employment CISB-Employment; CISB-Employment-Routine; PSB-  
Employment-Capabilities; PSB-Employment-Leave. 
(b) Migration CISB-Migration; CISB-Migration-Transfer letters. 
(c) Disability grants CISB-Disability grants-Poverty; CISB-Disability grants- 
Misconceptions; CISB-Disability grants-Patient factor; 
PAISB-Disability grants Difficulties-Administration; 
PAISB-Disability grants-Patient factor; PAISB-Poverty-
Disability grants; PSB-Disability grants-Poverty; PSB-
Disability grants-Difficulties; PSB-Disability grants-
Patient factor. 
(d) Food insecurity CISB-Poverty-Food insecurity; PAISB-Poverty-Food 
insecurity; PSB-Poverty-Food insecurity. 
(e) Living arrangements CISB-Lack of routine; CISB-Living arrangements; PSB-
Poverty-Housing. 
(f) Reminder tools CISB-Reminder tools. 
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Poverty-related barriers (continued) 
Sub themes Codes included in the sub-theme 
(g) Transport 
 
CISB-Poverty-Transport; CISB-Transport distance; 
CISB-Transport-Taxi’s-Riots; PAISB-Poverty-Transport; 
PAISB-Transport-Distance; PAISB-Transport-Taxi’s-
Routes; PSB-Poverty-Transport; PSB-Transport-
Distance; PSB-Transport-Taxi’s-Routes. 
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3. Institution-related barriers 
Sub themes Codes included in the sub-theme 
(a) Access to healthcare system CISB-Access to healthcare system. 
(b) Open access to treatment CISB-Open access to treatment. 
(c) Administration and staff   
protocol 
CISB-Clinic-Administration; CISB-Staff protocol. 
(d) Language patients are 
attended to  
CISB-Language. 
(e) Overcrowding CISB-Clinic-Overcrowding; PAISB-Clinic-
Overcrowding; PSB-Clinic-Overcrowding. 
(f) Waiting CISB-Clinic-Waiting; PAISB-Clinic-Waiting;  
PSB-Clinic-Waiting. 
(g) Lack of privacy CISB-Clinic-Privacy. 
(h) Patient’s experiences with 
staff 
CISB-Experiences with healthcare workers; PAISB-
Experiences with healthcare workers; PSB-Experiences 
with healthcare providers. 
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Institution-related barriers (Continued) 
Sub themes Codes included in the sub-theme 
(i) Experiences of staff in 
treating patients with ART 
CE. 
(j) Burnout CISB-Burnout. 
(k) Lack of resources CISB-Healthcare facility-Limited resources. 
(l) Staff’s health literacy CISB-Health literacy-Staff 
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4. Social- and community-related barriers 
Sub themes Codes included in the sub-theme 
(a) Stigma CISB-Stigma; PAISB-Stigma; PSB-Stigma. 
(b) Disclosure CISB-Disclosure; CISB-Stigma disclosure; PAISB-
Stigma-Disclosure; PSB-Stigma-Disclosure. 
(c) PAs access to patients 
 
CISB-Patient advocates-Lack of access to patients; 
PAISB-Access of patient advocates to patients-Safety. 
(d) Religion CISB-Religion; PAISB-Religion. 
(e) Tradition and culture CISB-Tradition and culture. 
(f) Substance abuse CISB-Substance abuse; CISB-Substance abuse-Lack of 
treatment programmes; PAISB-Substance abuse; PSB-
Substance abuse. 
(g) Support CISB-Support-Social; PAISB-Support-Social; PSB-
Support-Financial; PSB-Support-Social. 
(h) Treatment support 
programmes 
PAISB-Implementation of treatment support programmes. 
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APPENDIX I 
MODIFIED ECOLOGICAL SYSTEMS THEORY 
 
 
 
   
MACROSYSTEM 
SOCIAL AND COMMUNITY-RELATED 
BARRIERS 
EXOSYSTEM 
MICROSYSTEM 
INDIVIDUAL BARRIERS 
 Forgetfulness 
 Mental health 
 Literacy 
 Health literacy 
 Medication 
INSTITUTION-RELATED BARRIERS 
Healthcare system 
 Open access to ART 
Healthcare facility 
 Administration and staff protocol 
 Language 
 Waiting 
 Overcrowding 
 Privacy 
 Experiences with staff 
Staff at healthcare facility 
 Experiences of staff 
 Burnout 
 Lack of resources 
 Staff’s health literacy 
INDIVIDUAL
 Stigma and disclosure 
 Religion 
 Culture 
 Patient advocates access to patients 
 Substance abuse 
 Social and tangible support 
POVERTY-RELATED BARRIERS 
 Employment 
 Disability grants 
 Food insecurity 
 Living arrangements 
 Reminder tools 
 Transportation 
 Migration  
Resources available in community 
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APPENDIX J 
WHO CLINICAL STAGING 
WHO Clinical Staging  
Clinical Stage Symptoms 
Clinical Stage 1 
 
• Asymptomatic 
• Persistent generalized lymphadenopathy 
Clinical Stage 2 
 
• Unexplained persistent hepatosplenomegaly 
• Papular pruritic eruptions 
• Extensive wart virus infection 
• Extensive molluscum contagiosum 
• Fungal nail infections 
• Recurrent oral ulcerations 
• Unexplained persistent parotid enlargement 
• Lineal gingival erythema 
• Herpes zoster 
• Recurrent or chronic upper respiratory tract infections (otitis 
media, otorrhoea, sinusitis or tonsillitis) 
Clinical Stage 3 
 
• Unexplained moderate malnutrition not adequately responding 
to standard therapy 
• Unexplained persistent diarrhoea (14 days or more) 
• Unexplained persistent fever (above 37.5°C intermittent or 
constant for longer than one month) 
• Persistent oral candidiasis (after first 6–8 weeks of life) 
• Oral hairy leukoplakia 
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WHO Clinical Staging (continued) 
Clinical Stage Symptoms 
 
• Acute necrotizing ulcerative gingivitis or periodontitis 
• Lymph node tuberculosis 
• Pulmonary tuberculosis 
• Severe recurrent bacterial pneumonia 
• Symptomatic lymphoid interstitial pneumonitis 
• Chronic HIV-associated lung disease including brochiectasis 
• Unexplained anaemia (< 8 g/dL), neutropaenia (< 0.5 × 109 
per litre) 
• And/or chronic thrombocytopaenia (< 50 × 109 per litre) 
Clinical Stage 4 
 
• Unexplained severe wasting, stunting or severe malnutrition 
not responding to standard therapy 
• Pneumocystis pneumonia 
• Recurrent severe bacterial infections (such as empyema, 
pyomyositis, bone or joint infection or meningitis but 
excluding pneumonia) 
• Chronic herpes simplex infection (orolabial or cutaneous of 
more than one month’s duration or visceral at any site) 
• Extrapulmonary tuberculosis 
• Kaposi sarcoma 
• Oesophageal candidiasis (or candidiasis of trachea, bronchi or 
lungs) 
• Central nervous system toxoplasmosis (after one month of life) 
• HIV encephalopathy 
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WHO Clinical Staging (continued)  
Clinical Stage Symptoms 
 
• Cytomegalovirus infection: retinitis or cytomegalovirus 
infection affecting another organ, with onset at age older than 
one month 
• Extrapulmonary cryptococcosis (including meningitis) 
• Disseminated endemic mycosis (extrapulmonary 
histoplasmosis, coccidiomycosis) 
• Chronic cryptosporidiosis 
• Chronic isosporiasis 42 
• Disseminated non-tuberculous mycobacterial infection 
• Cerebral or B-cell non-Hodgkin lymphoma 
• Progressive multifocal leukoencephalopathy 
• Symptomatic HIV-associated nephropathy or HIV-associated 
cardiomyopathy 
• HIV-associated rectovaginal fistula 
Note: Department of Health (2010) 
 
